AU2637895A - Compositions for treatment of chronic inflammatory diseases - Google Patents

Compositions for treatment of chronic inflammatory diseases

Info

Publication number
AU2637895A
AU2637895A AU26378/95A AU2637895A AU2637895A AU 2637895 A AU2637895 A AU 2637895A AU 26378/95 A AU26378/95 A AU 26378/95A AU 2637895 A AU2637895 A AU 2637895A AU 2637895 A AU2637895 A AU 2637895A
Authority
AU
Australia
Prior art keywords
daily
dosage range
derivatives
well
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU26378/95A
Other versions
AU698881B2 (en
Inventor
Howard K. Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2637895A publication Critical patent/AU2637895A/en
Application granted granted Critical
Publication of AU698881B2 publication Critical patent/AU698881B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the clinical treatment of chronic inflammatory diseases, including chronic gingivitis; chronic periodontitis; chronic autoimmune gastritis; ileitis; inflammatory bowel disease, including colitis; interstitial cystitis; psoriasis; arthritis; tendinitis; carpel tunnel syndrome and other cumulative trauma disorders; lupus erythematosus; pneumoconiosis; chronic obstructive pulmonary disease; inflammatory myopathies; inflammatory neuropathies, including Alzheimer's disease, myasthenia gravis and multiple sclerosis; epilepsy; as well as lessening of inflammatory site edema, and treatment of post-event ischemia and reperfusion symptomology resulting from acute central nervous system trauma, stroke, kidney ischemia or myocardial infarction.
2. Description of Prior Art
The logic and potential value, even εynergistic value, of using two or more therapeutic agents in combination for treatment of chronic inflammatory diseases has been recognized previously (Calhoun and coworkers, 1992; Hirschelmann and coworkers, 1991; Brooks and Schwarzer (1991) ; Wright and coworkers, 1977) .
The present disclosure describes the inventive concept of using the therapeutic technology of US Patent Application 07/906,909 in combination with pharmaceutical agents having some medicinal value for treatment of the disease entities noted above. The inventive concept embodied in my earlier US Patent Application 07/906,909 filed 30 June 1992 is the use of compositions consisting of a primary agent which sequesters carbonyl products in combination with co-agents that have known anti-oxidant properties. The primary agents of the present invention, such as p-aminobenzoic acid (PABA) , contain a primary amine group, so as to enable reaction with carbonyl groups of disease-related substances. No pharmacological treatment of comprehensive effectiveness is currently avail¬ able for any of the chronic inflammatory disorders discussed herein. However, a variety of pharmaceutical agents have been described which may offer at least some degree of symptomatic relief from the clinical effects of these diseases.
Clinical use of the drug sulfasalazine (SAZ) represents a well documented example of the use of a benzoic acid deriva¬ tive as a trapping agent for the hydroxyl radical and other free radicals in the treatment of a chronic inflammatory dis¬ ease. In the colon SAZ undergoes reductive cleavage to liber¬ ate 5-aminosalicylic acid (5-amino-2-hydroxybenzoic acid, or 5-ASA) , which is the therapeutically active agent. Ahnfelt- Ronne and coworkers (1990) presented research findings which docoment the use of SAZ for successful treatment of chronic inflamatory bowel disease (CIBD) , also known as ulcerative colitis. SAZ is also recognized for use in treatment of ileitis (Budavari and coworkers, 1989, pg. 1412) . Ahnfelt- Ronne (1990) compared their in vivo 5-ASA metabolic products to products observed after .in vitro hydroxylation of 5-ASA by the Fenton reaction and tentatively identified 5-ASA metab¬ olites as being hydroxylated derivatives. They never at¬ tempted to look for evidence of in vivo trapping of carbonyl products. Under the brand name Asacol and the generic name mesalamine, 5-amino-2-hydroxybenzoic acid in delayed-release tablets has also been marketed in the United States for use in treatment of CIBD (Dowd and coworkers, 1993, pgs. 1868-1869). Dull and coworkers (1987, pg. 2469) used mass spectrometry to definitively identify two of the several hydroxylation/oxida- tive deamination products which result from in vitro incuba¬ tion of 5-ASA with activated human mononuclear cells. They identified these products as gentisic acid (2,5-dihydroxy- benzoic acid) and salicylic acid (2-hydroxybenzoic acid) , while five other 5-ASA metabolic products remained uniden¬ tified (pg. 2470) .
Ahnfelt-Ronne and colleagues, Dull and coworkers, and earlier investigators never recognized the possibility of using a therapeutic agent to scavenge carbonyl products of inflammation. Hence they never recognized the possibility of intentionally using a composition consisting of a primary agent which sequesters carbonyl products in combination with co-agents that have known anti-oxidant properties.
Further distinctions should be noted between the inven¬ tion disclosed in US Patent Application 07/906,909 and previ¬ ously recognized clinical use of SAZ. SAZ releases sulfapyri- dine, a somewhat toxic substance, into the body (Peppercorn, 1984, pgs. 377-379 and 383), while the invention of US Patent Application 07/906,909 does not. In addition, use of sulfa- salazine depends on intestinal bacteria for activation of the drug, while the primary agents of the present invention do not. Besides use in treatment of CIBD, SAZ has been recog¬ nized, at least at the experimental level, for treatment of ileitis, radiation bowel disease, scleroderma, dermatitis herpetiformis and rheumatoid arthritis (Peppercorn, 1984, pgs. 380-381) .
Other examples of amine drugs recognized as having anti- inflammatory properties include para-substituted N-benzene- sulfonyl derivatives of anthrilic acid (Borne and coworkers, 1974) , 4-amino benzoic acid anilides (Thiele, 1971; Deutsche Gold- und Silber-Scheideanstalt vorm. Roessler, 1972) , tinori- dine (Shimada and Yasuda, 1979) and benzothiazolinone deriva¬ tives (Takashima and coworkers, 1972) . The chemical struc¬ tures of these agents lie beyond those of the primary agents of the present invention. They are not presently recognized as carbonyl sequestering therapeutic agents. They have not been used in multiple ingredient compositions analogous to those of the present invention.
Several drug products containing PABA have been marketed for human use in the United States. However, it is believed that none have been proposed as effective for the treatments claimed herein. Potassium p-aminobenzoate has been marketed as Poϋaba (R) in the pure form as an antifibrotic, that is, skin softening, agent (Drug Information for the Health Care Professional, 8th ed., 1988, pgs. 111-113). As such it has been recognized for treatment of Peyronie's disease; diffuse systemic sclerosis; morphea and linear scleroderma; and dermatomyositis. For such purposes, Potaba is taken orally in average doses of 12 gm/day for up to two years, although human use of 15 - 20 gm/day is recognized. As an ingredient in analgesic tablets, PABA has been marketed for domestic human use (300 mg/tablet) in Pabirin (R) buffered tablets (with aspirin) , in Pa alate (R) tablets (with sodium salicylate) and in Pabalate-SF (R) tablets (with potassium salicylate) , as described in Physicians' Desk Reference (Huff and coworkers, 1980, pgs. 849, with aspirin and 1430, with salicylates) . Five percent PABA in a cream base has also been marketed as a sunscreen product (Physicians' Desk Reference. Huff and coworkers, 1980, pg. 849) .
In its summary on systemic use of potassium p-aminobenzo- ate the Druσ Information for the Health Care Professional text (8th ed. , 1988, pg. Ill) presented the following statement regarding recognized pharmacology (reproduced herein its entirety) :
Mechanism of action: The mechanism by which aminobenzoate potassium exerts its antifibrotic effect is not known. It has been postulated that fibrosis results from an im¬ balance of serotonin and monoamine oxidase (MAO) mechan¬ isms at the tissue level. Fibrosis is believed to occur when an excessive serotonin effect is sustained over a period of time. This could be the result of too much serotonin or too little MAO activity. Aminobenzoate potassium increases oxygen utilization at the tissue level. It has been suggested that this increased oxygen utilization could enhance the degradation of serotonin by enhancing MAO activity or other activities that decrease the tissue concentration of serotonin.
In its summary on systemic use of potassium p-aminobenzo- ate the Physician's Desk Reference (Dowd and coworkers, 1993, pg. 1103) presented the following statement (reproduced herein its entirety) :
INDICATIONS
Based on a review of this drug by the National Acad¬ emy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: 'Possibly' effective: Potassium aminobenzoate is possi- bly effective in the treatme rnt of scleroderma, dermato- myositis, morphea, linear scleroderma, pemphigus, and Peyronie's disease.
Final classification of the less-than-effective indi¬ cations requires further investigation. ADVANTAGES
POTABA offers a means of treatment of serious and often chronic entities involving fibrosis and nonsuppurative inflammation. PHARMACOLOGY
P-Aminobenzoate is considered a member of the vitamin B complex. Small amounts are found in cereal, eggs, milk and meats. Detectable amounts are normally pre¬ sent in human blood, spinal fluid, urine, and sweat. PABA is a component of several biologically important systems, and it participates in a number of funda¬ mental biological processes. It has been suggested that the antifibrosis action of POTABA is due to its mediation of increased oxygen uptake at the tissue level. Fibrosis is believed to occur from either too much serotonin or too little monoamine oxidase activity over a period of time. Monoamine oxidase requires an adequate supply of oxygen to function properly. By increasing oxygen supply at the tissue level POTABA may enhance MAO activity and prevent or bring about re¬ gression of fibrosis.
This inventor sees no relationship of such comments to the present invention. In particular, the comments noted above clearly do not recognize the potential use of PABA and derivatives thereof as carbonyl trapping agents, that is, as agents which may generally inhibit chronic inflammatory disorders by virtue of their ability to chemically bind to and sequester aldehyde and ketone products of lipid peroxidation which result from and contribute to the continuation of chronic inflammatory disorders. In addition, prior art information has not anticipated or disclosed the particular composi tions set forth in the present disclosure. Hence the clinical applications of PABA and derivatives thereof claimed in the present invention are regarded by the inventor as new and novel. ^
Certain amine agents have recognized anti-oxidant proper¬ ties. These include N, N' -di- (sec-butyl) -p-phenylenediamine (Scott, 1965, pg. 120), aniline (Scott, 1965, pg. 125), aniline N-substituted agents (Scott, 1965, pg. 125), N, N' - diphenyl-p-phenylenediamine (Swingle and coworkers, 1985, pg. 112) and ethoxyquin (Swingle and coworkers, 1985, pg. 112) . In the present invention focus is placed on primary amine agents, as such agents are known to covalently react with carbonyl agents to yield Schiff base-type products (Feeney and coworkers, 1975, pg. 141) . By contrast, N-substitution with hydrocarbon functional groups tends to increase amine anti- oxidant activity (Scott, 1965, pgs. 125 and 148) . These are two distinct chemical phenomena. The anti-oxidant property of amines depends on their ability to act as electron donors to alkoxy or alkylperoxy radicals (Scott, 1965; pgs. 127, 145 and 158) . The carbonyl trapping property of amines depends on their ability to form Schiff base-type addition products.
Zarafonetis (1953) has reported some success in treatment of rheumatoid arthritis by use of potassium p-aminobenzoate in combination with acetylsalicylic acid and cortisone. In this report Zarafonetis also described some success in clinical treatment of dermatomyositis and scleroderma by use of potas¬ sium p-aminobenzoate alone, and referred to earlier work on these disorders and other clinically related syndromes, in¬ cluding forms of lupus erythematosus.
Yet Zarafonetis based his logic for diversifying clinical studies on PABA or its potassium salt solely on similarities of clinical symptoms, comparisons among clinical syndromes which feature some common symptomology (Zarafonetis, 1953, pgs. 667-668; Zarafonetis, 1964, pgs. 550 and 560; Priestley and Brown, 1979, pg. 161; Zarafonetis and coworkers, 1988, pg. 194) . Zarafonetis never stated an understanding or recognized that PABA has the physiological potential of serving as an aldehyde chemical trapping agent (Zarafonetis, 1953, pg. 671) . Hence, he never recognized its potential to sequester aldehyde products resulting from increased lipid peroxidation secondary to site-specific inflammation. In failing to recognize this principle, Zarafonetis failed to recognize the potential full scope of clinical applications of PABA.
Failing to recognize the potential of synergistic anti- oxidant co-agents, the procedures of Zarafonetis for treatment of scleroderma, rheumatoid arthritis and dermatomyositis re¬ lied on use of high PABA dosages (12-18 gm/day; see Zarafone¬ tis, 1953, pg. 666) . In principle, it is the understanding of the present inventor that the clinical prognosis of any disease which features increased lipid peroxidation as part of its etiology may be improved by clinical application of the inventive concept embodied herein.
Zarafonetis (1953) also referred to an earlier study which used a combination of p-aminobenzoic acid and α-toco- pherol to treat scleroderma. Gougerot and Hewitt (1951) described the logic of their scleroderma treatment protocol as follows:
This observation is to be added to the file of the treatment of sclerodermas. Zarafonetis and his collab¬ orators have already published 5 cases of sclerodermas improved by para-aminobenzoic acid, and in the same therapeutic series Shaffer and his collaborators treated a generalized scleroderma with para-aminobenzoic acid with improvement. In a study of a completely different nature, vitamin E (a-tocopherol) was used by Klemperer, etc. and in France by Bazex (Lyon, July 1949) . This is why we have associated the two therapies because of their effect on diseases of collagen.
As such, they perceived their clinical treatment strategy to address the status of collagen, with no discussion of pos¬ sible physiological mechanisms. Compared to the invention embodied herein, Gougerot and Hewitt: (1) failed to recognize that either of their therapeutic agents may interfere with the inflammatory cascade, (2) failed to recognize that primary amine and amine-related derivatives of benzoic acid, as a class, may bind to and sequester aldehydes which result from the inflammatory process, (3) failed to understand that the combination of a water soluble aldehyde-trapping primary amine agent and a lipophilic anti-oxidant agent may have clinical application to the treatment of a broad spectrum of chronic inflammatory diseases, and (4) failed to disclose the unique positions of the present invention.
In 1967 Mel'nikova and Ryzhova presented the results of a clinical trial wherein PABA was used to treat post-event trauma in experimental myocardial infarction, as studied in rabbits and dogs. They reported a coronary vasodilator effect of PABA based on their understanding of the drug's antihist- amine property. They recognized no anti-inflamnmatory proper¬ ty of PABA and did not understand their findings within such a context.
Subsequent work by Kurdin (1978) has presented evidence of increased lipid peroxidation in the process of myocardial infarction. Actually, the association of increased levels of reactive oxygen species with ischemic myocardial dysfunction, with resulting lipid peroxidation is now well recognized (Dowling and coworkers, 1990, pg. 465). Viewing the reports of Mel'nikova and Ryzhova, Kurdin, and Dowling and coworkers within the context of the present invention, the inventor proposes that, to some degree, the beneficial effects of PABA in the Mel'nikova and Ryzhova study reflected an anti-inflam¬ matory property of PABA unrecognized by the investigators, and that such a beneficial effect may be optimized by use of the multi-component compositions as defined in the present inven¬ tion. Seekamp and Ward (1993) , using a rodent hind limb ligature model of ischemia/reperfusion, have presented some data which demonstrated the value of anti-oxidant pre-treat- ment of animals with catalase, superoxide dismutase, dimethyl- sulfoxide, dimethylthiourea or deferoxamine. As itemized by Entman and coworkers (1991) , a variety of therapeutic strat¬ egies has been proposed for treatment of ischemia/reperfusion trauma, yet none of these proposed strategies include the present invention.
The phenomenon of hypoxia/reperfusion injury is now un¬ derstood to be an important aspect of several traumatic dis¬ ease states, including coronary infarction, ischemic acute renal failure and cerebral ischemia (Dowling and coworkers, 1990, pg. 466) . Hence, the present invention has significant clinical value in the post-event treatment of ischemia and reperfusion injury subsequent to myocardial infarction, acute kidney failure, and acute central nervous system trauma and stroke. In light of the common physiological relationship of hypoxia/reperfusion conditions and chronic inflammatory diseases, both of which include tissue damage caused by lipid peroxidation and subsequent liberation of carbonyl substances, hypoxia/reperfusion conditions are considered to be varieties of chronic inflammatory diseases within the context of this invention. Likewise, as the etiology of Alzheimer's disease is believed to have an autoimmune component, and use of drugs such as deferoxamine (McGeer and Rogers, 1992, pg. 448; Halliwell, 1991, pg. 593) and indomethacin (Schnabel, 1993) has been previously noted in this regard, this disease also will be considered to be a variety of chronic inflammatory disease within the context of this invention.
Broad spectrum clinical use of anti-inflammatory vitamin compositions which feature PABA as a primary agent, and the methodological reasoning for doing so, has not been previously recognized or described prior to submission of US Patent Application 07/906,909. p-Aminobenzoic acid is not presently recognized as a nonsteroidal anti-inflammatory drug (NSAID) . Hence, for example, it is not included in the lists of such drugs published in (a) the Merck Index. (Budavari and cowork¬ ers, 1989, pgs. THER-15 to THER-16) , (b) Scientific American (Weissmann, 1991, pg. 86) , (c) Understanding Arthritis (Kushner, 1984, pgs. 52-53) and (d) the American Journal of Medicine (Houston, 1991) . Likewise, PABA is not recognized as being a "slow acting" anti-inflammatory agent (Understanding Arthritis. Kushner, 1984, pgs. 55-57).
Both PABA and D-penicillamine are primary amine agents which also function as anti-oxidant free radical trapping agents. Yet as anti-oxidant agents PABA and D-penicillamine are presently regarded as being of secondary, nominal value, due either to weak anti-oxidant properties or toxic side effects, respectively. Thus their use as anti-inflammatory agents has been quite limited. Their potential value for trapping the aldehyde products of inflammation-related lipid peroxidation has never been recognized. Hence the formulation of a new composition, such as one having PABA as its primary agent, optionally having known anti-oxidant free radical scavenging chemicals as co-agents, lacking vitamin C in excess / of its RDA and additionally including a recognized medicament as defined herein, has never been previously described, and the potential for clinical use of such a novel composition in treatment of chronic inflammatory diseases has never been recognized.
Further distinctions should be made between the present invention and previously recognized use of penicillamine, one of the "slow-acting" anti-inflammatory drugs mentioned in Understanding Arthritis (Kushner, 1984) , a publication of the Arthritis Foundation. The primary amine agents described in the present invention are all derivatives of aminobenzoic acid or aminophenylacetic acid, which should facilitate their safe elimination from the body by normal kidney filtration. D- Penicillamine is not a derivative of aminobenzoic acid or aminophenylacetic acid. In addition, D-penicillamine has a reduced sulfhydryl group, unlike any of the primary agents claimed herein.
The invention embodied herein constitutes an alternative slow-acting anti-inflammatory protocol which is believed to be inherently safer for the patient and to act via a mechanism not previously recognized or described. PABA is not among the antimalarial drugs discussed by Kushner (1984, pg. 57) , nor is it among the antimalarial drugs listed in the Merck Index (Budavari and coworkers, 1989, pg. THER-16) .
Many NSAID's are known to commonly induce side effects which include gastrointestinal damage, liver toxicity and kidney toxicity (Brune and Beck, 1991; Kraag, 1985) . Most of these drugs antagonize the actions of many antihypertensive drugs (Houston, 1991) . A variety of less common side effects of these drugs have also been reported (O'Brien and Bagby, 1985) . Use of the present invention in combination with such previously recognized medicaments permits the effective use of such drugs at lower dosage levels, serves to permit use, in at least some cases, of previously known medicaments for more extended periods of time and serves to supplement the overall clinical benefit to patients. Recognized nonsteroidal anti- inflammatory drugs include aminoarylcarboxylic acid deriva¬ tives, arylacetic acid derivatives, arylbutyric acid deriva¬ tives, arylcarboxylic acids, arylpropionic acid derivatives, // pyrazoles, pyrazolones, salicylic acid derivatives, thiazine- carboxamides, e-acetamidocaproic acid, S-adenosylmethionine, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, perisoxal, pifoxime and proquazone. Within the context of the present invention, the following additional drugs should also be regarded as nonsteroidal anti- inflammatory drugs: phenidone; ketoconazole; disodium azodisalicylate (a dimer of mesalamine) ; diazo sulfanilamide ethylene polymer of 5-aminosalicylate; cyclophosphamide; 6- (2,4-difluorophenoxy) -5-methylsulfonylamino-1-indanone; ditazol; droxicam; azapropazone; etoclofene; prenazone; 7- [3- (4-acetyl-3-methoxy-2-propylphenoxy)propoxy] -3,4-dihydro-8- propyl-2fi*-l-benzopyran-2-carboxylicacid; W-acetylcysteine; S- carboxymethylcysteine; naphthypramide; flavonoids such as sideritoflavone, cirsiliol, hypolaetin-8-glucoside, hypo- laetin, oroxindin, quercetagetin-7-glucoside, gossypin, hibi- folin, gossypetin and leucocyanidol; tepoxalin, sodium 2- [4- (2-oxocyclopentylmethyl)phenyl]propionate dihydrate, l-[(4- chlorophenyl)methyl] -2-methyl-5- (quinolinylmethoxy) -lH-indole- 3-acetic acid, DL-2- (4-hexyloxyphenyl)glycine octyl ester, DL- 2- [4- (5.5-dimethylhexyloxy)phenyl]glycine octyl ester; and 6- methoxy-2-naphthylacetic acid. Likewise, within the context of the present invention various gastrointestinal anti-inflam¬ matory drugs, antimalarial drugs and antiarthritic/antirheuma- tic drugs as disclosed in the Merck Index. 11th edition (Buda- vari and coworkers, 1989) are regarded as nonsteroidal anti- inflammatory drugs.
Glucocorticoid drugs are well known. A more complete listing of specific examples of such drugs, and of the various forms in which these therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) .
Henceforth reference to sanguinarine will include refer¬ ence to hydrated and salt derivatives thereof, such as for example sanguinarine monohydrate, sanguinarine chloride and sanguinarine chloride dihydrate. Co-agent use of all forms of amino-glycoside, amphenicol, ansamycin, 3-lactam, lincosamide, macrolide, polypeptide and tetracyclme anitbiotics are claimed within the scope of the present invention, as well as use of cycloserine, mupirocin and tuberin. The various forms of these antibiotics are known to those skilled in the art and information regarding them can be found in various reference works, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) . Information regarding nonsteroidal anti-inflammatory drugs recognized for use by local adminis¬ tration or oral administration is known to those skilled in the art and may be found in reference works such as the Physi¬ cians' Desk Reference. 47th edition (Dowd and coworkers, 1993) . Henceforth reference to prednisone will include reference to its pharmaceutically acceptable ester derivatives thereof, such as for example prednisone 21-acetate. Henceforth refer¬ ence to prednisolone will include reference to its pharmaceu¬ tically acceptable ester and salt derivatives thereof, such as for example prednisolone 21-diethylaminoacetate, prednisolone 21-stearoylglycolate, prednisolone 21-tert-butylacetate, prednisolone 21-trimethylacetate, prednisolone 21-acetate, prednisolone sodium succinate, prednisolone sodium 21-m-sulfo- benzoate, and prednisolone sodium phosphate. Henceforth reference to cortisone will include reference to its pharma¬ ceutically acceptable ester and salt derivatives thereof, such as for example cortisone 21-acetate, 21-/S-cyclopentanepropion- ate cortisone, cortisone phosphate, cortisone monosodium phos¬ phate, cortisone disodium phosphate and cortisone phosphate dimethyl ester. Henceforth reference to hydrocortisone will include reference to its pharmaceutically acceptable ester and salt derivatives thereof, such as for example hydrocortisone 21-acetate, hydrocortisone 21-bendazac, hydrocortisone 17- butyrate, hydrocortisone 17-valerate, hydrocortisone tebutate, hydrocortisone 21-sodium succinate, hydrocortisone disodium phosphate and its progenitor, hydrocortisone phosphate. Henceforth reference to methylprednisolone will include refer¬ ence to its pharmaceutically acceptable ester and salt deriva¬ tives thereof, such as for example methylprednisolone 21-acet¬ ate, methylprednisolone sodium 21-succinate and methylpredni¬ solone disodium 21-phosphate. Henceforth reference to triam- cinolone will include reference to its pharmaceutically ac- ceptable ester and ether deri nvatives thereof, such as for example triamcinolone 16α,21-diacetate, triamcinolone aceton- ide, triamcinolone acetonide 21-acetate, triamcinolone aceton- ide di-sodium 21-phosphate, triamcinolone acetonide 21-hemi- succinate, triamcinolone benetonide and triamcinolone' hexace- tonide. Henceforth reference to betamethasone will include reference to its pharmaceutically acceptable ester and salt derivatives thereof, such as for example betamethasone 21- acetate, betamethasone 21-adamantoate, betamethasone 17- benzoate, betamethasone 17,21-dipropionate, betamethasone 17- valerate, betamethasone 17,21-divalerate, betamethasone di¬ sodium phosphate and betamethasone monosodium phosphate. Henceforth reference to dexamethasone will include reference to its pharmaceutically acceptable ester and salt derivatives thereof, such as for example dexamethasone 21-acetate, dexa¬ methasone21- (3,3-dimethylbutyrate) , dexamethasonetetrahydro- phthalate, dexamethasone21-diethylaminoacetate, dexamethasone 21-isonicotinate, dexamethasone17,21-dipropionate, dexametha¬ sone 21-palmitate, dexamethasone 21-phosphate and dexametha¬ sone disodium 21-phosphate. Additional forms of glucocorti- coids are known to those skilled in the art and information regarding them can be found in various reference works, for example, the Merck Index. 11th edition (Budavari and cowork¬ ers, 1989) .
The various forms of anticholinergic drugs such as sco- polamine, trihexyphenidyl, benztropinemesylate, procyclidine, biperiden, ethopropazine, propantheline and oxybutynin are known to those skilled in the art and information regarding them can be found in various reference works, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) .
Salicylic acid is recognized as being both an antiseptic and a keratolytic agent (Budavari and coworkers, 1989) .
Based on its clinical and structural similarities to D- penicilla ine, 5-thiopyridoxine may be regarded within the context of the present invention as an example of a non¬ steroidal anti-inflammatory drug which may be useful in the treatment of rheumatoid arthritis.
Immunomodulator substances as defined within the context of the present invention include, for example, those noted in /Y
Budavari and coworkers (1989, pg. THER-25) , as well as leflu- nomide, diaveridine, apocynin, l-p-chlorobenzyl-2-dimethyl- aminomethylcyclohexen-1,2, (Z) -3- [4- (acetyloxy) -5-ethyl-3- methoxy-1-naphthalenyl] -2-methyl-2-propenoic acid, diacetyl- splenopentin, solubilized chicken type II collagen, 'dapsone, capsaicin, (10-methoxy-4H-benzo[4,5] -cyclohepta- [1,2-b] -thio- phene-4-yliden)acetic acid, eicosapentaenoic acid, lobenzarit, tiopronin (also known as iV-2-mercaptopropionylglycine) , teni- dap, diacetylrhein, interferons, copolymer-1 and 2,6-Diamino- N- { [1- (1-oxotridecyl) -2-piperidinyl]methyl}hexanamide, tilomi- sole, indoxole, bi etopyrol, flumizole, scalaradial, kojic acid, misoprostol, 1- [3- (naphth-2-ylmethoxy)phenyl] -1- (thiazol-2-yl)propyl methyl ether, and 4- (2-chlorophenyl) -2- [2- (4-isobutylphenyl) -ethyl] -6, 9-dimethyl-6tf-thieno[3,2- f] [1,2,4]triazolo- [4,3a] [1,4] -diazepine.
Hydroxychloroquine, quinacrine, chloroquine and amodia- quine are examples of antimalarial drugs in the present in¬ vention. A more complete listing of specific examples of this group, and of the various forms in which the respective thera¬ peutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) .
Within the context of the present invention, diazepam and lorazepam are regarded as anxiolytic drugs of the benzodiaze- pine variety. A more complete listing of specific examples of benzodiazepine anxiolytic drugs, and of the various forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) . Carbamazepine, clonazepam, ethosuximide, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, vigabatrin and zonisamide are anticonvulsant drugs. Likewise, as phenytoin-polyvinylpyrrolidone coprecipitate releases phenytoin in vivo, this drug may also be regarded within the context of this invention as an example of an anticonvulsant drug. As acetazolamide is regarded as an al¬ ternative to ethosuximide, clonazepam or valproate for treat¬ ment of petit mal seizures, this drug and its sodium salt derivative may also be regarded as examples of anticonvulsant drugs within the context of t /hTe present invention. A more complete listing of specific examples of anti-convulsant drugs, and of the various forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index, 11th edition (Budavari and coworkers, 1989) .
Captopril and ketanserin are examples of antihypertensive drugs. A more complete listing of specific examples of anti- hypertensive drugs which may be useful in the treatment of Alzheimer's disease as defined herein, and of the various forms in which the respective therapeutic agents may be admin¬ istered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) .
Henceforth reference to ephedrine will include reference to derivatives thereof, such as, for example, ephedrine hydro- chloride, ephedrine sulfate and ephedrine tannate. Pyrido- stigmine and neostigmine are cholinergic drugs. A more com¬ plete listing of specific examples of cholinergic drugs, and of the various forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) . Atropine and propan- theline are anticholinergic drugs. A more complete listing of specific examples of anticholinergic drugs, and of the various forms in which the respective therapeutic agents may be admin¬ istered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) .
Baclofen and tizanidine are skeletal muscle relaxant drugs. A more complete listing of specific examples of skeletal muscle relaxant drugs, and of the various forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) . Amitriptyline and imipramine are tricyclic anti-depressant drugs. A more complete listing of specific examples of tricyclic antidepressant drugs, and of the vari¬ ous forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index, 11th edition (Budavari and coworkers, 1989) .
Cyproheptadine is an example of an antihistaminic drug of the tricyclic variety, and clemastine and setastine are exam¬ ples of anti-histaminic drugs of the aminoalkyl ether variety. A more complete listing of specific examples of antihistaminic drugs, and of the various forms in which the respective thera¬ peutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index, 11th edition (Budavari and coworkers, 1989) .
A more complete listing of specific examples of antico¬ agulant drugs beyond those disclosed below, and of the various forms in which the respective therapeutic agents may be admin¬ istered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) . Tissue plasminogen activator and strep- tokinase are thrombolytic drugs. Likewise, a more complete listing of specific examples of thrombolytic drugs than those disclosed below, and of the various forms in which the re¬ spective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Budavari and coworkers, 1989) .
Aminophylline is a member of the xanthine derivative class of bronchodilators. Isoproterenol is a member of the ephedrine class of bronchodilators. A more complete listing of specific examples of bronchodilator drugs, and of the various forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index. 11th edition (Bu¬ davari and coworkers, 1989) . Within the context of the pres¬ ent invention, aminophylline, isoproterenol and methohexital sodium may be regarded as examples of antithrombόtic drugs.
The various forms of S-adrenergic blockers are known to those skilled in the art and information regarding them can be found in various reference works, for example, the Merck Index, 11th edition (Budavari and coworkers, 1989) . The various forms of calcium channel blockers are known to those skilled in the art and information regarding them can be found in various reference works, for example, the Merck Index, llth edition (Budavari and coworkers, 1989) . Glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate are examples of antianginal drugs. A more complete listing of specific examples of antianginal drugs, and of the various forms in which the respective therapeutic agents may be administered, can be found in various well known reference works such as, for example, the Merck Index, llth edition (Budavari and coworkers, 1989) .
SUMMARY OF THE INVENTION
These and other objects of this invention are achieved by pro¬ viding a novel method and compositions for clinical treatment of chronic inflammatory diseases. This invention involves use of orally administered amine derivatives of benzoic acid and partially or fully saturated analogs as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone prod¬ ucts of lipid peroxidation. Increased levels of lipid perox¬ idation have been repeatedly demonstrated as a part of the "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary absorbable pharma¬ cological agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group which should react with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The present invention is directed to the use of carbonyl sequestering agents administered in oral dosages, optionally in combination with co-agents consisting of clinically effective anti-oxidant free radical trapping agents and agents related thereto, and in combination with medicaments so as to produce a physiologi¬ cal effect of an anti-inflammatory nature. Optional co-agents of the present invention include anti-oxidants (e.g., alpha- tocopherol) , suspending reagents (e.g., carboxymethyl cellu¬ lose) , other vitamins, vitamin-related agents, chemical con¬ jugating agents which may facilitate kidney drug elimination (e.g., glycine) , and orally administered non-absorbable /f polyamine or polyamine-related agents (e.g., chitosan or cholestyramine) . Particular additional medicaments useful in the present invention are disclosed herein.
OBJECTS OF THE INVENTION
Accordingly, it is a general object of this invention to treat chronic inflammatory diseases by use of compositions comprising carbonyl trapping agents optionally but preferably in combination with known anti-oxidant free radical trapping co-agents, factors related to anti-oxidant free radical trap¬ ping co-agents, and additionally with known medicaments, so as to create compositions with additive or synergistic physiolog¬ ical therapeutic characteristics and so as to overcome the disadvantages of the prior art.
It is a further object of this invention to facilitate the effectiveness of this anti-inflammatory procedure by use of orally consumed carbonyl trapping polymeric co-agents which are of a nonabsorbable nature, so as to bind and sequester carbonyl chemical agents which are present in food, thus pre¬ venting such toxic agents from being absorbed into the body.
In particular, it is an object of the present invention to use absorbable amine primary agents; optional nonabsorb¬ able amine polymeric co-agents, co-agents which inhibit lipid peroxidation, vitamin co-agents which may be inadvertently depleted, co-agent metabolites such as glycine which may be depleted within the body, sulfhydryl co-agents as defined herein, co-agents which may facilitate glutathione activity; and various additional known medicament co-agents which have been shown to or may contribute to the alleviation of symptom- ology of the diseases addressed herein, thus improving upon the prior art.
It is an object of the present invention to provide compositions that may be used to provide increased clinical value in the treatment of disease sy ptomology for disorders featuring lipid peroxidation and resultant formation of toxic carbonyl compounds, including: chronic gingivitis; chronic periodontitis; chronic autoimmune gastritis; ileitis; inflam¬ matory bowel disease, including colitis; interstitial cysti¬ tis; psoriasis; arthritis; tendinitis; carpel tunnel syndrome and other cumulative trauma di ts9orders; lupus erythematosus; pneumoconiosis; chronic obstructive pulmonary disease; inflam¬ matory myopathies; inflammatory neuropathies, including Alz¬ heimer's disease, myasthenia gravis and multiple sclerosis; epilepsy; as well as lessening of inflammatory site edema, and treatment of post-event ischemia and reperfusion symptomology resulting from acute central nervous system trauma, stroke, kidney ischemia or myocardial infarction.
It is another object of the present invention that in so far as the therapeutic procedures described herein may serve to delay the necessity of initiating the use of known medica¬ ments or to decrease the dosages of known medicaments required to achieve beneficial effects, the period of prior art drug therapeutic value may be extended and detrimental clinical side effects resulting from use of known medicaments may be decreased, so that overall patient treatment may be improved.
It is a further object of this invention that the absorb¬ able amine and amine-related substances and derivatives there¬ of described herein when used in combination with specified co-agents may be clinically applied to treat veterinary dis¬ orders comparable to at least some of those human disorders described above.
These and other objects of the present invention will be apparent from the following detailed description.
DETAILED STATEMENT OF THE INVENTION
It is known that aldehyde chemical metabolites, which contain carbonyl functional groups, are generated during the process of chronic inflammation. These aldehyde products result from pathologically increased lipid peroxidation, which may be initiated by a variety of activated oxygen chemical species such as the hydroxyl radical, HO- (Halliwell and Gut- teridge, 1985, pp. 119-120) . The reactive cascade of free radical propagation -> lipid peroxidation -> aldehyde forma¬ tion and other subsequent effects of inflammation is well documented in the prior art (Halliwell and Gutteridge, 1985, pp. 102-103) . The secondary carbonyl products of lipid peroxidation include saturated and unsaturated aldehydes, dialdehydes, epoxyaldehydes, lactones, furans, ketones and oxo acids (Merry and coworkers, 1999-01, pg. 362S) . As reactive oxygen species are generated in vivo during states of limited oxygen availability, followed by reperfusion, a similar series of reactions takes place at sites of hypoxia/reperfusion injury (Demopoulos and coworkers, 1980; Dowling and coworkers, 1990, pg. 465) . Aldehyde products of this reactive cascade are known to react with amino acids to form Schiff bases, and to react with free amino groups of proteins, nucleic acids and phospholipids (Hatherill and coworkers, 1991, pg. 352) .
Prior to submission of my above-cited US patent applica¬ tion, the method concept of using carbonyl-trapping agents such as primary amine or amine-related derivatives of benzoic acid to treat chronic inflammatory diseases was not recognized or disclosed. Thus, the application of this principle in con¬ junction with use of known anti-oxidant free radical trapping agents to produce new and novel compositions which have improved, synergistic therapeutic properties also was not recognized.
The invention embodied herein is based on use of a com¬ position of a primary amine derivative as defined herein as a primary agent for chemically binding to and sequestering alde¬ hyde products of inflammation site lipid peroxidation together with a medicament, and optionally their use in combination with anti-oxidant free radical trapping co-agents. This unique, multiple-level approach to interference with certain steps in the inflammatory cascade has not been previously recognized by other research investigators. This is, in fact, the first anti-inflammatory agent invention which addresses the issue of aldehyde formation at inflammation sites. As aldehydes are highly reactive molecules capable of reacting with proteins, lipids and nucleic acids (Jellum and coworkers, 1973, pg. 200; Carden and coworkers, 1986; Halliwell and Gut- teridge, 1985, pg. 123) , their increased formation at inflam¬ mation sites can be a significant contributing factor in the evolution of the clinical pathology of inflammatory disorders.
The results of several published research studies suggest that dysfunctional lipid peroxidation may be a contributing factor in the etiology of a variety of chronic inflammatory diseases, such as rheumatoid arthritis (Jasin, 1993; Merry and coworkers, 1991; Panetta and coworkers, 1991; Rowley and coworkers, 1984) , multiple sclerosis (Hunter and coworkers, 1985) , silicosis (Katsnelson and coworkers, 1989, pg. 318) , Duchenne muscular dystrophy (Kar and Pearson, 1979; Jackson and coworkers, 1984) , colitis (Tamai and coworkers, 1992) and chronic inflammatory bowel disease (Ahnfelt-Ronne and cowork¬ ers, 1990) . As exposure to asbestos fibers can stimulate lipid peroxidation (Halliwell and Gutteridge, 1985, pg. 152) and a chronic inflammatory response (Rom and coworkers, 1991, pg. 415) , asbestosis should also be included in this category. Published evidence has also documented the generation of high free radical concentrations at the inflamed site of experi¬ mental foot pad edema (Dowling and coworkers, 1990, pg. 464), the ability of carbonyl compounds resulting from lipid peroxi¬ dation to induce foot edema in the rat (Benedetti and cowork¬ ers, 1980) , and that formaldehyde is known to be an inflamma¬ tory and edematogenic agent (Wheeler-Aceto and Cowan, 1991) . In addition, a role for reactive oxygen radicals has been proposed for numerous other disorders, including inflammatory vasculitis, emphysema, mineral dust pneumoconiosis and auto¬ immune nephrotic syndromes (Halliwell and Grootveld, 1987, pg. 10) .
Ischemia/reperfusion damage to various tissues appears to occur by a common mechanism, involving generation of free radicals and lipid peroxidation (Fleckenstein and coworkers, 1991) . Increased lipid peroxidation has also been demon¬ strated in acute central nervous system trauma (Hall, 1987, pgs. 421 and 424; Demopoulos and coworkers, 1980, pgs. 97 and 112; Kontos and coworkers, 1981, pg. 2329), as a result of stroke (Zivin and Choi, 1991, pg. 61) , subsequent to myocardi¬ al infarction (Kurdin, 1978) and in an experimental model of myocardial ischemia (Siminiak and Wysocki, 1992) . Increased lipid peroxidation under such circumstances appears to be initiated by extravasation of blood, as iron-containing substances such as hematin catalytically accelerate lipid autoxidation (Demopoulos and coworkers, 1980, pgs. 97 and 115) . Status epilepticus has also been linked to increased intracellular concentrations of free radicals, with subsequent lipid peroxidation (Del Maestro, 1980, pg. 163) . Recent studies have also disclosed the possibility that the etiology of Alzheimer's disease may include an autoimmune component, thus establishing a conceptual link to disorders such as rheumatoid arthritis and systemic lupus erythematosus (Saso and coworkers, 1993) . Evidence of an etiological role for lipid peroxidation in Alzheimer's disease has been dis¬ closed (Ceballos and coworkers, 1990) .
It is further understood that oral use of nonabsorbable carbonyl trapping agents may serve to prevent absorption of dietary aldehydes and ketones from the alimentary tract into the body, thus complementing the intended therapeutic results, (i) Mechanism of Action of Primary Agents
For the most part, these pharmacological reactions are based on the ability of the primary amine compounds of the present invention to react with aldehyde functional groups of potentially toxic agents, yielding covalently bound Schiff base products. Several examples of chemically analogous reactions, presented within other contexts, have been publicly presented (Holdren and Hixon, 1946; Sawicki and coworkers, 1963; Chio and Tappel, 1969; Dunlop and Peters, 1953, pgs. 353, 371 and 373) . These model chemical systems are directly analogous to the mechanism of drug action which is the basis of the present invention.
Additionally, self-polymerization of o-aminobenzaldehyde has been described. In the 1994 edition of the Sigma Chemical Company catalog of biochemical reagents the following state¬ ment appears on page 90 of its listing: "o-A INOBENZALDEHYDE Unstable! [store at] -20°C Polymerizes rapidly when exposed to room temperature. May yield slightly hazy solution in ethanol due to presence of a small amount of polymer. Shipped in dry ice." This information directly indicates that a primary amino group covalently linked to a benzene ring possesses sufficient reactivity for significant reaction with aldehyde functional groups at room temperature. It is apparent that no form of activation of the amino group is required and that a Schiff base product forms readily.
Comments by Feeney and coworkers (1975, pg. 141) provide an appropriate summary of this prior art:
A wide variety of substances with -NH2 groups con- 9-3 dense with carbonyl compounds...This condensation of primary amines with aldehydes and ketones to give imines was first discovered by Schiff (1900) . The overall equilibrium greatly favors hydrolysis in aqueous solution for aliphatic aldehydes. With aromatic aldehydes, the equilibrium is shifted in favor of Schiff base formation. It is important to note that increasing the nucleophilic strength of the amine will increase the rate of the carbonyl- a ine reaction but will have almost no effect on the position of the equilibrium.
These comments suggest that the amine-containing carbon¬ yl-trapping drugs described herein should have particular ■promise for binding furanaldehydes, which are aromatic. These comments also suggest that doses of absorbable amine drugs may require in vivo concentrations in the range of 1:100 to 1:1,000 (carbonyl:amine) in order to achieve clinical effec¬ tiveness. This, in turn, suggests that therapeutic dosages may lie in the range of grams per day and that only drugs of particularly low toxicity will have human applications.
Feeney and coworkers (1975, pg. 144) also noted the phenomenon of Schiff base transimination, which occurs to a significant extent at neutral pH:
The existence of such non-enzymatic reversible trans¬ imination reactions is important within the context of this invention, as it suggests that in vivo both bound carbonyl agents, in addition to free carbonyl agents, may be se¬ questered by amine-containing drugs.
The small molecular weight, absorbable, primary amine compounds described herein have analogous behavior in vivo, as well as an additional characteristic which facilitates dispos¬ al as urine metabolites. All of these compounds contain a carboxylic acid group to facilitate uptake and processing by the kidneys. The metabolic fate of PABA in humans has been actively investigated and well reported in the biomedical literature (Young and coworkers, 1971; Howie and Bourke, 1979) . It is so actively metabolized via several mechanisms and quantitatively removed in urine (Bingham and Cummings, 1983; Weizman and coworkers, 1985) that PABA excretion has become a widely recognized standard for measuring urinary clearance. Small amounts of PABA are normally present in the human diet. It is recognized as being a vitamin for many organisms and is clas¬ sified as a member of the vitamin B complex (Scott and Rob- bins, 1942; Winitz and coworkers, 1970, pgs. 527-528; Smith, 1976, pg. 194) . As a vitamin for human use PABA is commer¬ cially marketed in the dosage range of 5 to 550 mg/day. (ii) Examples of Absorbable Drug Primary Agents
Primary agents of this invention are selected from the group consisting of six-carbon cyclic compounds containing a primary amino substituent group and a carboxylic substituent group wherein the carbon ring can be phenyl, cyclohexane, cyclohexene or cyclohexadiene. The carboxyl group can be attached directly to the carbon ring, or can be separated from the ring by one carbon atom. The primary amino group can be attached directly to the carbon ring, or it can be part of a larger functional group that is a substituent of the ring, either in the omega position or at some intermediate point in the larger functional group. The primary amino group may be attached to the six-member carbon ring at the p-, o- or m- position relative to the carboxyl substituent group. p-Amino- benzoic acid (PABA) is an example of this group. p-Amino- benzoic acid is known as a water-soluble B vitamin, and sever¬ al published studies have presented evidence to the effect that PABA functions, in part, as a weak anti-oxidant and a weak free radical trapping agent (Maksimov and Rebachuk, 1985, Table 2; Pryor and coworkers, 1976, pg. 201) . In so far as benzoic acid or derivatives thereof have been recognized as anti-oxidants or free radical trapping agents, their mechanism of action is understood to consist of hydroxyl radical trap¬ ping by the benzene ring (Grootveld and Halliwell, 1988; Hal¬ liwell and Gutteridge, 1985, pgs. 105 and 130; Richmond and coworkers, 1981; Repine and coworkers, 1979, pg. 1642) . This has been explicitly demonstrated for PABA (Nakken, 1964, pgs. 446, 448, 454-457; Nakken and Pihl, 1966, pgs. 21, 22, 24, 25 and 28) .
In addition to any carboxylic acid primary agent listed herein as useful in the present invention, the pharmaceuti¬ cally acceptable salt forms, pharmaceutically acceptable ester and amide derivatives thereof are useful. The class of pri¬ mary agents of the present invention are water soluble com¬ pounds (molecular weight range 100 to 1,400) of the formula:
wherein Rx is -NH2; -aminoalkyl having 1-10 carbons; -NHC(=NH)NH2; - (CH2)nNHC(=NH)NH2 wherein n is 1-10; C(=NH)NH2;
- (CH2)n-CH=NC(=NH)NH2 wherein n is 1-10; -NHC(=NH)NHNH2;
- (CH2)nNHC(=NH)NHNH2 wherein n is 1-10; - (CH2)n-CH=NC(=NH)NHNH2 wherein n is 1-10; -NHNHC(=NH)NH2; - (CH2)n-NHNHC(=NH)NH2 wherein n is 1-10; and - (CH2)n-CH=N-NHC(=NH)NH2 wherein n is
1-10.
R2 is H; -OH; -0-CH3; -O-R' wherein R' is alkyl of 2-10 carbons; aminoalkyl wherein the alkyl group is 1-10 carbons; -S03H; -CH3; and -(CH2)rCH3 wherein n is 1-10;
R' and R" are -H, OH or CH3; and n is 0 or 1.
These compounds are used in the compositions of the present invention in dosage levels of from 600 mg to about 20 gm per day in one or more divided doses, preferably from about 1 gm to about 20 gm per day, more preferably from about 3 gm to about 20 gm per day, and most preferably from about 6 gm to about 20 gm per day. Alternatively expressed, the dosage of these compounds is in the range of 15 mg/kg daily to about 800 mg/kg daily, preferably 30 mg/kg daily to about 800 mg/kg, more preferably 60 mg/kg daily to about 800mg/kg, and most preferably 120 mg/kg daily to about 800 mg/kg. (iii) Mechanism of Action of Nonabsorbable Primary Amine and Amine-Related Polymeric Co-Agents The presence of aldehydes and ketones in the human diet (Dunlop and Peters, 1953, pgs. 280, 308 and 403; Rice, 1972; Schauenstein and Esterbauer, 1977, pgs. 181-194; Shimizu and Watanabe, 1979; Baltes, 1985; Lever and coworkers, 1985) may be a factor which may put a patient suffering from a' chronic inflammatory disease further at risk. This might be especial¬ ly important for victims of chronic autoimmune gastritis, ileitis and colitis, as the damaging effects of inflammation site carbonyl compounds may be accentuated by direct exposure to dietary carbonyl agents.
As such, it is apparent that the diet is a significant source of carbonyl agents, and their presence may be a con¬ tributing factor in the etiology of chronic inflammatory dis¬ eases. Toxic properties of furanaldehyde derivatives have been demonstrated in both in vivo and in vitro studies (Konecki and coworkers, 1974; Ulbricht and coworkers, 1984) . The nonabsorbable dietary supplements such as those defined below can be of health benefit by virtue of their ability to covalently trap dietary aldehydes and ketones. The agents described in this section can accomplish this function because they bear primary amine groups or derivatives thereof. As large molecular weight molecules which are non-digestible they have the capacity to pass through the digestive tract, acting in effect as another form of dietary fiber. These nonabsorb¬ able polyamine trapping substances may be divided into three classes; naturally occurringpolyamine polysaccharides, chemi¬ cal derivatives of naturally occurring polysaccharides, and synthetic polyamine polymers.
The fate of malondialdehyde given orally to rats may serve as an example of the metabolism of dietary aldehydes, and how an understanding of this process can be used to define nonabsorbable carbonyl-trapping drugs. Studies by Draper and coworkers (1986) demonstrated that the primary form of "bound" MDA in rat or human urine is N-α-acetyl- e - (2-propenal)lysine. This is the biologically acetylated derivative of the MDA- lysine adduct N- e - (2-propenal)lysine. Draper and coworkers (1986) were able to generate N- e - (2-propenal)lysine in vitro by exposing beef muscle protein to MDA, followed by treatment with pepsin and hog intestinal juice. This indicates that the e-amino groups of dietary protein lysine residues can coval¬ ently bind dietary aldehyde under conditions found in the intestinal tract. As such, chemically analogous primary amine groups on nonabsorbable drugs should also be capable of coval¬ ently binding dietary aldehydes under conditions to'be found in the intestinal tract. In this case, however, the bound carbonyl species would be excreted in the feces, thus prevent¬ ing subsequent in vivo exposure to dietary carbonyl agents.
In their study Draper and coworkers noted that N- - acetyl-e- (2-propenal) lysine was found in urine of fasted rats or animals fed on MDA-free diets, indicating that the MDA- lysine adduct also forms n vivo. These investigators re¬ ferred to earlier work which demonstrated that the MDA con¬ centration normally found in food is in the range of <0.1 to 10 ppm (0.1 to 10 μM) , which gives some idea of dietary aldehyde concentrations.
(iv) Examples of Nonabsorbable Drug Products Useful in the Method of the Present Invention
(a) Naturally Occurring Amine-Containing Polysaccharides Any naturally occurring polysaccharide featuring β-1,2, S-1,3, S-1,4 and/or β-1,6 linkages which contains aminosugars may be regarded as a non-digestible, potentially active car¬ bonyl trapping agent. The chitin class of biopolymers may be cited as an example of such an agent, having the general structure of poly-S- (l->4) -W-acetyl-D-glucosa ine A form of microcrystalline chitin has been described in which some of the acetyl groups have been removed, revealing free amine groups (Austin and coworkers, 1981, pg. 750) . Chitins obtained from different sources feature different degrees of amine deacetylation (Austin and coworkers, 1981, pg. 752) .
(b) Chemical Derivatives of Naturally Occurring
Polysaccharides Various pretreatment procedures may be applied to natur¬ ally occurring polysaccharides prior to generation of chemical derivatives. Generation of microcrystalline polysaccharides is one example of such a pretreatment procedure. As applied to cellulose or chitin (Yalpani, 1988, pg. 389), this yields a colloidal processed form of polysaccharide featuring high porosity and enhanced susceptibility to chemical reactions. Generation of "microfibrillated" cellulose or chitin is another example of a pretreatment procedure which produces enhanced surface area, increased water retention capacity and enhanced chemical accessibility (Yalpani, 1988, pg. 39O) . Use of strong (> 18%) sodium hydroxide is still another recognized pretreatment, or activation, procedure found to be helpful as a starting point for preparing chemical derivatives of poly¬ saccharides (Yalpani, 1988, pg. 214) .
(b) (1) Deacetylation of Naturally Occurring Polysaccharides. A variety of polysaccharides have been identified which are rich in iV-acetylated residues. Upon chemical deacetyla¬ tion these carbohydrates yield high molecular weight deriva¬ tives bearing primary amine groups directly linked to sugar carbons, that is, no sidearm spacer units present, i. Chitosan. This is the deacylated form of chitin. As des¬ cribed in the Merck Index (Budavari and coworkers, 1989, pg. 316) chitin is a cellulose-like biopolymer the composition of which consists mostly of JV-acetyl-D-glucosamine residues covalvently linked by β-1,4 bonds. Chemical deacylation re¬ moves acetate, generating primary amine groups still covalent¬ ly bound to the polysaccharide. Chitosan has recognized uses in water treatment, in photographic emulsions, and in improv¬ ing the dyability of synthetic fabrics and fibers. The free amine groups in this substance also give it chelating proper¬ ties (Austin and coworkers, 1981) . ii. Chondroitin sulfate. This is a mucopolysaccharide found commonly in mammalian tissue. It consists of repeating disac- charide units, each of which has a D-glucuronic acid residue jS-1,4 linked to an jV-acetylchondrosine residue (Budavari and coworkers, 1989, pg. 344) . iii. Hyaluronic acid. This mucopolysaccharide is also found commonly in mammalian tissues. It consists of glucuronic acid and glucosamine residues bound by /S-1,3 and S-1,4 linkages (Budavari and coworkers, 1989, pp. 751-752) . iv. Keratan sulfate. This mammalian glycosaminoglycan con¬ sists of a repeating disaccharide unit of a C-6 sulfated C-2 N-acetylated sugar residue and a galactose residue linked by S-1,4 bonds (Yalpani, 1988, pp. 27-28) . (b) (2) Chemical Amination of Polysaccharides i. 2-Amino-2-deoxycellulose. Cellulose can be aminated by a process of selective oxidation, oximation and subsequent reduction with lithium aluminum hydride (Yalpani, 1988, pp. 281-282) . ii. Alternative amination procedures. Aminodeoxy polysac¬ charides can also be prepared via azide or hydrazide inter¬ mediates or by reductive amination using sodium cyanoboro- hydride (Yalpani, 1988, pg. 281) . Besides being applied to cellulose, other non-digestible polysaccharides such as curdlan (Yalpani, 1988, pg. 22) may be aminated by such chemical procedures. iii. 3-Aminopropylcellulose. Reaction of cyanoethylcellulose with borane-tetrahydrofuran or borane-dimethyl sulfide com¬ plexes in tetrahydrofuran generates 3-aminopropylcellulose (Yalpani, 1988, pgs. 250 and 255) . In this derivative each primary amine group is at the end of a three carbon sidearm. iv. Aminoethylcellulose. This chemical has been previously marketed as an anion exchange column chromatography resin (Sigma Chemical Co. catalog, Feb. 1981) and used as such in protein purification studies (Fasold, 1975, pp 481-482) . v. Other aminoalkyl-, amino(hydroxyalkyl) -, aminoalkyl-ether- and amino(hydroxyalkyl) -ether- derivatives of cellulose, chi¬ tin and other naturally occurring non-digestible carbohy¬ drates. Noting that the chemical methodology for producing such derivatives is documented in public domain literature, the biomedical application of such derivatives for therapeutic purposes described herein is also claimed. This would include: aminoalkyl derivatives of the formula
H2N- (CH2)_,- [carbohydrate] where n = 1 - 30, including alkyl isomers; amino(hydroxyalkyl) - derivatives of the formula
H2N- (CH2)a-CHOH- (CH2)a- [carbohydrate] , where m = 0 - 15 n = 0 - 15; aminoalkyl-ether- derivatives of the formula
H2N- (CH2)a-0- [carbohydrate] , where n = 1 - 30; and amino(hydroxyaklyl) -ether- derivatives of the formula
H2N-(CH2)-.-CHOH-(CH2)n-0- [carbohydrate] , where m = 0 - 15 Jό n = 0 - 15 vi. Aminobenzyl- derivatives of cellulose, chitin or other naturally occurring non-digestible carbohydrates. As the aro¬ matic amine group is a weaker base than its aliphatic counter¬ part, this class of nonabsorbable amines should be less chemi¬ cally active than amino- and aminoalkyl- derivatives described above. These derivatives are of the following general structures:
H2N-C6H4- (CH2)n- [carbohydrate] ,
H2N-CH2-CSH4- (CH2)n- [carbohydrate] ,
H2N-C6H4- (CH2)n-0- [carbohydrate] where n = 0 - 30, and
H2N-C6H4-(CH2)B-CHOH-(CH2)n-0- [carbohydrate]where m = 0-15 n = 0-15 This includes p-, o- and m-benzene ring amino- and aminomethyl- isomers, and alkyl group isomers. vii. guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring nonabsorbable carbo¬ hydrates selected from the group consisting of:
H2N-C(=NH) - [carbohydrate] ;
H2N-C(=NH) - (CH2)n- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -O- (CH2)n- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydrox¬ ylated derivatives thereof;
H2N-C(=NH) -NH- [carbohydrate] ;
H2N-C(=NH)-NH-(CH2)n- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-NH- (CH2)n-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-N=CH-(CH2)n- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-N=CH-(CH2)n-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof;
H-N-NHC(=NH) -NH- [carbohydrate] ; H2N-NHC(=NH)-NH-(CH2)n- [caarrbboohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-NHC(=NH)-NH-(CH2)B-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-NHC(=NH)-N-=CH-(CH2)n- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-NHC(=NH) -N=CH- (CH2)n-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hy¬ droxylated derivatives thereof;
H2N-C(=NH) -NH-NH- [carbohydrate] ;
H2N-C(=NH) -NH-NH-(CH2)n- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -NH-NH-(CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-NH-N=CH- (CH2)n- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-C(=NH)-NH-N=CH-(CH2)n-0- [carbohydrate] , where n = 1- 10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; (b) (3) Aminated Sucrose Polyesters
Mixtures of fatty acid hexa-, hepta- and octaesters of sucrose, known as sucrose polyester, are not hydrolyzed by pancreatic lipase enzymes and are not absorbed in the intes¬ tine (Jandacek, 1984) . It is disclosed and claimed herein that primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters are of benefit in reduction of dietary carbonyl substances, analogous to the proposed action of other nonabsorbable agents described herein. Such derivatives of sucrose polyesters would include structures in which the carbonyl trapping functional group is in the ω-, ω-1 or other isomeric position(s) within the fatty acyl chains, fatty acyl chains having more than one nitrogen functional group and fatty acyl chains having hydroxyl groups. Such aminated 3 ^ sucrose polyesters may be used in pure form as a dietary supplement, or may be prepared as a coating on a particulate carrier such as, for example, cellulose or styrene divinyl- benzene copolymer resin, (c) Synthetic Polyamine Polymers
(c) (1) Synthetic polysaccharides consisting partly or entire¬ ly of aminosugars bound by S-1,2, β-1,3, /S-1,4 and/or jS-1,6 linkages may be regarded as nonabsorbable carbonyl trapping agents.
(c) (2) Mixed polysaccharide polymeric derivatives. Primary amine, aminoalkyl (one to ten carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, amino- guanidinyl-alkyl (one to ten carbons per alkyl group) , amino- alkylguanidinyl (one to ten carbons per alkyl group) , guani- dine, aminobenzene and aminoalkylbenzene (one to ten carbons per alkyl group) functional groups may be covalently attached to matrices such as, for example, epi-chlorohydrin copolymers of cellulose or chitin. Functional group spacer groups may include alkene as well as alkyl groups.
(c) (3) Non-polysaccharide polymeric derivatives. Primary amine, aminoalkyl (one to ten carbons per alkyl group) , aminohydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, aminoguanidinylalkyl (one to ten carbons per alkyl group) , aminoalkylguanidinyl (one to ten carbons per alkyl group) , guanidine, aminobenzene and aminoalkylbenzene (one to ten carbons per alkyl group) functional groups may be covalently attached to a wide variety of synthetic non-digestible poly¬ mers. Functional group spacer groups may include alkene as well as alkyl groups. Like their sugar-based counterparts, these agents should be capable of reacting with dietary carbonyl compounds. Nitrogen-containing functional groups may be covalently attached to synthetic supports such as, for example, polystyrene, styrene-divinylbenzene copolymer, poly- vinyl alcohol and crosslinked derivatives thereof.
These nonabsorbable polyamine compounds that sequester carbonyl substances present in the diet are used in the compo¬ sitions of the present invention in dosage levels of from 600 mg to about 20 gm per day i .n o 3ne 3or more divided doses, pre¬ ferably from about 1 gm to about 20 gm per day, more prefer¬ ably from about 3 gm to about 20 gm per day, and most prefer¬ ably from about 6 gm to about 20 gm per day. Alternatively expressed, the dosage of these compounds is in the range of 15 mg/kg daily to about 800 mg/kg daily, preferably 30 mg/kg daily to about 800 mg/kg, more preferably 60 mg/kg daily to about 800mg/kg, and most preferably 120 mg/kg daily to about 800 mg/kg. (v) Co-Administration of Anti-Oxidants and Lipid Peroxidation
Inhibitors
As regards the use of anti-oxidant and lipid peroxidation inhibitor co-agents, vitamin co-agents, co-agents which are metabolites at risk of depletion, sulfhydryl co-agents, and co-agents which may facilitate glutathione activity, it is assumed herein that these substances are administered orally unless stated otherwise. Dosage ranges for these co-agents refer to human use and may be adjusted accordingly for use by other mammals on a per kilogram basis. It is claimed herein that the therapeutic value of the primary amine agents of the present invention can be maximized by administration in conjunction with recognized anti-oxidant free radical trapping compounds such as α-tocopherol (Ferrari and coworkers, 1991, pg. 97S; Stuckey, 1968, pp. 214-215), dosage range from 100 I. U. daily to 3,500 I. U. daily, or other agents previously recognized as adjunts which facilitate in vivo capability to inhibit lipid peroxidation. The dosage range noted above for α-tocopherol is also claimed for other vitamin E derivatives such as jβ-tocopherol, γ-tocopher-ol, δ-tocopherol, e-toco- pherol, ^-tocopherol, f2-tocopherol and 17-tocopherol, as well as ester derivatives thereof such as the corresponding acet¬ ate, succinate and nicotinate forms.
Citric acid, dosage range from 200 mg daily to 20 gm daily, may be included in this catagory of co-administered agents, as it is recognized as having anti-oxidant properties (Merck Index. Budavari, 1989, pg. 363) . Alternatively, this co-agent may be consumed as a combination of potassium citrate monohydrate and citric acid monohydrate in a weight ratio of 3.3 to 1, or other weight ratio selected so as to alkalinize ^ a composition. Citric acid is also recognized as an inhibitor of Maillard reactions (Stuckey, 1968, pg. 210) .
In a published list of agents which function to supple¬ ment the chain-breaking anti-oxidant property of vitamin E, Tappel (1970, pg. 1138) mentioned ubiquinol, seleho-amino acids and sulfhydryl compounds (e.g., glutathione, sulfhydryl proteins, cysteine and methionine) . An intravenous, intra¬ muscular, subcutaneous or oral dosage range from 10 mg daily to 500 mg daily for the class of ubiquinols, coenzyme Qn where n = 1 - 12, is proposed herein. An intravenous, intramuscu¬ lar, subcutaneous or oral dosage range from 10 mg daily to 500 mg daily for glutathione is proposed herein. Other substances in this general group include butylated-hydroxytoluene (Frank- el, 1987, pg. 81) , dosage range from 10 mg daily to 1 gm daily; butylated hydroxyanisole (Sies, 1991, pg. 32S) , dosage range from 5 mg daily to 40 mg daily; propyl gallate (Verhagen and coworkers, 1991, pg. 113) , dosage range from 10 mg daily to 1 gm daily; dodecylgallate (Verhagen and coworkers, 1991, pg. 113) , dosage range from 10 mg daily to 1 gm daily; tert- butylhydroquinone (Verhagen and coworkers, 1991, pg. 113) , dosage range from 10 mg daily to 1 gm daily; β-carotene, dosage range from 20 mg daily to 300 mg daily (Frankel, 1987, pg. 82); dihydrolipoic acid (Sies, 1991, pgs. 33S and 36S) , intravenous, intramuscular, subcutaneous or oral dosage range from 10 mg daily to 500 mg daily; iV-acetyl-cysteine (Le Guen and coworkers, 1992) , dosage range from 10 mg/kg daily to 150 mg/kg daily; prostaglandin B oligomers (also known as poly¬ meric 15-keto prostaglandin B or PGBX) , intravenous, intramus¬ cular, subcutaneous or oral dosage range from 5 mg/kg daily to 400 mg/kg daily; 2-aminomethyl-4-tert-butyl-6-iodophenol, dosage range from 0.5 mg/kg daily to 600 mg/kg daily (Swingle and coworkers, 1985, pg. 120); 2-aminomethyl-4-tert-butyl-6- propionylphenol, dosage range from 20 mg/kg daily to 500 mg/kg daily (Swingle and coworkers, 1985, pgs. 120-121); 2,6-di- tert-butyl-4- [2'-thenoyl]phenol, dosage range from 3 mg/kg daily to 300 mg/kg daily (Swingle and coworkers, 1985, pg. 121); N, N' -diphenyl-p-phenylenediamine, dosage range from 5 mg/kg daily to 500 mg/kg daily (Swingle and coworkers, 1985, pg. 118) ; ethoxyquin, dosage range from 5 mg/kg daily to 500 mg/kg daily (Swingle and coworkers, 1985, pg. 118) ; probucol, a synthetic anti-oxidant (Halliwell, 1991, pg. 586) , dosage range from 25 mg daily to 1 gm daily; ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily; 5- [ [3,5-bis(1,1-dimethylethyl) -4- hydroxyphenyllmethylene] -3- (dimethylamino) -4-thiazolidinone (LY221068; Panetta and coworkers, 1991), dosage range from 1 mg/kg daily to 100 mg/kg daily; 5- [ [3,5-bis(1,1-dimethyl¬ ethyl) -4-hydroxyphenyljmethylene] -3- (methylamino) -4-thiazo- lidinone (LY269415, Panetta and coworkers, 1991) , dosage range from 1 mg/kg daily to 100 mg/kg daily; D-myoinositol-1.2.6- trisphosphate (Claxson and coworkers, 1990) , intravenous, intramuscular, subcutaneous or oral dosage range from 10 mg/kg daily to 1.5 gm/kg daily; nordihydroguaiaretic acid, intra¬ venous, intramuscular, subcutaneous or oral dosage range from 100 mg/kg daily to 2 gm/kg daily; deferoxamine mesylate, intravenous, intramuscular or subcutaneous dosage range from 100 mg daily to 2 gm daily; tirilazad mesylate (U-74006F) , intravenous, intramuscular or subcutaneous dosage range from 150 μg/kg/hr to 15 mg/kg/hr; derivative of tirilazad in which the steroid portion of the chemical structure has been re¬ placed with the tetra ethyl chroman portion of d-α tocopherol (U78517F, Upjohn) , intravenous, intravenous or subcutaneous dosage range from 150 μg/kg/hr to 15 mg/kg/hr; trimetazidine, dosage range from 100 μg/kg daily to 3.0 mg/kg daily; N, N' - dimethylthiourea (Repine, 1991) , intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 100 mg/kg daily; and 2- (2-hydroxy-4-methylphenyl)aminothiazole hydrochloride (Bonne and coworkers, 1990) , dosage range from 0.1 mg/kg daily to 50 mg/kg daily. Selenium may also be in¬ cluded in this group, dosage range from 25 μg daily to 0.5 mg daily, as it has recognized indirect anti-oxidant properties (Stuckey, 1968, pg. 236). Some in vivo experimental data has been presented which indicates that α-tocopherol; butylated- hydroxytoluene; propyl gallate; 2-aminomethyl-4- ert-butyl-6- iodophenol; 2-aminomethyl-4-tert-butyl-6-propionylphenol; 2,6- di-tert-butyl-4- [2' -thenoyl] -phenol; N, N' -diphenyl-p-phenyl¬ enediamine; ethoxyquin; ebselen; 5- [ [3,5-bis(1,1-dimethyl¬ ethyl) -4-hydroxyphenyljmethylene] -3- (dimethylamino)-4-thiazo- lidinone; 5- [ [3,5-bis(1,1-dimethylethyl) -4-hydroxyphenyl] - methylene] -3- (methylamino) -4-thiazolidinone; nordihydro- guaiaretic acid; 2- (2-hydroxy-4-methylphenyl)aminothiazole hydrochloride; and D-myoinositol-1.2.6-trisphosphate possess both anti-inflammatory and anti-oxidant properties (Swingle and coworkers, 1985, pgs. 114, and 118-121; Claxson and coworkers, 1990; Schmidt and Bayer, 1990, pg. 149; Honkanen and coworkers, 1990, pg. 190; Gado and Gigler, 1991; Panetta and coworkers, 1991; Parnham and coworkers, 1991) . (vi) Prophylactic Vitamin Co-Administration
It is yet still another object of this invention that the safety and effectiveness of the products described herein may be optimized by co-administration of vitamins which may be inadvertently depleted by the treatment or which may otherwise contribute to the clinical effectiveness of the compositions. This group includes:
-retinol, dermal, subcutaneous, intravenous, intramuscu¬ lar or oral dosage range from 10 μg/kg daily to 1 mg/kg daily;
-vitamin A aldehyde (retinal) , dermal, subcutaneous, in¬ travenous, intramuscular or oral dosage range from 10 μg/kg daily to 1 mg/kg daily;
-vitamin A acid (retinoic acid) , dermal, subcutaneous, intravenous, intramuscular or oral dosage range from 10 μg/kg daily to 1 mg/kg daily;
-retinyl acetate, dermal, subcutaneous, intravenous, in¬ tramuscular or oral dosage range from 10 μg/kg daily to 1 mg/kg daily;
-vitamin B1 (thiamine HCl) , dosage range from 1 mg daily to 1.5 gm daily;
-thiamine propyl disulfide, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine disulfide, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine disulfide 0,O-diisobutyrate, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine disulfide hydrochloride, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine disulfide phosphate, dosage range from 1 mg daily to 1.5 gm daily; -thiamine mononitrate, do 3sa9ge range from 1 mg daily to 1.5 gm daily;
-thiamine 1,5-salt, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine phosphoric acid ester chloride, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine phosphoric acid ester phosphate salt, dosage range from 1 mg daily to 1.5 gm daily;
-thiamine triphosphoric acid ester, dosage range from l mg daily to 1.5 gm daily;
-vitamin B2 (riboflavin) , dosage range from 1 mg daily to 1 gm daily;
-riboflavin tetrabutyrate, dosage range from 1 mg daily to 1 gm daily;
-riboflavine 5'-phosphate ester monosodium salt, dosage range from 1 mg daily to 1 gm daily;
-vitamin B6 (pyridoxine HCl) , dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxal, dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxal HCl, dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxal 5-phosphate, dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxal 5-phosphate calcium salt, dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxamine, dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxamine dihydrochloride, dosage range from 10 mg daily to 1.75 gm daily;
-pyridoxamine phosphate, dosage range from 10 mg daily to 1.75 gm daily;
-vitamin B12 (cyanocobalamin) , intravenous or oral dosage range from 1 μg daily to 1 mg daily;
-methyl vitamin B12 (co-methylcobalamin) , intravenous or oral dosage range from 1 μg daily to 1 mg daily;
-vitamin D2, dosage range from 400 units daily to 40,000 units daily;
-vitamin D3, dosage range from 400 units daily to 40,000 units daily;
-vitamin D4, dosage range from 400 units daily to 40,000 units daily;
-vitamin H (biotin) , intravenous, subcutaneous or oral dosage range from 150 μg daily to 200 mg daily;
-vitamin Kx (phytonadione) , intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-diacetyl dihydro vitamin Kl t intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K oxide, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin(s) K2 (menaquinones) , intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg;
-vitamin K2(35), intravenous, subcutaneous or oral dosage range from 100 μg daily 100 mg daily;
-vitaminK2(35) dihydrodiacetate, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K2(30), intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitaminK2(30) dihydrodiacetate, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K5, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K5 hydrochloride, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-W-acetyl vitamin K5, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K6, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K6 dihydrochloride, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K7, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K7 hydrochloride, intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin K-S(II), intravenous, subcutaneous or oral dosage range from 100 μg daily to 100 mg daily;
-vitamin Llf dosage range from 10 mg daily to 500 mg daily; -vitamin L2, dosage range 3<?from 10 mg daily to 500 mg daily;
-vitamin U, dosage range from 25 mg daily to 1 gm daily;
-methylmethioninesulfonium bromide (bromide analog of vitamin U) , dosage range from 25 mg daily to 1 gm daily;
-α-carotene, dosage range from 20 mg daily to 300 mg daily;
-jβ-carotene, dosage range from 20 mg daily to 300 mg daily;
-γ-carotene, dosage range from 20 mg daily to 300 mg daily;
-ω-carotene, dosage range from 20 mg daily to 300 mg daily;
-•■-,--/--carotene (also known as lycopene; Sies, 1991, pg. 33S) , dosage range from 5 mg daily to 300 mg daily;
-7,7' ,8,8' ,11,12-hexahydro-i--,^-carotene (also known as phytofluene; Halliwell, 1991, pg. 576), dosage range from 5 mg daily to 300 mg daily;
-L-carnitine (vitamin Bτ; Carnitor, Sigma-Tau Pharma¬ ceuticals) , dosage range from 100 mg daily to 3 gm daily;
-acetyl-L-carnitine, dosage range from 100 mg daily to 3 gm daily;
-folic acid (vitamin Be), dosage range from 0.5 mg daily to 50 mg daily;
-folinic acid, dosage range from 0.5 mg daily to 50 mg daily;
-folinic acid calcium salt pentahydrate, dosage range from 0.5 mg daily to 50 mg daily;
-niacinamide, dosage range from 100 mg daily to 10 gm daily;
-nicotinic acid (vitamin B3; Nicolar, Rhone-Poulenc Rorer) , dosage range from 100 mg daily to 10 gm daily;
-nicotinic acid sodium salt sesquihydrate, dosage range from 100 mg daily to 10 gm daily;
-nicotinic acid monoethanolamine salt, dosage range from 100 mg daily to 10 gm daily;
-pantothenic acid, dosage range from 5 mg daily to 2 gm daily;
-pantothenic acid sodium salt, dosage range from 5 mg daily to 2 gm daily; and
-pantothenic acid calcium salt, dosage range from 5 mg daily to 2 gm daily.
Several of these vitamins possess carbonyl functional groups and thus may be depleted by clinical use of the present invention. Others have a reported anti-oxidant effect, such as the carotenes, or may possess an anti-inflammatory effect, such as carnitine (Elliott and coworkers, 1991) , retinoic acid (Fumarulo and coworkers, 1991) and retinyl acetate (Fumarulo and coworkers, 1991) . (vii) Co-Administration of Metabolites at Risk of Depletion
It is another object of this invention that the safety and effectiveness of the products described herein may be optimized by co-administration of other metabolites, such as glycine, which may be depleted within the body during long term drug use. Use of glycine within the dosage range of from 1 gm daily to 20 gm daily is claimed herein. As many of the absorbable amine drugs described herein are excreted from the body as glycine conjugates, co-administration of glycine may be advisable. Coenzyme A is a required cofactor for hippuric- ase, the liver enzyme which adds glycine to benzoic acid derivatives. Activity of hippuricase in glycinating some of the absorbable carbonyl-trapping drugs described herein may sequester a disproportionate fraction of the endogenous coenzyme A pool. Hence co-administration of pantothenic acid, a metabolic precursor of coenzyme A, may also serve to optimize the therapeutic procedures described herein. A dosage range of from 5 mg daily to 2 gm daily for pantothenic acid is claimed herein, (viii) Co-Administration of Sulfhydryl Agents
Noting the well documented ability of carbonyl agents to react with sulfhydryl groups (Jellum and coworkers, 1973), it is a further object of this invention that L-methionine, dosage range from 200 mg daily to 4 gm daily and homocysteine, dosage range from 200 mg daily to 2 gm daily may also be of clinical benefit as absorbable drugs capable of covalently binding aldehyde or ketone agents. Homocysteine contains a free sulfhydryl group. Likewise, acetyl-homocysteine thio- lactone, intravenous, intramuscular, subcutaneous or oral dosage range from 0.5 mg/kg da Vil/y to 25 mg/kg daily may also be included in this group. Methionine is converted in vivo to homocysteine by several enzymatic reactions which remove a methyl group. L-Methionine also has a demonstrated ability to scavenge hypochlorous acid, a reactive oxygen specie which may contribute to the degradation of hyaluronic acid seen in rheumatoid arthritis (Saari and coworkers, 1993, pgs. 404 and 408) . Thioctic acid, also known as α-lipoic acid, is also included in this category in a dosage range from 10 mg daily to 500 mg daily, including its sodium salt and ethylenediamine derivatives, as its structure includes a disulfide group. This agent, a recognized growth factor (Budavari and cowork¬ ers, 1989, pg. 1469) , may tend to be depleted in the tissues of patients having chronic inflammatory diseases involving etiologies which include dysfunction of aldehyde and/or ketone metabolism. The ability of acetaldehyde to combine with thioctic acid, thus deactivating it, has been reported (Smith, 1976, pg. 195) .
(ix) Co-Administration of Agents Which May Facilitate Gluta¬ thione Activity In addition, the present invention includes use of vari¬ ous co-agents which may facilitate glutathione activity. Use of iV-acetylcysteine (Dansette and coworkers, 1990) , dosage range from 10 mg/kg daily to 150 mg/kg daily, has been report¬ ed to increase the levels of plasma cysteine, plasma glutathi¬ one and red blood cell glutathione (Bernard, 1991) , and to induce a 100-fold increase in myocardial glutathione subse¬ quent to experimental ischemia and reperfusion (Ferrari and coworkers, 1991) . N-Acetylcysteine reacts with hypochlorous acid, HO- and H202 (Bernard, 1991) , as well as with reactive aldehydes found in tobacco smoke (Ohman and coworkers, 1992) . Other substances in this class include L-2-oxothiazolidine-4- carboxylic acid, reported to hydrolyse in vivo to cysteine (Halliwell, 1991, pg. 590), dosage range from 0.3 mmol/kg daily to 3 mmol/kg daily; timonacic, also known as 4-thi- azolidinecarboxylic acid (Dansette and coworkers, 1990) , dosage range from 10 mg daily to 500 mg daily; cysteamine (Dansette and coworkers, 1990) , dosage range from 200 mg daily to 4 gm daily; lipoamide derivatives (Dansette and coworkers, 1990) such as malotilate (Kantec) , dosage range from 100 mg daily to 2 gm daily; sulfarlem (ADT; Dansette and coworkers, 1990) , intravenous, intramuscular, subcutaneous or oral dosage range from 100 mg/kg daily to 1 gm/kg daily; and oltipraz (Dansette and coworkers, 1990) , intravenous, intramuscular, subcutaneous or oral dosage range from 100 mg/kg daily to 1 gm/kg daily, as these co-agents may further serve to improve the invention described herein, (x) Factors Affecting Daily Dosage Schedule
A daily protocol of amine and amine-related drug consump¬ tion, in combination with co-agents defined herein, may be defined such that drug products are administered in timed- release and/or color coded tablets or capsules, so as to facilitate patient compliance and maximize therapeutic value. Alternatively, a therapeutic composition may be incorporated into a foodstuff product, so as to encourage regular, long term patient compliance, (xi) Therapeutic Utilization
As indicated above the present invention is intended for the treatment of chronic inflammatory diseases and is useful for this purpose in various animal species, e. g., rodents, cats, dogs, cattle, sheep, horses, pigs, monkeys and other primates.
Two case histories regarding human subjects may serve to illustrate the practical application of the invention origin¬ ally disclosed in US Patent Application 07/906,909. Case History One: Pearson and Shaw (1982, pg. 299) described the following summary of an arthritis patient taking vitamin E and vitamin A:
The correct dose of antioxidants for effective arthritis therapy must be determined by experi¬ mentation. The effective dose may be quite high. For example, a friend of ours who is a well-known artist in his fifties developed arthritis in his hands. This man's hands became so painful and stiff he could no longer use his fingers to remove the caps from his tubes of paint. He tried vitamin E at increasing dose levels. It was not until he got up to 10,000 I.U. of E and 20,000 I.U. of A per day that he obtained relief from the pain and crip¬ pling stiffness. His hands are now flexible and can be used to draw without difficulty. But they remain so only as long as our friend takes 10,000 I.U. of E and 20,000 I.U. of A a day, not less (he's tried). This dosage of vitamin E far exceeds presently accepted levels of daily usage, which are generally regarded as being in the range of 400 I.U. per day. This particular combination of vitamins E and A, both lipophilic, would not be expected to inhibit any of the free radical reactions taking place in aqueous microenvironments. Nor would it chemically bind and thus deactivate any reactive aldehydes generated by the in¬ flammatory process, as such aldehydes are water soluble. Case History Two: Patient L.S. has a history of arthritis dating back to a serious automobile accident in 1980. By January of 1991 she had serious arthritic involvement of the lumbar spine and chronic hip and knee joint pain on a contin¬ uous basis. She had difficulty raising herself from a chair, required the assistance of a cane for activities as simple as walking from her front door to her car, was no longer able to go up or down a flight of stairs, and required use of a pre¬ scription analgesic drug every two hours during the night to sleep. She had participated in a program at the Pain Clinic of the University of Miami Medical School and at doctor's advice had used prescription drugs which included Clinoril (R) and Anaprox (R) , both nonsteroidal anti-inflammatory agents. At the recommendation of this inventor, patient L.S. began taking 800 I.U. vitamin E, 1. gm of methionine and 1.1 gm PABA per day for two months. Subsequently, vitamin E and methion¬ ine usage remained the same and PABA usage was increased to 2.2 gm per day, with the protocol continued on an indefinite basis.
When previously examined by an orthopedics physician a diagnosis was established which included:
...Lumbar spine X-Rays in AP and lateral views show extensive degenerative arthritic changes at multiple levels of the lumbar spine...severe arthritic changes lumbar spine. Bursitis left greater trochanter clin¬ ically...She will always have a problem related to her underlying degenerative disease involving her lower back...She is favoring her left leg...Her straight leg raising is limited on the left side...
Ten weeks after after initiating this inventor's PABA/ methionine/vitamin E protocol, patient L.S. reported that her arthitis-related pain was much decreased and her functional status much improved. By four months into use of this thera¬ peutic protocol patient L.S. had stopped using her cane, had a walking gait which was much improved, had taken to raking leaves in the yard as a form of exercise, and no longer required nighttime analgesics to sleep. At twelve months on this protocol, patient L. S. reported climbing and descending a flight of stairs without difficulty, and her ability to climb stairs has continued to improve. When re-examined by her orthopedic physician, who was not informed of her use of the PABA/ methionine/vitamin E protocol, seven months after beginning therapy the doctor noted, in part:
This patient is markedly better. She has normal straight leg raising. She has no significant leg pain. She walks well on her toes and walks well on her heels now without any evidence of motor weakness. There is no limp present.
Unaware of the patient's collaborative effort with this inventor, the orthopedic physician was unable to provide an explanation of the marked improvement in the clinical status of patient L.S. At her office visit patient L. S. noted that she had stopped taking Anaprox, which her orthopedics physician had prescribed seven months earlier.
This inventor recognizes the novel and original combina¬ tion of primary amine benzoic acid derivatives as a primary agent to be used with anti-oxidant free radical trapping co- agents as a type of composition likely to have increased, or possibly even synergistic properties for the treatment of chronic inflammatory diseases. This inventive strategy for the clinical treatment of these diseases has not been previously recognized.
PABA, many of the other amine primary agents, the anti- oxidant free radical trapping co-agents, substances related thereto and previously known medicaments described herein are chemicals which have been previously synthesized and des¬ cribed. Yet the present invention recognizes a new and novel combination of therapeutic properties, never recognized previ¬ ously, and the clinical applications thereof. My original invention, as defined in US patent application 07/906,909, constitutes a significant and practical advancement of clini¬ cal therapeutic technology available for treating chronic inflammatory diseases, and the present invention constitutes a further practical extension of the original inventive concept.
(xii) Use of the Invention of US Patent Application 07/906,909 in Combination with Previously Known Medicaments As summarized above, it is evident that presently avail¬ able pharmaceutical technology for treatment of the diseases addressed herein is almost entirely symptomatic, as well as temporary and of partial clinical benefit, at best. The dosages of any of the known medicaments discussed herein, except those which are still the subjects of preliminary laboratory studies, are well known to those skilled in the art. Significant adverse side effects accompany many of these treatments, which limit their use. The present invention de¬ fines the use of previously recognized technology in combina¬ tion with the invention originally described in US patent application 07/906,909, so as to achieve greater clinical effectiveness in treatment of these diseases. In using the therapeutic technology defined herein, physicians may achieve in some cases the clinical benefits of previously recognized drugs while using lower dosage levels, thus minimizing adverse side effects. Within the context of the present invention, it is important to note the documentation provided by Flood and coworkers (1988) . Their findings indicate that when drugs are used in combination they may provide beneficial effect at re¬ duced dosages which are ineffective when drugs are adminis¬ tered alone. This approach may permit wider and more effec¬ tive use of previously recognized drug technology. It is acknowledged herein that for many of the previously known medicaments the optimum dosage must be determined on an in¬ dividualized basis, and may be below or above the dosage range generally recognized for public use. It is to be understood that dosage ranges listed below refer to adult usage and that in particular cases it may be desirable to go beyond the dos¬ age ranges noted below. Various oral compositions as noted below which exemplify the present invention may be formulated with additional components or coatings so as to function in a slow acting, delayed release manner. Except where stated otherwise, the drugs listed in the following examples are to be administered orally. It is understood, however, that var¬ ious combinations of administration via oral route and admin¬ istration via injected route or topical route may be en¬ visioned for the compositions listed below. Example 1
Clinical treatment of chronic gingivitis and/or chronic periodontitis can be improved by use of a composition, admin¬ istered in various oral, topical, intravenous, intramuscular, subcutaneous and intralesional combinations, comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat chronic gingivitis and/or chronic periodontitis, such as, for example, (a) antibiotics such as penicillin G potassium {Pfizerpen, Roerig) , intramuscular, intravenous, local infusion or intrathecal dosage range from one million units daily to twenty million units daily; penicillin G benzathine and penicillin G procaine combination (Bicillin C-R, Wyeth-Ayerst Laboratories) , intramuscular dos¬ age range from 300,000 units to 2,400,000 units administered for one day or daily until subsidence of abnormally high body temperature; penicillin V potassium (Veetids, Apothecon) , dosage range from 500 mg daily to 2 gm daily; erythromycin (E-Mycin, Boots Laboratories) , dosage range from 250 mg daily to 5 gm daily; amoxicillin (Amoxil , SmithKline Beecham) , dosage range from 750 mg daily to 1.5 grams daily; amoxicillin in combination with clavulanate potassium
{ ugment i , SmithKline Beecham) , dosage range from 750 mg amoxicillin and 187.5 mg clavulanate potassium daily to 1.5 grams amoxicillin and 375 mg clavulanate potassium daily; tetracycline (Achromycin V, Lederle) , dosage range from 500 mg daily to 2 gm daily; doxycycline ( Vibramycin, Pfizer) , dosage range from 50 mg daily to 300 mg daily; and minocycline (Minocin, Lederle) , dosage range from 50 mg daily to 300 mg daily;
(b) nitroimidazoles such as metronidazole (Flagyl , Searle) , dosage range from 250 mg daily to 2.5 gm daily;
(c) antiseptics such as chlorhexidine gluconate (Peridex oral rinse, Proctor & Gamble) , one to three oral rinses per day;
(d) surfactants such as triclosan, as ingredient in mouthwash or toothpaste, dosage range of one to three applications of 0.01% to 5% solution or suspension daily; and sanguinarine, as ingredient in mouthwash or toothpaste, dosage range of one to three applications of 0.01% to 5% solution or suspension daily;
(e) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily, or application of 1% to 25% topical compositions;
(f) nonsteroidal anti-inflammatory drugs administered orally including suprofen; dosage range from 5 mg/kg daily to 100 mg/kg daily; and
(g) locally administered corticosteroid preparations such as hydrocortisone acetate, 0.5% (Ora ase HCA, Colgate-Hoyt/Gel-
Kam) , topical application one to four times daily.
The following illustrate specific formulations according to the present invention.
p-aminobenzoic acid 1 gm d-of-tocopheryl succinate 500 I.U. penicillin G potassium one million units
p-aminobenzoic acid, potassium salt 20 gm N-acetylcysteine 10 gm suprofen 5 gm
p-aminomethylbenzoic acid 5 gm acetylhomocysteine thiolactone 1 gm metronidazole 2 gm
Example 2
Clinical treatment of chronic autoimmune gastritis can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent compris¬ ing a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option¬ ally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat autoimmune gastritis, such as, for example,
(a) sodium guaiazulene-3-sulfonate, dosage range from 1 mg/kg daily to 20 mg/kg daily; and
(b) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily.
The following illustrate specific formulations according to the present invention.
4-amino-3-hydroxybenzoic acid 1 gm mixed tocopherols 1, 000 I.U sodium guaiazulene-3-sulfonate 75 mg
p-aminobenzoic acid, potassium salt 15 gm
L-Methionine 1 gm sodium guaiazulene-3-sulfonate 1. ,5 gm
5-amino-2-hydroxybenzoic acid 5 gm N, N' -diphenyl-p-phenylenediamine 5 gm ebselen 5 gm Example 3 T '
Clinical treatment of ileitis, including Crohn's disease can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat ileitis, including Crohn's disease, such as, for example,
(a) sulfasalazine (Azulfidine EN- tabs delayed release tablets and Azulfidine tablets, Kabi Pharmacia) , dosage range from 1 gram daily to 5 grams daily;
(b) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(c) methylprednisolone acetate (Depo-Medrol , Upjohn) , intra- synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(d) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(e) metronidazole (Flagyl , Searle) , dosage range from 250 mg daily to 2.5 gm daily;
(f) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily;
(g) sustained-release tablets of 5-aminosalicylic acid (mesalamine; (Asacol delayed-release tablets, a composition consisting of 5-aminosalicylic acid coated with Eudragit-S, an acrylic-based resin pH-dependent delayed release substance; Procter & Gamble Pharmaceuticals) , dosage range from 500 mg daily to 5 grams daily;
(h) sustained-release tablets of 5-aminosalicylic acid
(Pentasa, a composition consisting of 5-aminosalicylic acid coated with a semipermeable membrane of ethyl cellulose; Ferring A/S Vanlose) , dosage range from 500 mg daily to 5 gm daily;
(i) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(j) cortisone (Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily; 5
(k) prednisone (Deltasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (1) methylprednisolone (Λfedrol, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (m) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (n) triamcinolone diacetate (Aristocort suspensions, Fujisawa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(o) betamethasone ( Celestone, Schering) , dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (p) betamethasone (Celestone Soluspan suspension, Schering) , intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(q) dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(r) cortisone ( Cortone suspension, Merck & Co.), intramuscular dosage range from 5 mg daily to 400 mg daily; (s) hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(t) prednisolone (Hydeltrasol injection, Merck & Co.), intravenous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily; (u) diphenoxylate, dosage range from 2.5 mg daily to 20 mg daily;
(v) diphenoxylate in combination with atropine sulfate
(Lomotil , Searle) , dosage range from 2.5 mg diphenoxylate and
25 μg atropine sulfate daily to 20 mg diphenoxylate and 200 μg atropine sulfate daily;
(w) deodorized opium tincture, dosage range from 0.5 ml daily to 3 ml daily;
(x) codeine, dosage range from 1 mg daily to 150 mg daily;
(y) azathioprine ( Imuran, Burroughs Wellcome) , dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily;
(z) 6-mercaptopurine (Purinethol, Burroughs Wellcome) , dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily;
(a') cyclosporin A (Sandimmune, Sandoz Pharmaceutical) , dosage range from 1 mg/kg daily to 15 mg/kg daily;
(b' ) methotrexate (Lederle) , dosage range from 2.5 mg daily to 30 mg daily, or doses from 5 mg to 50 mg once or twice weekly; and
(C) methotrexate sodium (Methotrexate LPF, Lederle), intra¬ muscular, intravenous, intra-arterial or intrathecal dosage range from 2.5 mg daily to 30 mg daily, or doses from 5 mg to 50 mg once or twice weekly.
The following illustrate specific formulations according to the present invention.
trans-4-aminocyclohexane- carboxylic acid 1 gm
Qf-tocopherol 500 I.U. prednisolone 5 mg
p-aminobenzoic acid 15 gm potassium citrate monohydrate 15 gm diphenoxylate 20 mg
5-amino-2-methoxybenzoic acid 5 gm butylated-hydroxytoluene 500 mg dihydrolipoic acid 250 mg ebselen 5 gm
Example 4
Clinical treatment of ulcerative colitis, a form of inflammatory bowel disease can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat ulcerative colitis, a form of inflammatory bowel disease, such as, for example,
(a) sulfasalazine (Azulfidine EN- tabs delayed release tablets and Azulfidine tablets, Kabi Pharmacia) , dosage range from 1 gm daily to 5 gm daily;
(b) 5-aminosalicylic acid, oral or intrarectal dosage range from 10 mg/kg to 500 mg/kg;
(c) 7- [3- (4-acetyl-3-methoxy-2-propylphenoxy)propoxy] -3,4- dihydro-8-propyl-2H-l-benzopyran-2-carboxylic acid, oral or intra-rectal dosage range from 0.1 mg/kg to 80 mg/kg;
(d) glutathione, intrarectal dosage range from 1 mg/kg to 20 mg/kg;
(e) zileuton, dosage range from 100 mg daily to 1 gram daily;
(f) olsalazine (Dipentum, Pharmacia Ltd.), dosage range from 200 mg daily to 2 gm daily;
(g) disodium azodisalicylate, dosage range from 200 mg daily to 4 gm daily;
(h) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(i) eicosapentaenoic acid (or commercial products containing this substance as the active ingredient, including MaxEPA capsules, 18 gm of which contains 3.2 gm eicosapentaenoic acid) , dosage range from 500 mg daily to 10 gm daily; (j) salicylsulfapyridine (Salazopyrin, Pharmacia AB) , dosage range from 1 gm daily to 5 gm daily;
(k) sustained-release tablets of 5-aminosalicylic acid (Pentasa, a composition consisting of 5-aminosalicylic acid coated with a semipermeable membrane of ethyl cellulose; Ferring A/S Vanlose) , dosage range from 500 mg daily to 5 gm daily;
(1) sustained-release tablets of 5-aminosalicylic acid (mesalamine; Asacol delayed-release tablets, a composition consisting of 5-aminosalicylic acid coated with Eudragit-S, an acrylic-based resin pH-dependent delayed release substance; Procter & Gamble Pharmaceuticals) , dosage range from 500 mg daily to 5 gm daily;
(m) diazo sulfanilamide ethylene polymer of 5-aminosalicylic acid, dosage range from 500 mg daily to 5 gm daily; (n) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily; (o) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(p) cortisone (Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(q) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (r) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (s) methylprednisolone acetate (Depo -Medrol, Upjohn), intra- synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(t) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (u) triamcinolone diacetate (Aristocort suspensions, Fujisa¬ wa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(v) betamethasone ( Celestone, Schering) , dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (w) betamethasone (Celestone Soluspan suspension, Schering) , intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(x) dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(y) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (z) hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(a') prednisolone (Hydel trasol injection, Merck & Co.), in¬ travenous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily; (b' ) azathioprine ( I uran, Burroughs Wellcome), dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily;
(c') 6-mercaptopurine (Purinethol , BurroughsWellcome) , dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily; (d' ) diphenoxylate, dosage range from 2.5 mg daily to 20 mg daily;
(e') diphenoxylate in combination with atropine sulfate (Lomotil , Searle), dosage range from 2.5 mg diphenoxylate and 25 μg atropine sulfate daily to 20 mg diphenoxylate and 200 μg atropine sulfate daily;
(f) deodorized opium tincture, dosage range from 0.5 ml daily to 3 ml daily;
(g' ) codeine, dosage range from 1 mg daily to 150 mg daily; (h' ) loperamide (Imodium, Janssen Pharmaceutica) , dosage range from 2 mg daily to 16 mg daily;
(i') corticotropin (ACTH) , intravenous dosage range from 25 units daily to 150 units daily;
(j') cyclosporinA (Sandimmune, Sandoz Pharmaceutical) , dosage range from 1 mg/kg daily to 15 mg/kg daily;
(k') benztropine mesylate ( Cogentin, Merck & Co.), dosage range from 0.5 mg daily to 10 mg daily;
(1') trihexyphenidyl (Artane, Lederle) , dosage range from 2 mg daily to 20 mg daily;
(m' ) procyclidine (Kemadrin, Burroughs Wellcome) , dosage range from 2 mg daily to 50 mg daily;
(n' ) biperiden (Akineton, Knoll Pharmaceuticals) , dosage range from 0.5 mg daily to 10 mg daily;
(o') ethopropazine, dosage range from 10 mg daily to 500 mg daily;
(p' ) scopolamine, dosage range from 0.1 mg daily to 1 mg daily;
(q' ) benztropine mesylate ( Cogentin injection, Merck & Co.), intravenous, intramuscular or subcutaneous dosage range from 0.5 mg daily to 10 mg daily;
(r' ) biperiden lactate (parenteral Akineton, Knoll Pharmaceu¬ ticals) , intravenous, intramuscular or subcutaneous dosage range from 0.5 mg daily to 10 mg daily;
(s') propantheline bromide (Pro -Ban thine, Schiapparelli Searle), dosage range from 7.5 mg daily to 120 mg daily; and (f) oxybutynin chloride (Di tropan, Marion Merrell Dow), dosage range from 5 mg daily to 20 mg daily. The following illustrate specific formulations according to the present invention. p-aminobenzoic acid 5 ~ 1 gm N-acetylcysteine 1 gm zileuton 100 mg
p-aminobenzoic acid, potassium salt 20 gm d-α-tocopheryl succinate 2,000 I.U. dexamethasone 10 mg
4-guanidinobenzoic acid HCl 5 gm prostaglandin B1 oligomers 5 gm acetylhomocysteine thiolactone 1 gm trihexyphenidyl 10 mg
Example 5
Clinical treatment of interstitial cystitis can be im¬ proved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat interstitial cystitis, such as, for example,
(a) propantheline bromide (Pro -Ban thine, Schiapparelli Searle) , dosage range from 7.5 mg daily to 120 mg daily;
(b) oxybutynin chloride (Di tropan, Marion Merrell Dow) , dosage range from 5 mg daily to 20 mg daily;
(c) benztropine mesylate (Cogentin, Merck & Co.), dosage range from 0.5 mg daily to 10 mg daily;
(d) trihexyphenidyl (Artane, Lederle) , dosage range from 2 mg daily to 20 mg daily;
(e) procyclidine (Kemadrin, Burroughs Wellcome) , dosage range from 2 mg daily to 50 mg daily;
(f) biperiden (Akineton, Knoll Pharmaceuticals) , dosage range from 0.5 mg daily to 10 mg daily;
(g) ethopropazine, dosage range from 10 mg daily to 500 mg daily; (h) scopolamine, dosage range from 0.1 mg daily to 1 mg daily;
(i) benztropine mesylate (Cogentin injection, Merck & Co.), intravenous, intramuscular or subcutaneous dosage range from 0.5 mg daily to 10 mg daily; and
(j) biperiden lactate (parenteral Akineton, Knoll Pharmaceu¬ ticals) , intravenous, intramuscular or subcutaneous dosage range from 0.5 mg daily to 10 mg daily.
The following illustrate specific formulations according to the present invention.
p-aminobenzoic acid 1 gm d-α-tocopheryl succinate 500 I.U. benztropine mesylate 1 mg
p-aminobenzoic acid, potassium salt 20 gm mixed tocopherols 3,500 I. .U iV-acetylcysteine 10 gm oxybutynin chloride 20 mg
o-aminomethylbenzoic acid 5 gm of-tocopherol nicotinate 1,500 I. ,U dihydrolipoic acid 250 mg ethopropazine 200 mg
Example 6
Clinical treatment of psoriasis can be improved by use of a corn-position, administered in various oral, topical, intra¬ venous, intramuscular, subcutaneous and intralesional combina¬ tions, comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat psoriasis, such as, for example,
(a) 7- [3- (4-acetyl-3-methoxy-2-propylphenoxy)propoxy] -3,4-di- hydro-8-propyl-2H-l-benzopyran-2-carboxylicacid, dosagerange from 0.1 mg/kg daily to 80 mg/kg daily; (b) eicosapentaenoic acid, dosage range from 1 gm daily to 5 gm daily;
(c) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(d) methotrexate (Rheumatrex, Lederle Laboratories)', dosage range from 1 mg weekly to 20 mg weekly;
(e) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(f) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(g) cortisone ( Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(h) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (i) methylprednisolone (Medrol , Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (j) methylprednisolone acetate (Depo -Medrol, Upjohn), intra- synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(k) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (1) triamcinolone diacetate (Aristocort suspensions, Fujisa¬ wa) , intramuscular, intrasynovial or intralesional dosage range from l mg daily to 200 mg daily, or alternate day dosing;
(m) betamethasone ( Celestone, Schering) , dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (n) betamethasone ( Celestone Soluspan suspension, Schering) , intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(o) dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(p) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (q) hydrocortisone (Hydrocortone phosphate injection, Merck £*. Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily; (r) hydrocortisone (Hydrocortone acetate suspension, Merck & Co.), intra-articular, intralesional or soft tissue injection dosage range from 1 mg daily to 400 mg daily; (s) prednisolone (Hydel trasol injection, Merck & Co.), intra¬ venous, intramuscular, intra-articular, intralesional'and soft tissue dosage range from 1 mg daily to 100 mg daily; (t) triamcinolone acetonide (Aristocort A topical cream, Fujisawa) , dosage range of from one to four applications per day to affected skin areas;
(u) alclometasone 17,21-dipropionate (Aclovate, Glaxo Derma¬ tology) , dosage range of from one to three applications per day;
(v) hydrocortisone (Anusol -HC, Parke-Davis) , dosage range of from one to four applications per day;
(w) fluticasone propionate (Cutivate cream, Glaxo Derma¬ tology) , dosage range of from one to three applications per day;
(x) betamethasone 17,21-dipropionate (Diprolene, Schering), dosage range of from one to three applications per day; (y) mometasone 17- (2-furoate) (Elocon, Schering), dosage range of from once weekly to once daily;
(z) clobetasol propionate (Temovate, Glaxo Dermatology) , dosage range of from one to three applications per day;
(a') 0.05% coal tar topical composition (DHS Tar Gel Shampoo, Person & Covey) , dosage range of from one use per day to one use per week;
(b') 12.5% coal tar topical composition (Denorex Extra Strength Shampoo, Whitehall Laboratories) , dosage range of from one use per day to one use per week;
(c') methoxsalen (Oxsoralen lotion, 1%, ICN) , dosage range from a topical application plus ultraviolet light exposure once per month to applications plus ultraviolet light exposure three times per week;
(d' ) methoxsalen ( Oxsoral en- Ul tra capsules, ICN), dosage range from one 10 mg capsule plus ultraviolet light exposure once per month to two 10 mg capsules plus ultraviolet light exposure three times per week;
(e') etretinate ( Tegison, Roche Dermatologies), dosage range from 0.125 mg/kg daily to 1.5 mg/kg daily;
(f) isotretinoin (Accutane, Roche Dermatologies), dosage range from 0.1 mg/kg daily to 2 mg/kg daily; (g' ) anthralin (Dri thocreme topical creams, American Dermal) , dosage range of from one application per week to one application per day for each concentration of drug, ranging from 0.1% to 1%;
(h') cyclosporinA ( Sandimmune, Sandoz Pharmaceutical) , dosage range from 1 mg/kg daily to 15 mg/kg daily;
(i#) vitamin D3, 0.001% to 0.5 % in cream, lotion or gel base, topical application from once weekly to four times daily; and
(j') salicylic acid, 0.001% to 0.5 % in cream, lotion or gel base, topical application from once weekly to four times daily.
The following illustrate specific formulations according to the present invention.
4- (aminoguanidino)benzoic acid 1 gm nordihydroguaiaretic acid 7.5 gm methylprednisolone 2.5 mg
p-aminophenylacetic acid 20 gm probucol 1 gm etretinate 100 mg
p-aminobenzoic acid 5 gm timonacic 250 mg cyclosporin A 500 mg
Example 7
Clinical treatment of rheumatoid arthritis can be im¬ proved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent compris¬ ing a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optional¬ ly at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat rheumatoid arthritis, such as, for example,
(a) meclofenamate (Meclomen) , dosage range from 100 mg daily to 800 mg daily;
(b) mefenamie acid (Ponstel ) , dosage range from 200 mg daily to 1.5 gm daily;
(c) flufenamic acid, dosage range from 100 mg daily to 1 gm daily;
(d) amfenac, dosage range from 1 μg/kg daily to 1 mg/kg d ily;
(e) ethyl 2-amino-3-benzoylphenylacetate, dosage range from 10 μg/kg daily to 10 mg/kg daily;
(f) diclofenac (Voltaren) , dosage range from 10 mg daily to 200 mg daily;
(g) etodolac (Lodine, Wyeth-Ayerst Laboratories) , dosage range from 200 mg daily to 2 gm daily;
(h) metiazinic acid, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(i) indomethacin (Indocin) , dosage range from 25 mg daily to 250 mg daily;
(j) fenclozic acid, dosage range from 25 mg daily to 500 mg daily;
(k) isofezolac, dosage range from 0.1 mg/kg daily to 25 mg/kg daily;
(1) sulindac ( Clinoril , Merck & Co.), dosage range from 50 mg daily to 500 mg daily;
(m) tolmetin ( Tolectiή) , dosage range from 100 mg daily to 2 gm daily;
(n) glucametacin, dosage range from 50 mg daily to 600 mg daily;
(o) cinmetacin, dosage range from 2 mg/kg daily to 400 mg/kg daily;
(p) fenclofenac, dosage range from 200 mg daily to 2 gm daily;
(q) fenbufen, dosage range from 250 mg daily to 1.25 gm daily;
(r) butibufen, dosage range from 40 mg/kg daily to 400 mg/kg daily; (s) ketorolac tromethamine ( iTofradol, Syntex) , dosage range from 5 mg daily to 150 mg daily;
(t) tinoridine, dosage range from 2.5 mg/kg daily to 250 mg/kg daily;
(u) fenoprofen (Nalfon) , dosage range from 250 mg daily to 3.2 gm daily;
(v) flurbiprofen (Ansaid) , dosage range from 50 mg daily to 500 mg daily;
(w) ibuprofen (Motrin) , dosage range from 200 mg daily to 3.2 gm daily;
(x) ketoprofen ( Orudis) , dosage range from 25 mg daily to 500 mg daily;
(y) naproxen (Naprosyn) , dosage range from 125 mg daily to 1.25 gm daily;
(z) bucloxic acid, dosage range from 200 mg daily to 2 gm daily;
(a' ) the (S) (+) enantiomer of carprofen, dosage range from 10 mg daily to 750 mg daily;
(b' ) phenylbutazone (Azolid) , dosage range from 2 mg/kg daily to 100 mg/kg daily;
(C) oxyphenbutazone ( Taneril) , dosage range from 100 mg daily to 1 gm daily;
(d' ) feprazone, dosage range from 100 mg daily to 1.5 gm daily;
(e') imidazole salicylate, dosage range from 50 μmol/kg daily to 0.5 mmol/kg daily;
(f) diflunisal, dosage range from 250 mg daily to 1.5 gm daily;
(g' ) sulfasalazine, dosage range from 200 mg daily to 3 gm daily;
(h' ) benorylate, dosage range from 1 gm daily to 7 gm daily;
(i') piroxicam (Feldene) , dosage range from 5 mg daily to 25 mg daily;
(j') isoxicam, dosage range from 50 mg daily to 500 mg daily;
(k') auranofin (Ridaura, SmithKline Beecham) , dosage range from 1 mg daily to 9 mg daily;
(1') aurothioglucose (Solganal , Schering), intramuscular dosage range from 1 mg weekly to 40 mg weekly;
(m' ) gold sodium thiomalate (Myochryisine, Merck & Co.), intramuscular dosage range from 1 mg weekly to 50 mg weekly; (n' ) hydroxychloroquine (Plaquenil , SanofiWinthrop Pharmaceu¬ ticals) , dosage range from 50 mg (equivalent to 39 mg base) daily to 600 mg (equivalent to 465 mg base) daily; (o' ) chloroquine, dosage range from 50 mg daily to 500 mg daily;
(p' ) methotrexate (Rheumatrex, Lederle Laboratories) , dosage range from 1 mg weekly to 20 mg weekly;
(q' ) D-penicillamine ( Cuprimine, Merck & Co.), dosage range from 25 mg daily to 1.5 grams daily;
(r') cyclophosphamide ( Cytoxan, Bristol-Myers Oncology) , dos¬ age range from 0.1 mg/kg daily to 5 mg/kg daily; (s') prednisone (Del tasone, Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (f) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(u' ) methylprednisolone (Medrol , Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (V) (10-methoxy-4H-benzo[4,5]cyclohepta- [1,2-b] -thiophene-4- yliden)acetic acid, dosage range from 0.5 mg/kg daily to 100 mg/kg daily;
(w' ) cyclosporinA (Sandimmune, Sandoz Pharmaceutical) , dosage range from 1 mg/kg daily to 250 mg/kg daily or three times weekly;
(x') neutral macrolide of molecular formula C44 H69 N012* H20 derived from Streptomyces tsukubaensis No. 9993 (FK506) , dosage range from 0.5 mg/kg daily to 50 mg/kg daily; (y' ) rapamycin, dosage range from 1 mg/kg daily to 250 mg/kg daily or three times weekly;
(z') azathioprine ( Imuran, Burroughs Wellcome) , oral or intra¬ venous dosage range from 75 μg/kg daily to 2.5 mg/kg daily; (a' ' ) nabumetone (Relafen, SmithKline Beecham) , dosage range from 200 mg daily to 2 gm daily;
(b' ') eicosapentaenoic acid, dosage range from 500 mg daily to 10 gm daily;
(c'') aloxiprin, dosage range from 1 gm daily to 7 gm daily; (d' ' ) azapropazone, dosage range from 500 mg daily to 5 gm daily; (e'') amiprilose, dosage range from 1 gm daily to 8 gm daily; (f') chlorambucil (Leukeran, Burroughs Wellcome), dosage range from 0.5 mg daily to 10 mg daily;
(g' ' ) aceclofenac, dosage range from 0.2 mg/kg daily to 10 mg/kg daily;
(h' ' ) apocynin, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(i'#) capsaicin, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 200 mg/kg daily; (j' ') 6- (2,4-difluorophenoxy) -5-methylsulfonylamino-1-indanone (Ciba-Geigy AG) , dosage range from 0.2 mg/kg daily to 20 mg/kg daily;
(k' ' ) dapsone, dosage range from 20 mg daily to 200 mg daily; (1'') solubilized chicken type II collagen, dosage range from 50 μg daily to 20 mg daily;
(m' ' ) 15-deoxyspergualin, intravenous, intramuscular, subcuta¬ neous or oral dosage range from 0.5 mg/kg daily to 10 mg/kg daily;
(n' ' ) diacetyl-splenopentin, intravenous, intramuscular or subcutaneous dosage range from 100 μg/kg daily to 3 mg/kg daily;
(o' ' ) diaveridine, dosage range from 25 mg/kg daily to 500 mg/kg daily;
(p' ' ) ditazol, dosage range from 25 mg/kg daily to 750 mg daily;
(q' ' ) droxicam, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(r' ' ) (Z) -3- [4- (acetyloxy) -5-ethyl-3-methoxy-l-naphthalenyl] - 2-methyl-2-propenoic acid, dosage range from 10 mg/kg daily to 500 mg/kg daily;
(s'') ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily; (f ' ) l-p-chlorobenzyl-2-dimethyl-amino-methylcyclohexen-l,2, dosage range from 2.5 mg/kg daily to 250 mg/kg daily; (u' ' ) etoclofene, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg/kg daily to 400 mg/kg daily; (v' ' ) felbinac, dosage range from 100 mg daily to 1.25 gm daily;
(w' ' ) fenclorac, dosage range from 0.5 mg/kg daily to 50 mg/kg daily; (x'') fenclozic acid, dosage range from 2.5 mg/kg daily to 250 mg/kg daily;
(y' ' ) fendosal, dosage range from 5 mg/kg daily to 200 mg/kg daily;
(z'#) isoxepac, dosage range from 200 mg daily to 2 gm daily;
(a'/ ;) leflunomide, dosage range from 50 μg daily to 50 mg daily;
(b'1') lobenzarit, dosage range from 50 mg daily to 750 mg daily;
(c''') lonazolac-Ca, dosage range from 100 mg daily to 1 gm daily;
(d' ") 5- [ [3,5-bis(1,1-dimethylethyl) -4-hydroxyphenyl]methyl- ene] -3- (dimethylamino) -4-thiazolidinone, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(e' ' ' ) 5- [[3,5-bis(1,1-dimethylethyl) -4-hydroxyphenyl]methyl- ene] -3- (methylamino) -4-thiazolidinone, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(f ' ' ) bumadizon-calcium (Eumotol) , dosage range from 100 mg daily to 1 gm daily;
(g' ' ' ) azapropazone, dosage range from 100 mg daily to 1 gm daily;
(h' ' ' ) D-myoinositol-1.2.6-trisphosphate, intravenous, intra¬ muscular, subcutaneous or oral dosage range from 10 mg/kg daily to 1.5 gm daily;
(i''') eicosapentaenoic acid (as commercial products contain¬ ing this substance as the active ingredient, including MaxEPA capsules, 18 gm of which contains 3.2 gm eicosapentaenoic acid) , dosage range of eicosapentaenoic acid from 500 mg daily to 10 gm daily;
(j''') ibufenac, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(k'#') nimesulide, dosage range from 100 mg daily to 2 gm daily;
(1''') oxametacine, dosage range from 50 mg daily to 500 mg daily;
(m' ' ' ) oxaprozin, dosage range from 150 mg daily to 1.5 gm daily;
(n' ' ' ) suxibuzone, dosage range from 2 mg/kg daily to 150 mg/kg daily; (o' ' '' ) pirprofen, dosage range from 100 mg daily to 1.5 gm daily;
(p' ' ' ) proquazone, dosage range from 150 mg daily to 1.5 gm daily;
(q' ' ' ) triamcinolone acetonide, intravenous, intramuscular, subcutaneous or oral dosage range from 5 μg/kg daily to 0.1 mg/kg daily;
(r' ' ' ) suprofen; dosage range from 5 mg/kg daily to 100 mg/kg daily;
(s' ' ' ) tenoxicam, dosage range from 5 mg daily to 40 mg daily;
(t''') tiaprofenic acid, dosage range from 100 mg daily to 1 gm daily;
(u' ' ' ) tolfenamic acid, dosage range from 100 mg daily to 600 mg daily;
(V ' ' ) difenpiramide, dosage range from 250 mg daily to 1.5 gm daily;
(w' ' ' ) isofezolac, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(x' ' ' ) tiopronin, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 100 mg/kg daily;
(y ' ' ) 5-thiopyridoxine, dosage range from 50 mg daily to 2 gm daily;
(z' ' ' ) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(a'*'') prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(b'''') cortisone ( Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(c'''') methylprednisolone acetate (Depo-Medrol , Upjohn), intrasynovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(d' ' ' ' ) triamcinolone (Aristocort, Fujisawa), dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(e' ' ' ' ) triamcinolone diacetate (Aristocort suspensions, Fuji¬ sawa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(f' ' ' ' ) betamethasone ( Celestone, Schering) , dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing;
(g' ' ' ' ) betamethasone ( Celestone Soluspan suspension, Scher¬ ing), intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(h' ' ' ' ) dexamethasone (Decadron phosphate injection,' Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(i' ' ' ' ) cortisone ( Cortone suspension, Merck & Co.) , intramus¬ cular dosage range from 5 mg daily to 400 mg daily;
(j'''') hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dos¬ age range from 1 mg daily to 400 mg daily;
(k' ' ' ' ) hydrocortisone (Hydrocortone acetate suspension, Merck & Co.), intra-articular, intralesional or soft tissue injec¬ tion dosage range from 1 mg daily to 400 mg daily;
(1'''') prednisolone (Hydel trasol injection, Merck & Co.), intravenous, intramuscular, intra-articular, intralesional and
soft tissue dosage range from 1 mg daily to 100 mg daily; (m' ' ' ' ) aspirin, dosage range from 300 mg daily to 6.5 gm daily;
(n' ' ' ' ) calcium acetylsalicylate, dosage range from 300 mg daily to 6.5 gm daily;
(o' ' ' ' ) choline salicylate, dosage range from 500 mg daily to 4 gm daily;
(p'''') choline magnesium trisalicylate ( Trilisate, Purdue Frederick) , dosage range from 500 mg daily to 4 gm daily; (q' ' ' ' ) magnesium salicylate, dosage range from 500 mg daily to 4 gm daily;
(r' ' ' ' ) salsalate (Salflex, Carnrick Laboratories) , dosage range from 500 mg daily to 4 gm daily;
(s'''') sulfasalazine (Azulfidine EN- tabs delayed release tablets and Azulfidine tablets, Kabi Pharmacia) , dosage range from 1 gm daily to 5 gm daily;
(t'#'') cyclophosphamide ( Cytoxan for injection, Bristol-Myers Oncology) , dosage range from 0.1 mg/kg daily to 5 mg/kg daily, 2 mg/kg to 5 mg/kg twice weekly or 10 mg/kg to 15 mg/kg every seven to ten days; (u' ' ' ' ) N, N' -diphenyl-p-phenylenediamine, dosage range from 10 mg/kg daily to 250 mg/kg daily;
(V ' ' ' ) tenidap (Pfizer) , dosage range from 25 mg daily to 2 gm daily;
(W ' ' ' ) ketorolac tromethamine ( Toradol IM, Syntex) , intramus¬ cular dosage range from 5 mg daily to 150 mg daily; and (x' ' ' ' ) carprofen, dosage range from 0.2 mg/kg daily to 50 mg/kg daily;
The following illustrate specific formulations according to the present invention.
4-guanidinobenzoic acid HCl 1 gm mixed tocopherols 500 I.U. prednisone 5 mg
p-aminobenzoic acid 20 gm d-α-tocopheryl succinate 3,500 I.U.
L-methionine 2 gm sulindac 500 mg
4- (aminoguanidino)benzoic acid 5 gm acetylhomocysteine thiolactone 1 gm azathioprine 75 mg
Example 8
Clinical treatment of ankylosing spondylitis can be im¬ proved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat ankylosing spondylitis, such as, for example,
(a) isoxicam, dosage range from 25 mg daily to 400 mg daily;
(b) ketoprofen, dosage range from 50 mg daily to 500 mg daily;
(c) diclofenac, dosage range from 25 mg daily to 500 mg daily; (d) fenclofenac, dosage range from 150 mg daily to 1.5 gm daily;
(e) phenylbutazone, dosage range from 50 mg daily to 400 mg daily;
(f) prenazone, dosage range from 1 mg/kg daily to '00 mg/kg daily;
(g) nabumetone, dosage range from 200 mg daily to 2 gm daily; (h) indomethacin, dosage range from 50 mg daily to 500 mg daily;
(i) sulindac ( Clinoril , Merck & Co.) , dosage range from 50 mg daily to 500 mg daily;
(j) carprofen, dosage range from 25 mg daily to 300 mg daily; (k) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(1) proquazone, dosage range from 150 mg daily to 1.5 gm daily;
(m) ibuprofen, dosage range from 200 mg daily to 2 gm daily; (n) tenoxicam, dosage range from 5 mg daily to 50 mg daily; (o) piroxicam, dosage range from 5 mg daily to 50 mg daily; (p) tiaprofenic acid, dosage range from 100 mg daily to 1 gm daily;
(q) tolfenamic acid, dosage range from 100 mg daily to 1 gm daily;
(r) pirprofen, dosage range from 150 mg daily to 1.5 gm daily;
(s) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(t) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(u) cortisone ( Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(v) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (w) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (x) methylprednisolone acetate (Depo-Medrol , Upjohn) , intra¬ synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg; (y) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (z) triamcinolone diacetate (Aristocort suspensions, Fujisa¬ wa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(a') betamethasone ( Celestone, Schering), dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (b') betamethasone (Celestone Sol uspan suspension, Schering), intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(c') dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(d' ) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (e') hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(f ) prednisolone (Hydel trasol injection, Merck & Co.) , intra¬ venous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily; (g' ) aspirin, dosage range from 300 mg daily to 6.5 gm daily; (h' ) calcium acetylsalicylate, dosage range from 300 mg daily to 6.5 gm daily;
(i') choline salicylate, dosage range from 500 mg daily to 4 gm daily;
(j') choline magnesium trisalicylate ( Trilisate, Purdue Fred¬ erick) , dosage range from 500 mg daily to 4 gm daily; (k' ) magnesium salicylate, dosage range from 500 mg daily to 4 gm daily;
(1') salsalate (Salflex, Carnrick Laboratories) , dosage range from 500 mg daily to 4 gm daily;
(m' ) imidazole 2-hydroxybenzoate, dosage range from 50 μmol/kg daily to 0.5 mmol/kg daily;
(n') diflunisal, dosage range from 250 mg daily to 1.5 gm daily;
(o') sulfasalazine, dosage range from 200 mg daily to 3 gm daily; (p') benorylate, dosage range from 1 gm daily to 7 gm daily;
(q' ) naproxen (Naprosyn) , dosage range from 125 mg daily to 1.25 gm daily; and
(r') oxyphenbutazone ( Taneril ) , dosage range from 100 mg daily to 1 gm daily.
The following illustrate specific formulations according to the present invention.
4-aminophenylacetic acid 1 gm propyl gallate 100 mg indomethacin 50 mg
4- (guanidino) -2-methoxybenzoic acid 15 gm tert-butylhydroquinone 1 gm glycine 10 gm cortisone 400 mg
4- (aminoguanidino)benzoic acid 5 gm homocysteine 1 gm naproxen 500 mg
Example 9
Clinical treatment of osteoarthritis can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat osteoarthritis, such as, for example,
(a) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(b) nabumetone (Relafen, SmithKline Beecham) , dosage range from 200 mg daily to 2 grams daily;
(c) ketoprofen ( Orudis) , dosage range from 25 mg daily to 500 mg daily;
(d) phenylbutazone, dosage range from 100 mg daily to 500 mg daily;
(e) the (S) (+) enantiomer of carprofen, dosage range from 50 mg daily to 750 mg daily; 4f
(f) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(g) diclofenac ( Vol taren) , dosage range from 10 mg daily to 200 mg daily;
(h) diflunisal, dosage range from 250 mg daily to 1.5 gm daily;
(i) diphenpyramide, dosage range from 250 mg daily to 1.5 gm daily;
(j) fenbufen, dosage range from 250 mg daily to 1.25 gm daily;
(k) oxyphenbutazone ( Taneril) , dosage range from 100 mg daily to 1 gm daily;
(1) indomethacin ( Indocin) , dosage range from 25 mg daily to 250 mg daily;
(m) gluca etacin, dosage range from 50 mg daily to 600 mg daily;
(n) isoxicam, dosage range from 50 mg daily to 500 mg daily; (o) lonazolac-Ca, dosage range from 100 mg daily to 1 gm daily;
(p) S-adenosylmethionine, dosage range from 500 mg daily to 10 gm daily;
(q) bumadizon-calcium (Eumotol) , dosage range from 100 mg daily to 1 gm daily;
(r) diacetylrhein, dosage range from 10 mg daily to 500 mg daily;
(s) proquazone, dosage range from 150 mg daily to 1.5 gm daily;
(t) naproxen (Naprosyn) , dosage range from 0.5 mg/kg daily to 25 mg/kg daily;
(u) nimesulide, dosage range from 100 mg daily to 2 gm daily; (v) oxametacine, dosage range from 50 mg daily to 500 mg daily;
(w) pirprofen, dosage range from 100 mg daily to 1.5 gm daily;
(x) prenazone, dosage range from 150 mg daily to 1.5 gm daily;
(y) sulindac ( Clinoril , Merck & Co.) , dosage range from 50 mg daily to 500 mg daily; (z) suprofen, dosage range from 5 mg/kg daily to 100 mg/kg daily;
(a') tenoxicam, dosage range from 5 mg daily to 40 mg daily; (b' ) tiaprofenic acid, dosage range from 100 mg daily to 1 gm daily;
(C) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from l mg daily to 400 mg daily;
(d' ) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(e') cortisone (Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(f) methylprednisolone (Afedrol, Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (g') methylprednisolone acetate (Depo -Medrol, Upjohn), intrasynovi-al, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 g;
(h') triamcinolone (Aristocort, Fujisawa), dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (i') triamcinolone diacetate (Aristocort suspensions, Fuji¬ sawa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(j') betamethasone ( Celestone, Schering), dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (k' ) betamethasone (Celestone Sol uspan suspension, Schering), intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(1') dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(m' ) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (n' ) hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(o' ) hydrocortisone (Hydrocortone acetate suspension, Merck & Co.), intraarticular, intralesional or soft tissue injection dosage range from 1 mg daily to 400 mg daily; (p') prednisolone (Hydel trasol injection, Merck & Co.) , intra¬ venous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily; (q' ) aspirin, dosage range from 300 mg daily to 6.5 gm daily; (r' ) calcium acetylsalicylate, dosage range from 300 mg daily to 6.5 gm daily;
(s') choline salicylate, dosage range from 500 mg daily to 4 gm daily;
(f) choline magnesium trisalicylate ( Trilisate, Purdue Fred¬ erick) , dosage range from 500 mg daily to 4 gm daily; (u' ) magnesium salicylate, dosage range from 500 mg daily to 4 gm daily;
(v' ) salsalate (Sal flex, Carnrick Laboratories) , dosage range from 500 mg daily to 4 gm daily; and
(W ) etodolac (Lodine, Wyeth-Ayerst Laboratories) , dosage range from 200 mg daily to 2 gm daily.
The following illustrate specific formulations according to the present invention.
4-amino-2-methylbenzoic acid 1 gm
N, N' -dimethylthiourea 300 mg etodolac 200 mg
p-aminobenzoic acid 15 gm β-carotene 300 mg dexamethasone 10 mg
(4-aminocyclohexane)acetic acid 5 gm D-myo-inositol-1.2.6-trisphosphate 20 gm suprofen 3 gm
Example 10
Clinical treatment of tendinitis or tenosynovitis can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat tendinitis or tenosynovitis, such as, for example,
(a) the (S) (+) enantiomer of carprofen, dosage range from 50 mg daily to 750 mg daily;
(b) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(c) diclofenac ( Vol taren) , dosage range from 10 mg daily to 200 mg daily;
(d) fenbufen, dosage range from 250 mg daily to 1.25 gm daily;
(e) nimesulide, dosage range from 100 mg daily to 2 gm daily;
(f) oxamethacin, dosage range from 50 mg daily to 500 mg daily;
(g) pirprofen, dosage range from 100 mg daily to 1.5 gm daily;
(h) proquazone, dosage range from 150 mg daily to 1.5 gm daily;
(i) sulindac ( Clinoril , Merck & Co.) , dosage range from 50 mg daily to 500 mg daily;
(j) tenoxicam, dosage range from 5 mg daily to 40 mg daily; (k) tiaprofenic acid, dosage range from 100 mg daily to 1 gm daily.
(1) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(m) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(n) cortisone ( Cortone, Merck S* Co.), dosage range from 5 mg daily to 400 mg daily;
(o) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (p) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (q) methylprednisolone acetate (Depo-Medrol , Upjohn) , intra¬ synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(r) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (s) triamcinolone diacetate (Aristocort suspensions, Fuji- sawa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(t) betamethasone ( Celestone, Schering) , dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (u) betamethasone ( Celestone Soluspan suspension, Schering) , intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(v) dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(w) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (x) hydrocortisone (Hydrocortone phosphate injection, Merck &• Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(y) hydrocortisone (Hydrocortone acetate suspension, Merck & Co.), intra-articular, intralesional or soft tissue injection dosage range from 1 mg daily to 400 mg daily; (z) prednisolone (Hydel trasol injection, Merck & Co.), intra¬ venous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily; (a') dexamethasone acetate (Decadron-LA, Merck & Co.), intra¬ muscular and local soft tissue injected dosage range from 0.1 mg daily to 10 mg daily;
(b') indomethacin ( Indocin) , dosage range from 25 mg daily to 250 mg daily;
(c') aspirin, dosage range from 300 mg daily to 6.5 gm daily, (d' ) vitamin B6 (pyridoxine HCl), dosage range from 10 mg daily to 1.75 gm daily;
(e') pyridoxal, dosage range from 10 mg daily to 1.75 gm daily;
(f) pyridoxal HCl, dosage range from 10 mg daily to 1.75 gm daily;
(g') pyridoxal 5-phosphate, dosage range from 10 mg daily to 1.75 gm daily;
(h' ) pyridoxal 5-phosphate calcium salt, dosage range from 10 mg daily to 1.75 gm daily; (i#) pyridoxamine, dosage range from 10 mg daily to 1.75 gm daily; W
(j') pyridoxamine dihydrochloride, dosage range from 10 mg daily to 1.75 gm daily; and
(k' ) pyridoxamine phosphate, dosage range from 10 mg daily to 1.75 gm daily.
The following illustrate specific formulations according to the present invention.
4-amino-2-hydroxycyclohexanecarboxylic acid 1 gm 2-aminomethyl-4- ert-butyl-6-propionylphenol 1.5 gm pyridoxine HCl 200 mg
p-aminobenzoic acid, potassium .salt 20 gm ebselen 20 gm carprofen 1 gm
3,5-diaminobenzoic acid 5 gm butylated hydroxyanisole 20 mg dexamethasone acetate 5 mg
Example 11
Clinical treatment of carpel tunnel syndrome and other cumulative trauma disorders can be improved by use of a com¬ position comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat carpel tunnel syndrome and other cumulative trauma disorders, such as, for example,
(a) diclofenac (Voltaren) , dosage range from 10 mg daily to 200 mg daily;
(b) dexamethasone acetate (Decadron-LA, Merck & Co.), intra¬ muscular and local soft tissue injected dosage range from 0.1 mg daily to 10 mg daily;
(c) hydrocortisone acetate (Hydrocortone suspension, Merck & Co.), intramuscular or local soft tissue injection dosage range from 1 mg daily to 400 mg daily; (d) methylprednisolone acetate (Depo-Medrol , Upjohn) , intra¬ muscular or local soft tissue dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(e) vitamin B6 (pyridoxine HCl) , dosage range from 10 mg daily to 1.75 gm daily;
(f) pyridoxal, dosage range from 10 mg daily to 1.75 gm daily;
(g) pyridoxal HCl, dosage range from 10 mg daily to 1.75 gm daily;
(h) pyridoxal 5-phosphate, dosage range from 10 mg daily to 1.75 gm daily;
(i) pyridoxal 5-phosphate calcium salt, dosage range from 10 mg daily to 1.75 gm daily;
(j) pyridoxamine, dosage range from 10 mg daily to 1.75 gm daily;
(k) pyridoxamine dihydrochloride, dosage range from 10 mg daily to 1.75 gm daily; and
(1) pyridoxamine phosphate, dosage range from 10 mg daily to 1.75 gm daily.
The following illustrate specific formulations according to the present invention.
4-amino-2- (methoxy) cyclohexanecarboxylic acid 1 gm 2- (2-hydroxy-4-methylphenyl)aminothiazole HCl 100 mg pyridoxal 5-phosphate calcium salt 50 mg
p-aminophenylacetic acid, potassium salt 20 gm d-α-tocopheryl succinate 3,000 I.U. diclofenac 200 mg
4-amino-2-methylbenzoic acid, potassium salt 5 gm N, N' -diphenyl-p-phenylenediamine 10 gm hydrocortisone acetate 100 mg
Example 12
Clinical treatment of chronic discoid or systemic lupus erythematosus can be improved by use of a composition compris¬ ing from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recog-nized as effective to treat chronic discoid or systemic lupus erythematosus, such as, for example,
(a) hydroxychloroquine (Plaquenil , Sanofi Winthrop Pharmaceu¬ ticals) , dosage range from 50 mg (equivalent to 39 mg base) daily to 400 mg (equivalent to 310 mg base) daily;
(b) quinacrine, dosage range from 10 mg daily to 200 mg daily;
(c) chloroquine, dosage range from 50 mg daily to 750 mg daily;
(d) amodiaquine, dosage range from 10 mg daily to 500 mg daily;
(e) triquine composition tablets (each tablet consisting of 25 mg quinacrine, 65 mg chloroquine and 50 mg hydroxychloroquine) , dosage range from one quarter tablet daily to two tablets daily;
(f) 15-deoxyspergualin, intravenous, intramuscular, subcuta¬ neous or oral dosage range from 0.5 mg/kg daily to 10 mg/kg daily;
(g) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(h) leflunomide, dosage range from 50 μg daily to 50 mg daily;
(i) cyclosporin A, dosage range from 0.1 mg daily to 100 mg daily;
(j) methylprednisolone (Medrol , Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (k) eicosapentaenoic acid (or commercial products containing this substance as the active ingredient, including MaxEPA capsules, 18 gm of which contains 3.2 gm eicosapentaenoic acid) , dosage range from 500 mg daily to 10 gm daily. (1) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(m) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily; (n) cortisone ( Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(o) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(p) methylprednisolone acetate ( Depo -Medrol , Upjohn) , intra¬ synovial, intralesional or intramuscular dosage range' from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(q) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(r) triamcinolone diacetate (Aristocort suspensions, Fuji¬ sawa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(s) dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(t) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily;
(u) hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(v) hydrocortisone (Hydrocortone acetate suspension, Merck & Co.), intra-articular, intralesional or soft tissue injection dosage range from 1 mg daily to 400 mg daily;
(w) prednisolone (Hydeltrasol injection, Merck & Co.), intra¬ venous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily;
(x) triamcinolone acetonide (Aristocort A topical cream, Fu¬ jisawa) , dosage range of from one to four applications per day to affected skin areas;
(y) fluocinolone acetonide (Synalar-HPcream, Syntex) , dosage range of from one to four applications per day to affected skin areas;
(z) fluocinonide (Lidex gel, Syntex) , dosage range of from one to four applications per day to affected skin areas;
(a') flurandrenolide 0.05% cream, lotion or ointment, dosage range of from one to four applications per day to affected skin areas;
(b') betamethasone valerate ( Be tatrex ointment, Savage Labor- atones) , dosage range of from one to four applications per day to affected skin areas;
(c') betamethasone 17,21-dipropionate (Diprolene, Schering), dosage range of from one to three applications per day;
(d' ) aspirin, dosage range from 300 mg daily to 6.5 gm daily;
(e') azathioprine ( Imuran, Burroughs Wellcome), dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily; and
(f) cyclophosphamide, dosage range from 0.1 mg/kg daily to 5 mg/kg daily.
The following illustrate specific formulations according to the present invention.
3,5-diaminobenzoic acid 1 gm
(+) -α-tocopherol acetate 500 I.U. hydroxychloroquine 50 mg
p-aminophenylacetic acid 20 gm mixed tocopherols 3,500 I.U.
15-deoxyspergualin 500 mg
4-guanidinobenzoic acid, potassium salt 5 gm coenzyme Q 200 mg cyclophosphamide 150 mg
Example 13
Clinical treatment of pneumoconiosis due to inhalation of asbestos particles (asbestosis) , inhalation of stone dust or quartz (silic-osis) or inhalation of other causitive agents such as graphite, coal dust, particles produced by metal grinding, talc or corn dust can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat pneumoconiosis due to inhalation of asbestos parti¬ cles (asbestosis) , inhalation of stone dust or quartz (silico- sis) or inhalation of other causitive agents such as graphite, coal dust, particles produced by metal grinding, talc or corn dust, such as, for example,
(a) D-penicillamine ( Cuprimine, Merck & Co.), dosage range from 25 mg daily to 1.5 gm daily;
(b) 4H-4-phenylthieno- [3,2-c] - [1] -benzopyran-2-carboxylic acid, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(c) 4H-2-carboxamido-4-phenylthieno- [3,2-c] - [1] -benzopyran, dosage; range from 0.5 mg/kg daily to 50 mg/kg daily;
(d) iV-acetylcysteine, dosage range from 10 mg/kg daily to 150 mg/kg daily;
(e) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(f) indomethacin (Indocin) , dosage range from 25 mg daily to 250 mg daily;
(g) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(h) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(i) hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(j) flurbiprofen (Ansaid) , dosage range from 50 mg daily to 500 mg daily;
(k) S'-carboxymethylcysteine, dosage range from 1 mg/kg daily to 100 mg/kg daily; and
(1) dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily.
The following illustrate specific formulations according to the present invention.
3,5-diaminophenylacetic acid 1 gm butylated hydroxyanisole 10 mg
N-acetylcysteine 500 mg
p-aminobenzoic acid 20 gm
2-aminomethyl-4-tert-butyl-6-propionylphenol 20 gm prednisolone 100 mg 4 -amino- 2 -methoxycyclohexanecarboxylic acid 5 gm tert-butylhydroquinone 500 mg
D-penicillamine 100 mg
Example 14
Clinical treatment of chronic obstructive pulmonary disease can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat chronic obstructive pulmonary disease, such as, for example,
(a) D-penicillamine ( Cuprimine, Merck & Co.), dosage range from 25 mg daily to 1.5 gm daily;
(b) 4H-4-phenylthieno- [3,2-c] - [1] -benzopyran-2-carboxylic acid, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(c) 4ff-2-carboxamido-4-phenylthieno- [3,2-c] - [1] -benzopyran, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(d) N-acetylcysteine, dosage range from 10 mg/kg daily to 150 mg/kg daily;
(e) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(f) indomethacin ( Indocin) , dosage range from 25 mg daily to 250 mg daily;
(g) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(h) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
(i) hydrocortisone (Hydrocortone phosphate injection, Merck
S Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(j) flurbiprofen (Ansaid) , dosage range from 50 mg daily to
500 mg daily;
(k) S-carboxymethylcysteine, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(1) dexamethasone (Decadron phosphate injection, Merck &
Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(m) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(n) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; and
(o) methylprednisolone ( Solu Medrol , Upjohn) , intravenous or intramuscular dosage range from 0.25 mg/kg daily to 3 mg/kg daily.
The following illustrate specific formulations according to the present invention.
4-amino-2-methylphenylacetic acid 1 gm
-V-acetylcysteine 500 mg
4H-2-carboxamido-4-phenylthieno- [3,2-c] - [1] -benzopyran 25 mg
p-aminobenzoic acid, potassium salt 20 gm
2-aminomethyl-4-tert-butyl-6-iodophenol 20 gm flurbiprofen 500 mg
4-amino-2-methoxybenzoic acid, potassium salt 5 gm acetyl-L-carnitine 1.5 gm methylprednisolone 50 mg
Example 15
Clinical treatment of inflammatory myopathies can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat inflammatory myopathies disease, such as, for example,
(a) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(b) methotrexate (Rheumatrex, Lederle Laboratories) , dosage range from 1 mg weekly to 20 mg weekly;
(c) methotrexate sodium (Methotrexate LPF, Lederle) , intra¬ muscular, intravenous, intra-arterial or intrathecal dosage range from 2.5 mg daily to 30 mgydaily, or doses from 5 mg to 50 mg once or twice weekly;
(d) cyclophosphamide (Cytσxan, Bristol-Myers Oncology) , dosage range from 0.1 mg/kg daily to 5 mg/kg daily;
(e) cyclophosphamide ( Cytoxan for injection, Bristol-Myers Oncology) , dosage range from 0.1 mg/kg daily to 5 mg/kg daily, 2 mg/kg to 5 mg/kg twice weekly or 10 mg/kg to 15 mg/kg every seven to ten days;
(f) chlorambucil (Leukeran, Burroughs Wellcome) , dosage range from 0.5 mg daily to 10 mg daily; and
(g) azathioprine (Imuran, Burroughs Wellcome) , dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily;
(h) diazepam (Valium, Roche Products) , dosage range from 2 mg daily to 40 mg daily;
(i) diazepam (Valium injectable, Roche Products) , dosage range from 2 mg daily to 40 mg daily; and
(j) diazepam (Valrelease, Roche Laboratories), dosage range from 5 mg daily to 30 mg daily.
The following illustrate specific formulations according to the present invention.
4- (aminoguanidino)benzoic acid 1 gm ebselen 250 mg prednisone 1 mg
p-guanidinobenzoic acid, potassium salt 20 gm 5- [ [3,5-bis(1,1-dimethylethyl) -4-hydroxyphenyl] - methylene] -3- (dimethylamino) -4-thiazolidinone 7.5 gm cyclophosphamide 500 mg
4-amino-2-methoxybenzoic acid, potassium salt 5 gm acetylhomocysteine thiolactone 750 mg chlorambucil 5 mg
Example 16
Clinical treatment of inflammatory neuropathies can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent compris¬ ing a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option¬ ally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat inflammatory neuropathies disease, such as, for example,
(a) cortisone ( Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(b) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(c) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(d) methylprednisolone acetate (Depo-Medrol , Upjohn) , intra¬ synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(e) triamcinolone (Aristocort, Fujisawa) , dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(f) triamcinolone diacetate (Aristocort suspensions, Fuji¬ sawa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(g) betamethasone ( Celestone, Schering) , dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing;
(h) betamethasone (Celestone Soluspan suspension, Schering) , intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(i) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(j) dexamethasone (Decadron phosphate injection, Merck S-. Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(k) cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (1) hydrocortisone (Hydrocortone, Merck & Co.), dosage range from 1 mg daily to 400 mg daily;
( ) hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily; (n) prednisolone (Hydel trasol injection, Merck & Co.) , intra- venous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily;
(o) prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily; and
(p) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily. The following illustrate specific formulations according to the present invention.
4-aminocyclohexanecarboxylic acid 1 gm d-α-tocopheryl acetate 500 I.U. prednisone 1 mg
p-aminophenylacetic acid, potassium salt 20 gm 2,6-di-tert-butyl-4- [2'-thenoyl]phenol 20 gm betamethasone 12 mg
4-amino-2-hydroxybenzoic acid 5 gm
L-methionine 2 gm hydrocortisone 50 mg
Example 17
Clinical treatment of epilepsy can be improved by use of a com-position comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat epilepsy, such as, for example,
(a) dizocilpine (Neurogard, Merck Sharp & Dohme) , dosage range from 0.1 μg/kg daily to 10 mg/kg daily;
(b) phenytoin (Dilantin-125, Parke-Davis) , dosage range from 50 mg daily to 625 mg daily;
(c) phenytoin-polyvinylpyrrolidone coprecipitate, dosage range from 50 mg daily to 1 gm daily;
(d) phenytion in combination with phenobarbital (Dilantin capsules, Parke-Davis) , dosage range from 100 mg phenytoin sodium and 16 mg phenobarbital daily to 600 mg phenytoin sodium and 192 mg phenobarbital daily;
(e) phenobarbital (Lilly) , dosage range from 5 mg daily to 200 mg daily;
(f) primidone (Mysoline, Wyeth-Ayerst Laboratories) , dosage range from 25 mg daily to 1.75 gm daily;
(g) carbamazepine (Tegretol, Basel) , dosage range from 50 mg daily to 1.2 gm daily;
(h) ethosuximide (Zarontin, Parke-Davis) , dosage range from 250 mg daily to 2 gm daily;
(i) clonazepam (Klonopin, Roche Laboratories) , dosage range from 0.5 mg daily to 20 mg daily;
(j) valproic acid (Depakene, Abbott Laboratories), dosage range from 1 mg/kg daily to 60 mg/kg daily; (k) divalproex sodium (Depa ote, Abbott Laboratories) , dosage range from 1 mg/kg daily to 60 mg/kg daily;
(1) acetazolamide (Diamox, Lederle) , dosage range from 50 mg daily to 2 gm daily;
(m) acetazolamide sodium (Diamox, Lederle) , intravenous dosage range from 50 mg daily to 2 gm daily; (n) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (o) corticotropin, intramuscular dosage range from 5 units daily to 60 units daily;
(p) diazepam (Valiuπi, Roche Products) , dosage range from 2 mg daily to 40 mg daily;
(q) diazepam (Valiuni injectable, Roche Products) , dosage range from 2 mg daily to 40 mg daily;
(r) lorazepam (Ativan, Wyeth-Ayerst Laboratories) , intravenous dosage range from 50 μg/kg daily to 300 μg/kg daily;
(s) felbamate (Felbatol , Wallace Laboratories) , intravenous, intramuscular, subcutaneous or oral dosage range from 100 μg/kg daily to 2 mg/kg daily;
(t) zonisamide (Excegran, Dainippon) , intravenous, intramus¬ cular, subcutaneous or oral dosage range from 100 μg/kg daily to 2 mg/kg daily;
(u) gabapentin (iYeuron in, Warner-Lambert) , dosage range from 100 μg/kg daily to 2 mg/kg daily; (v) lamotrigine (Lamictal , Burroughs Wellcome) , dosage range from 100 μg/kg daily to 2 mg/kg daily; and
(w) vigabatrin (Sa ril, Marion Merrell Dow) , dosage range from 100 μg/kg daily to 2 mg/kg daily.
The following illustrate specific formulations according to the present invention.
5-amino-2-hydroxybenzoic acid 1 gm d-α-tocopheryl succinate 750 I.U. phenytoin 50 mg
p-aminobenzoic acid 10 gm ebselen 10 gm dizocilpine 500 mg
4-aminophenylacetic acid 5 gm prostaglandin Bx oligomers 7.5 gm primidone 1 gm
Example 18
Clinical treatment of Alzheimer's disease can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option¬ ally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat Alzheimer's disease, such as, for example,
(a) vasodilator or other nootropic direct brain metabolic enhancer drugs such as idebenone, dosage range from 5 mg/kg daily to 150 mg/kg daily; propentophylline, intravenous, intramuscular, subcutaneous or oral dosage range from 50 mg daily to 3 gm daily; pentoxifylline, dosage range from 50 mg daily to 3 gm daily; citicoline, dosage range from 50 mg daily to 5 gm daily; ebiratide, subcutaneous dosage range from 3 μg/kg daily to 1 mg/kg daily; vinpocetine ( Cavinton, Chemical Works of Gedeon Richter, Ltd.) , intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 300 mg/kg daily; bromvincamine, dosage range from 25 mg daily to 3 gm daily; cyclandelate, dosage range from 25 mg daily to 3 gm daily; isoxsuprene, dosage range from 25 mg daily to 3 gm daily; nafronyl, dosage range from 25 mg daily to 3 gm daily; papaverine, dosage range from 25 mg daily to 3 gm daily; suloctidil, dosage range from 25 mg daily to 3 gm daily; vinburnine, dosage range from 25 mg daily to 3 gm daily; vincamine, dosage range from 25 mg daily to 3 gm daily; vindeburnol, dosage range from 25 mg daily to 3 gm daily; naloxone, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg daily to 300 mg daily; ethyl 5-isopropyloxy-4-methyl-3-carboline-3-carboxylate, intravenous, intramuscular, subcutaneous or oral dosage range from 2 mg/kg daily to 100 mg/kg daily;
N' -methyl-jS-carboline-3-carboxamide, intravenous, intramus¬ cular, subcutaneous or oral dosage range from 2 mg/kg daily to 100 mg/kg daily; methyl 6,7-dimethoxy-4-ethyl-/3-carboline-3-carboxylate, intra¬ venous, intramuscular, subcutaneous or oral dosage range from 0.1 mg/kg daily to 10 mg/kg daily; ethyl 5-methoxy-4-ethyl-S-carboline-3-carboxylate, intraven¬ ous, intramuscular, subcutaneous or oral dosage range from 1 mg/kg daily to 30 mg/kg daily; ifenprodil tartrate, dosage range from 0.5 mg/kg daily to 120 mg/kg daily; piracetam, dosage range from 1 mg daily to 100 mg daily; aniracetam, dosage range from 50 mg/kg daily to 1 gm/kg daily; pyroglutamic acid, intravenous, intramuscular, subcutaneous or oral dosage range from 100 mg/kg daily to 5 gm/kg daily; tenilsetam, dosage range from 10 mg daily (or alternate day) to 1 gm daily (or alternate day) , or from 25 mg once a week to 1 gm once a week; pramiracetam, dosage range from 50 mg/kg daily to 8 gm/kg daily; oxiracetam, dosage range from 200 mg daily to 2 gm daily; rolziracetam, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg daily to 1 gm daily; razobazam, intravenous, intramuscular, subcutaneous or oral dosage range from 0.1 mg/kg daily to 25 mg/kg daily; exifone, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg daily to 1 gm daily; rolipram, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg daily to 1 gm daily; sabeluzole, dosage range from 2 mg daily to 40 mg daily; nimodipine (Nimotop, Miles Pharmaceutical) , dosage range from 300 mg daily to 3.6 gm daily; flunarizine, dosage range from 2 mg daily to 100 mg daily; nicergoline (Sermion) , intravenous, intramuscular, subcuta¬ neous or oral dosage range from 6 mg daily to 10 gm daily; phosphatidylserine, intravenous or oral dosage range from 1 mg/kg daily to 250 mg/kg daily; etiracetam, dosage range from 50 mg/kg daily to 8 gm/kg daily; dupracetam, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg daily to 1 gm daily; and ergoloid mesylates (Hydergine, Sandoz Pharmaceuticals) , dosage range from 0.5 mg daily to 40 mg daily;
(b) neurotransmission enhancer drugs such as amantadine (Symmetrel , Du Pont Multi-Source Products) , dosage range from 10 mg daily to 400 mg daily; calcium hopantenate, dosage range from 100 mg daily to 4 gm daily; lisuride, dosage range from 0.1 mg daily to 2 mg daily; and indeloxazine, dosage range from 50 mg daily to 1.5 gm daily;
(c) tiapride, dosage range from 1 mg daily to 400 mg daily;
(d) psychotherapeutic drugs such as haloperidol (Haldol , McNeil Pharmaceutical) , dosage range from 0.2 mg daily to 15 mg daily; bromperidol, dosage range from 20 μg/kg daily to 0.25 mg/kg daily; thioridazine (Mellaril, Sandoz Pharmaceutical) , dosage range from 10 mg daily to 800 mg daily; thiothixene (Navane, Roerig) , dosage range from 2 mg daily to 60 mg daily; fluphenazine (Prolixin, Apothecon) , dosage range from 0.2 mg daily to 40 mg daily; perphenazine in amitriptyline/perphenazine combinations (Etrafon, Schering) , dosage range from 4 mg perphenazine and 50 mg amitriptyline daily to 16 mg perphenazine and 100 mg amitriptyline daily; and molindone (MoJban, Du Pont Multi-Source Products) , dosage range from 3 mg daily to 225 mg daily;
(e) acetylcholinesterase inhibitors such as physostigmine (Antilirium Injectable, Forest Pharmaceuticals) , oral dosage range from 0.1 mg daily to 20 mg daily, or intravenous, intramuscular or subcutaneous dosage range from 5 μg daily to 3 mg daily, optionally with phosphatidylcholine co-agent, oral dosage range from zero to 15 gm daily; heptylphysostigmme, dosage range from 1 mg daily to 1 gm daily; tacrine ( Cognex, Warner-Lambert) , dosage range from 5 mg daily to 200 mg daily, optionally with phosphatidylcholine co-agent, dosage range from zero to 15 gm daily;
(*/.) -9-amino-l,2,3,4-tetrahydroacridin-l-ol, dosage range from 2 mg daily to 200 mg daily; metrifonate, intramuscular, intravenous, subcutaneous or oral dosage range from 0.1 mg/kg daily to 125 mg/kg daily; velnacrine (Mentane, Hoechst-Roussel) , dosage range from 10 mg daily to 350 mg daily; phenylmethylsulfonyl fluoride, intravenous, subcutaneous, intramuscular or oral dosage range from 5 mg/kg daily to 60 mg/kg daily; methanesulfonyl fluoride, intravenous, intramuscular, sub¬ cutaneous or oral dosage range from 5 mg/kg daily to 350 mg/kg daily; huperzine A, intramuscular, intravenous, subcutaneous or oral dosage range from 10 μg/kg daily to 1 mg/kg daily; huperzine B, intramuscular, intravenous, subcutaneous or oral dosage range from 10 μg/kg daily to 1 mg/kg daily; edrophoniu chloride (Hoffman LaRoche) , intravenous, intramus¬ cular, subcutaneous or oral dosage range from 2 mg daily to 400 mg daily; galanthamine, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg daily to 100 mg daily; and miotine, intravenous, intramuscular, subcutaneous or oral dosage range from 2 mg daily to 400 mg daily;
(f) calcium channel blocker agents such as diltiazem ( Cardizem or Cardizem SR) , dosage range from 10 mg daily to 360 mg daily; verapamil ( Calan or Calan SR) , dosage range from 10 mg daily to 480 mg daily; nifedipine (Procardia) , dosage range from 3 mg daily to 180 mg daily; nifedipine (Procardia XL) , dosage range from 3 mg daily to 90 mg daily; nicardipine ( Cardene) , dosage range from 6 mg daily to 120 mg daily; isradipine (DynaCirc) , dosage range from 0.5 mg daily to 20 mg daily; amlodipine (Norvasc, Pfizer Labs Division) , dosage range from 0.5 mg daily to 10 mg daily; and felodipine (Plendil , Merck & Co.), dosage range from 0.5 mg daily to 20 mg daily;
(g) biogenic amines and substances related thereto such as clonidine ( Catapres, Boehringer Ingelheim) , dosage range from 0.25 mg daily to 2.4 mg daily; guanfacine ( Tenex, Robins) , dosage range from 0.25 mg daily to 3 mg daily; alaproclate, dosage range from 0.25 mg daily to 3 mg daily; fipexide, dosage range from 0.25 mg daily to 3 mg daily; zimeldine, dosage range from 0.25 mg daily to 3 mg daily; and citalopram, dosage range from 0.25 mg daily to 3 mg daily; (h) antirage drugs such as propranolol (Inderal , Wyeth-Ayerst Laboratories) , dosage range from 30 mg daily to 640 mg daily; carbamazepine (Tegrretol, Geigy) , dosage range from 40 mg daily to 1.6 gm daily; and fluoxetine (Prozac Pulvules, Dista) , dosage range from 20 mg daily to 80 mg daily;
(i) minor tranquilizers such as benzodiazepine agents including diazepam ( Valium, Roche Products), dosage range from 0.5 mg daily to 40 mg daily; lorazepam (Ativan, Wyeth-Ayerst Laboratories) , dosage range from 0.5 mg daily to 10 mg daily; prazepam ( Centrax, Parke-Davis), dosage range from 5 mg daily to 60 mg daily; ' -? chlordiazepoxide (Libri tabs, Roche Products) , dosage range from 5 mg daily to 300 mg daily; chlordiazepoxide/clidinium combination (Librax, Roche
Products), dosage range from 5 mg chlordiazepoxide and 2.5 mg clidinium daily to 20 mg chlordiazepoxide and 10 mg clidinium daily; chlordiazepoxide/amitriptyline combination (Limbi trol DS,
Roche Products) , dosage range from 10 mg chlordiazepoxide and
25 mg daily to 60 mg chlordiazepoxide and 150 mg amitriptyline daily; chlordiazepoxide/esterified estrogen combination (Menrium,
Roche Products) , dosage range from 5 mg chlordiazepoxide and
0.2 mg esterified estrogen daily to 30 mg chlordiazepoxide and
1.2 mg esterified estrogen daily; oxazepam (Serax, Wyeth-Ayerst) , dosage range from 10 mg daily to 120 mg daily; and clorazepate dipotassium (rranxene, Abbott Laboratories) , dosage range from 3.75 mg daily to 60 mg daily;
(j) angiotensin converting enzyme inhibitors such as captopril ( Capoten, Squibb) , dosage range from 5 mg daily to
300 mg daily; captopril in combination with hydrochlorothiazide ( Capozide,
Squibb) , dosage range from 5 mg captopril and 3 mg hydrochloro-thiazide daily to 150 mg captopril and 50 mg hydrochlorothiazide daily; enalapril maleate (Vasotec, Merck & Co.), dosage range from
0.5 mg daily to 100 mg daily; enalaprilat, dosage range from 0.5 mg daily to 100 mg daily; enalapril maleate/hydrochlorothiazide combination ( Vaseretic, Merck & Co.)., dosage range from 2.5 mg enalapril maleate and
6.25 mg hydrochlorothiazide daily to 20 mg enalapril maleate and 50 mg hydrochlorothiazide daily; fosinopril (Monopril , Mead Johnson Pharmaceuticals) , dosage range from 2 mg daily to 60 mg daily; lisinopril (Zestril , Stuart) , dosage range from 1 mg daily to
40 mg daily; ramipril (Altace, Hoechst-Roussel) , dosage range from 0.5 mg daily to 10 mg daily; epi-captopril, dosage range fro? <mY1 mg daily to 300 mg daily; alacepril, dosage range from 5 mg daily to 300 mg daily; quinapril, dosage range from 0.5 mg daily to 40 mg daily; perindopril, dosage range from 0.2 mg daily to 40 mg daily; delapril, dosage range from 4 mg daily to 1.5 gm daily; cilazapril, dosage range from 0.2 mg daily to 40 mg daily; pivalopril, dosage range from 2 mg daily to 250 mg daily; rentiapril, dosage range from 1 mg daily to 150 mg daily; zofenopril, dosage range from 1 mg daily to 150 mg daily; and zofenoprilat, dosage range from 1 mg daily to 150 mg daily; (k) substances which may enhance acetylcholine synthesis, storage or release such as phosphatidylcholine, dosage range from 1 gm daily to 15 gm daily;
4-aminopyridine, intravenous, intramuscular, subcutaneous or oral dosage range from 0.25 mg/kg daily to 10 mg/kg daily; 3,4-diaminopyridine, intravenous, intramuscular, subcutaneous or oral dosage range from 50 μg daily to 100 mg daily; choline chloride, dosage range from 500 mg daily to 30 gm daily; choline bitartrate, dosage range from 500 mg daily to 30 gm daily; bifemelane, dosage range from 1 mg/kg daily to 1.2 gm/kg daily; vesamicol, dosage range from 50 μg/kg daily to 500 mg/kg daily; secoverine, dosage range from 50 μg/kg daily to 500 mg/kg daily; tetraphenylurea, dosage range from 50 μg/kg daily to 500 mg/kg daily; and nicotinamide, dosage range from 1 mg/kg daily to 500 mg/kg daily;
(1) postsynaptic receptor agonists such as arecoline, intravenous, intramuscular, subcutaneous or oral dosage range from 2 mg daily to 25 mg daily; oxotremorine, intravenous, intramuscular, subcutaneous or oral dosage range from 1 μg/kg daily to 0.2 mg/kg daily; ethyl nipecotate, intravenous, intramuscular, subcutaneous or oral dosage range from 2 mg daily to 250 mg daily; bethanechol ( Urecholine, Merck & Co.), dosage range from 5 mg daily to 200 mg daily; and ' " levacecarnine (acetyl-L-carnitine or Alcar, Sigma-Tau) , dosage range from 500 mg daily to 5 gm daily;
(m) ganglioside GM1 intravenous, intramuscular or subcutaneous dosage range from 20 mg daily to 200 mg daily; (n) mixed cow brain gangliosides ( Cronassial , Fidia Pharma¬ ceutical, marketed in several countries in Western Europe, South America and the Far East) , intravenous, intramuscular or subcutaneous dosage range from 20 mg daily to 200 mg per day; (o) specific monoamine oxidase-A inhibitors such as moclobemide (Aurorix, Hoffmann-La Roche) , dosage range from 50 mg daily to 600 mg daily;
(p) iV-methyl-D-aspartate glutamate receptor antagonists ad¬ ministered orally, intravenously, intramuscularly or subcuta- neously such as milacemide, dosage range from 50 mg daily to 2.5 gm daily; trihexyphenidyl (Artane, Lederle), dosage range from 0.1 mg daily to 20 mg daily; ethopropazine (Paridol) , dosage range from 10 mg daily to 400 mg daily; procyclidine (Kemadrin, Burroughs Wellcome) , dosage range from 1 mg daily to 40 mg daily; diphenhydramine (Benadryl , Parke-Davis) , dosage range from 5 mg daily to 200 mg daily; dizocilpine (Neurogard, Merck Sharp & Dohme) , dosage range from 0.1 μg/kg daily to 10 mg/kg daily; amantadine (Symmetrel , Du Pont Multi-Source Products) , dosage range from 10 mg daily to 400 mg daily; and memantine, dosage range from 10 mg daily to 400 mg daily; (q) nonsteroidal anti-inflammatory agents such as those recognized for treatment of rheumatoid arthritis, including flurbiprofen (Ansaid, Upjohn) , dosage range from 20 mg daily to 300 mg daily; aspirin (Arthritis Pain Formula, Whitehall Laboratories) , dosage range from 250 mg aspirin daily to 4 gm daily; mesalamine (Asacol , Procter & Gamble Pharmaceuticals), dosage range from 250 mg daily to 2.4 gm daily; phenylbutazone (Butazolidin, Geigy) , dosage range from 30 mg daily to 400 mg daily; fά> sulindac ( Clinoril, Merck & Co) , dosage range from 40 mg daily to 400 mg daily;
D-penicillamine ( Cuprimine, Merck & Co.) , dosage range from 25 mg daily to 2 gm daily; oxaprozin (Daypro, Searle) , dosage range from 25 mg' daily to
2 gm daily; salsalate (Disalcid, 3M Pharmaceuticals) , dosage range from
300 mg daily to 3 gm daily; diflunisal (Dolobid, Merck & Co.), dosage range from 100 mg daily to 1.5 gm daily; piroxicam (Feldene, Pfizer Labs Division) , dosage range from
2 mg daily to 20 mg daily; indomethacin (Indocin, Merck & Co.), dosage range from 10 mg daily to 200 mg daily; etodolac (Lodine, Wyeth-Ayerst Laboratories) , dosage range from 100 mg daily to 1.2 gm daily; meclofenamate sodium (Meclomen, Parke-Davis) , dosage range from 20 mg daily to 400 mg daily; ibuprofen (Motrin, Upjohn) , dosage range from 100 mg daily to
3.2 gm daily; fenoprofen calcium (Nalfon, Dista) , dosage range from 100 mg daily to 3.2 gm; naproxen sodium (Anaprox, Syntex) , dosage range from 50 mg daily to 1.65 gm daily; naproxen (Naprosyn, Syntex) , dosage range from 50 mg daily to
1.5 gm daily; ketoprofen (Orudis, Wyeth-Ayerst) , dosage range from 15 mg daily to 300 mg daily; mefenamie acid (Ponstel , Parke-Davis) , dosage range from 150 mg daily to 1.5 gm daily; nabumetone (Relafen, SmithKline Beecham) , dosage range from
100 mg daily to 2 gm daily; auranofin (Ridaura, SmithKline Beecham) , dosage range from 1 mg daily to 9 mg daily; tolmetin sodium ( Tolectin, McNeil Pharmaceutical) , dosage range from 100 mg daily to 1.8 gm daily; ketorolac tromethamine ( Toradol , Syntex Laboratories) , dosage range from 4 mg daily to 40 mg daily; diclofenac sodium (Voltaren, Geigy) , dosage range from 10 mg daily to 200 mg daily; and ' deferoxamine mesylate (Desferal, CIBA Pharmaceutical) , intra¬ venous, intramuscular or subcutaneous dosage range from 100 mg daily to 2 gm daily;
(r) selegiline (Eldepryl , Somerset) , dosage range from 5 mg daily to 10 mg daily;
(s) thiamine, dosage range from 500 mg daily to 3 gm daily; (t) anfacine, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg/kg daily to 350 mg/kg daily; (u) sulbutiamine (Arcalion, Laboratories Servier) , dosage range from 1 mg/kg daily to 350 mg/kg daily; (v) anti-oxidant agents which may be used in combination such as ascorbic acid, dosage range from 1 mg daily to 60 mg daily; α-tocopherol, dosage range from 100 I. U. daily to 3,500 I. U. daily; iV-acetylcysteine, dosage range from 100 mg daily to 1 gm daily; jβ-carotene, dosage range from 20 mg daily to 300 mg daily; penicillamine, dosage range from 25 mg daily to 2 gm daily; cysteamine, dosage range from 200 mg daily to 4 gm daily; deferoxamine mesylate (Desferal , CIBA Pharmaceutical) , intra¬ venous, intramuscular or subcutaneous dosage range from 100 mg daily to 2 gm daily; and ebselen, dosage range from 5 mg/kg daily to 1 gm/kg daily; (w) specific monoamine oxidase-B inhibitors such as lazabemide (Hoffmann-La Roche) , dosage range from 10 mg daily to 200 mg daily;
(x) linopirdine (Aviva, DuPont Merck) , dosage range from 1 mg daily to 500 mg daily;
(y) D-cycloserine, dosage range from 0.1 mg/kg daily to 15 mg/kg daily;
(z) serotonergic receptor antagonists such as ketanserin (Ketan, Janssen Pharmaceutica) , intravenous, intra¬ muscular, subcutaneous or oral dosage range from 0.1 mg/kg daily to 20 mg/kg daily; and mianserin (Mian, Organon International), intravenous, intra¬ muscular, subcutaneous or oral dosage range from 0.1 mg/kg daily to 20 mg/kg daily; and (a') estrogen, dosage range fro fmf0.2 mg daily to 1.2 mg daily.
The following illustrate specific formulations according to the present invention.
trans-4-aminocyc1ohexane- carboxylic acid 1 gm d-α-tocopherol 500 I.U. V'-methyl-S-carboline-3-carboxamide 200 mg
p-aminobenzoic acid, potassium salt 15 gm 2- (2-hydroxy-4-methylphenyl) - aminothiazole hydrochloride 4 gm lazabemide 200 mg
4-guanidinophenylacetic acid 5 gm tert-butylhydroquinone 500 mg dizocilpine 100 mg
Example 19
Clinical treatment of myasthenia gravis can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option¬ ally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat myasthenia gravis, such as, for example,
(a) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(b) azathioprine ( Imuran, Burroughs Wellcome) , dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily;
(c) pyridostigmine (Mestinon, ICN) , dosage range from 100 mg daily to 1.5 gm daily;
(d) pyridostigmine (Mestinon injectable, ICN) , intramusular or slow intravenous dosage range from 100 mg daily to 1.5 gm daily;
(d) neostigmine bromide (Prostigmin, ICN) , dosage range from 5 mg daily to 375 mg daily;
(e) neostigmine methylsulfate (Prostigmin injectable, ICN) , intramuscular or subcutaneous fdofsage range from 0.5 mg daily to 10 mg daily;
(f) atropine, dosage range from 0.2 mg daily to 2 mg daily;
(g) propantheline ( Pro -Ban thine, Schiapparelli Searle) , dosage range from 15 mg daily to 75 mg daily; and
(h) ephedrine, dosage range from 10 mg daily to 100 mg daily. The following illustrate specific formulations according to the present invention.
4-amino-2-methylbenzoic acid 1 gm mixed tocopherols 500 I.U. pyridostigmine 100 mg
4-amino-2-methoxybenzoic acid, potassium salt 15 gm D-myo-inositol-1.2.6-trisphosphate 20 gm azathioprine 150 mg
4- (aminoguanidino)phenylacetic acid 5 gm deferoxamine mesylate 200 mg propantheline 25 mg
Example 20
Clinical treatment of multiple sclerosis can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option¬ ally at least one sub-stance selected from those noted above in section (v) through section (ix) , and a medicament recog¬ nized as effective to treat multiple sclerosis, such as, for example,
(a) 15-deoxyspergualin, intravenous, intramuscular, subcuta¬ neous or oral dosage range from 0.5 mg/kg daily to 10 mg/kg daily;
(b) leflunomide, dosage range from 50 μg daily to 50 mg daily;
(c) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(d) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(e) dexamethasone (Decadron, Merck & Co.), dosage range from 0.1 mg daily or every other day to 10 mg daily or every other day;
(f) corticotropin (Depo-ACTH, Upjohn) , intravenous, intramus¬ cular or subcutaneous dosage range from from 10 units daily to 150 units daily;
(g) cyclosporinA (Sandimmune, Sandoz Pharmaceutical) , dosage range from 1 mg/kg daily to 15 mg/kg daily;
(h) amantadine (Symmetre!, Du Pont Multi-Source Products) , dosage range from 10 mg daily to 400 mg daily; (i) diazepam (Valiuπ, Roche Products), dosage range from 0.5 mg daily to 40 mg daily;
(j) clonazepam (Klonopin, Roche Laboratories), dosage range from 0.5 mg daily to 20 mg daily;
(k) carbamazepine ( Tegretol , Geigy) , dosage range from 40 mg daily to 1.6 gm daily;
(1) phenytoin (Dilantin-125, Parke-Davis) , dosage range from 50 mg daily to 625 mg daily;
(m) isoniazid (INH isoniazid, CIBA) , dosage range from 10 mg daily to 300 mg daily;
(n) primidone (Mysoline, Wyeth-Ayerst Laboratories) , dosage range from 25 mg daily to 1.75 gm daily;
(o) propranolol (Jnderal, Wyeth-Ayerst Laboratories) , dosage range from 30 mg daily to 640 mg daily;
(p) amitriptyline (Elavil , Stuart) , dosage range from 50 mg daily to 300 mg daily;
(q) oxybutynin (Di tropan, Marion Merrell Dow) , dosage range from 2.5 mg daily to 20 mg daily;
(r) propantheline (Pro-Banthine, Schiapparelli Searle) , dosage range from 2.5 mg daily to 75 mg daily; (s) imipramine, dosage range from 2 mg daily to 150 mg daily; (t) carbachol, dosage range from 50 μg/kg daily to 5 mg/kg daily;
(u) bethanechol ( Urecholine, Merck & Co.), dosage range from 5 mg daily to 200 mg daily;
(v) phenoxybenzamine (Dibenzyline, SmithKline Beecham) , dosage range from 5 mg daily to 150 mg daily; (w) tizanidine, dosage range from 50 μg/kg daily to 5 mg/kg daily; /^
(x) chlorpromazine ( Thorazine, SmithKline Beecham) , dosage range from 10 mg daily to 200 mg daily;
(y) baclofen (Atrofen, Athena Neurosciences) , dosage range from 1 mg daily to 80 mg daily;
(z) diacetylrhein, dosage range from 10 mg daily to 500 mg daily;
(a') alfa-2a interferon (Roferon-A, Roche Laboratories), in¬ travenous, intramuscular or subcutaneous dosage range from 300,000 IU daily to 36,000,000 IU daily;
(b' ) alfa-2b interferon (Jntron-A, Schering), intravenous, intramuscular or subcutaneous dosage range from 300,000 IU daily to 5,000,000 IU daily;
(c') alfa-N3 interferon (Alferon N Injection, Purdue Frederick) , intravenous, intramuscular or subcutaneous dosage range from 250,000 IU daily to 2,500,000 IU daily; (d' ) beta interferon (Betaseron, Berlex) , intravenous, intra¬ muscular or subcutaneous dosage range from 5,000 U/kg daily to 50,000 U/kg daily;
(e') gamma-lb interferon (Actimmune, Genentech) , intravenous, intramuscular or subcutaneous dosage range from 5,000 U/kg daily to 50,000 U/kg daily;
(f) copolymer-1 (random polymer of L-alanine, L-glutamic acid, L-lysine and L-tyrosine, ratio of 6.0:1.9:4.7:1.0, of molecular weight between 14,000 and 23,000 Daltons), intra¬ venous, subcutaneous or intramuscular dosage range 2 mg daily to 40 mg daily;
(g' ) 4-aminopyridine, intravenous, intramuscular, subcutaneous or oral dosage range from 0.25 mg/kg daily to 10 mg/kg daily; (h' ) 3,4-diaminopyridine, dosage range from 50 μg daily to 100 mg daily;
(i') cyclophosphamide ( Cytoxan, Bristol-Myers Oncology) , dos¬ age range from 0.1 mg/kg daily to 5 mg/kg daily; (j') cyclophosphamide ( Cytoxan for injection, Bristol-Myers Oncology) , intravenous, intramuscular or subcutaneous dosage range from 0.1 mg/kg daily to 5 mg/kg daily, 2 mg/kg to 5 mg/kg twice weekly or 10 mg/kg to 15 mg/kg every seven to ten days; (k') prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(1') methylprednisolone acetate (Depo -Medrol, Upjohn), intra¬ synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(m' ) triamcinolone (Aristocort, Fujisawa), dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (n' ) triamcinolone diacetate (Aristocort suspensions, Fujisa¬ wa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(o') methylprednisolone (Solu Medrol , Upjohn), intramuscular or intravenous maintenance dosage range from 0.25 mg/kg daily to 3 mg/kg daily;
(p') azathioprine (Imuran, Burroughs Wellcome), dosage range from 5 mg daily to 300 mg daily; and
(q' ) bovine myelin, dosage range from 25 mg daily to 1 gm daily.
The following illustrate specific formulations according to the present invention.
4-guanidino-2-methylbenzoic acid 1 gm prostaglandin B1 oligomers 300 mg diacetylrhein 10 mg
4-amino-2-hydroxybenzoic acid 20 gm
N, N' -dimethylthiourea 5 gm baclofen 80 mg
4- (aminoguanidino) -2-methoxyphenylacetic acid 5 gm N, N'-diphenyl-p-phenylenediamine 10 gm carbamazepine 500 mg
Example 21
Clinical treatment of inflammatory site edema can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent compris¬ ing a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option- ally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat inflammatory site edema, such as, for example,
(a) cyproheptadine, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 50 mg/kg daily;
(b) clemastine, intravenous, intramuscular, subcutaneous or oral dosage range from 20 mg/kg daily to 200 mg/kg daily;
(c) setastine, intravenous, intramuscular or subcutaneous dosage range from 20 mg/kg daily to 200 mg/kg daily;
(d) indomethacin, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg/kg daily to 100 mg/kg daily;
(e) piroxicam, intravenous, intramuscular, subcutaneous or oral dosage range from 20 mg/kg daily to 200 mg/kg daily;
(f) phenylbutazone, intravenous, intramuscular, subcutaneous or oral dosage range from 50 mg/kg daily to 500 mg/kg daily;
(g) dexamethasone (Decadron, Merck & Co.), dosage range from 0.25 mg daily to 18 mg daily;
(h) phenidone, intravenous, intramuscular, subcutaneous or oral dosage range from 25 mg/kg daily to 1 gm/kg daily; (i) nordihydroguaiaretic acid, intravenous, intramuscular, subcutaneous or oral dosage range from 100 mg/kg daily to 2 gm/kg daily;
(j) ketoconazole, intravenous, intramuscular, subcutaneous or oral dosage range from 100 mg/kg daily to 2 gm/kg daily; (k) suprofen, dosage range from 5 mg/kg daily to 100 mg/kg daily;
(1) ketoprofen, dosage range from 2 mg/kg daily to 50 mg/kg daily;
(m) indoprofen, dosage range from 1 mg/kg daily to 30 mg/kg daily;
(n) sudoxicam, dosage range from 0.5 mg/kg daily to 40 mg/kg daily,-
(o) naproxen, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(p) meclofenamic acid, dosage range from 15 mg/kg daily to 150 mg/kg daily;
(q) ibuprofen, dosage range from 15 mg/kg daily to 150 mg/kg daily; (r) diclofenac, dosage range from 1 mg/kg daily to 25 mg/kg; (s) fenoprofen, dosage range from 5 mg/kg daily to 100 mg/kg daily,-
(t) hydroxychloroquine, dosage range from 20 mg/kg daily to 400 mg/kg daily;
(u) 2,6-diamino-N-{ [1- (1-oxotridecyl) -2-piperidinyl] -methyl}- hexanamide, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(v) bucloxic acid, dosage range from 200 mg daily to 2 gm daily;
(w) butibufen, dosage range from 40 mg/kg daily to 400 mg/kg daily;
(x) carprofen, dosage range from 0.2 mg/kg daily to 50 mg/kg daily;
(y) the (S) (+) enantiomer of carprofen, dosage range from 50 mg daily to 750 mg daily;
(z) 6- (2,4-difluorophenoxy) -5-methylsulfonylamino-l-indanone (Ciba-Geigy AG) , dosage range from 0.2 mg/kg daily to 20 mg/kg daily;
(a') loxoprofen, dosage range from 0.1 mg/kg daily to 25 mg/kg daily;
(b' ) diaveridine, dosage range from 25 mg/kg daily to 500 mg/kg daily;
(c') ditazol, dosage range from 25 mg/kg daily to 750 mg daily;
(d' ) droxicam, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(e' ) (Z)-3- [4- (acetyloxy)-5-ethyl-3-methoxy-l-naphthalenyl] -2- methyl-2-propenoic acid, dosage range from 10 mg/kg daily to 500 mg/kg daily;
(f) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily; (g' ) l-p-chlorobenzyl-2-dimethyl-aminomethylcyclohexen-l,2, dosage range from 2.5 mg/kg daily to 250 mg/kg daily; (h' ) etoclofene, intravenous, intramuscular, subcutaneous or oral dosage range from 1 mg/kg daily to 400 mg/kg daily; (i') flufenamic acid, dosage range from 1 mg/kg daily to 400 mg/kg daily; (j') benzydamine, dosage range from 10 mg/kg daily to 1 gm/kg daily; /of
(1') mefenamie acid, dosage range from 1 mg/kg daily to 400 mg/kg daily;
(m' ) fenbufen, dosage range from 250 mg daily to 1.25 gm daily;
(n') felbinac, dosage range from 100 mg daily to 1.25 gm daily;
(o') fenclorac, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(p' ) fenclozic acid, dosage range from 25 mg daily to 500 mg daily;
(q' ) fendosal, dosage range from 5 mg/kg daily to 200 mg/kg daily;
(r' ) isoxepac, dosage range from 200 mg daily to 2 gm daily;
(s') imidazole salicylate, dosage range from 50 μmol/kg daily to 0.5 mmol/kg daily;
(f) isoxicam, dosage range from 50 mg daily to 500 mg daily;
(u' ) tolmetin, dosage range from 50 mg daily to 500 mg daily;
(v' ) leflunomide, dosage range from 50 μg daily to 50 mg daily;
(w' ) isofezolac, dosage range from 0.1 mg/kg daily to 25 mg/kg daily;
(x' ) l-isobutyl-3,4-diphenylpyrazole-5-acetic acid, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(y' ) S-adenosylmethionine, dosage range from 500 mg daily to 10 gm daily;
(z') D-myo-inositol-1.2.6-trisphosphate, intravenous, intra¬ muscular, subcutaneous or oral dosage range from 10 mg/kg daily to 1.5 gm daily;
(a' ' ) diacetylrhein, dosage range from 10 mg daily to 500 mg daily;
(b' ' ) cinmetacin, dosage range from 2 mg/kg daily to 400 mg/kg daily;
(c'') tinoridine, dosage range from 2.5 mg/kg daily to 250 mg/kg daily;
(d' ' ) nimesulide, dosage range from 100 mg daily to 2 gm daily;
(e'#) prenazone, dosage range from 0.5 mg/kg daily to 400 mg/kg daily; (f' ') naphthypramide, dosage range from 0.5 mg/kg daily to 400 mg/kg daily;
(g' ' ) perisoxal, dosage range from 0.5 mg/kg daily to 400 mg/kg daily;
(h' ' ) proquazone, dosage range from 150 mg daily to 1.5 gm daily;
(i'') ketorolac, dosage range from 20 μg/kg daily to 2 mg/kg daily;
(j'') hydrocortisone (Hydrocortone, Merck &Co.), dosage range from 1 mg daily to 400 mg daily;
(k'') prednisolone (Pediapred, Fisons) , dosage range from 1 mg daily or every other day to 250 mg daily;
(1'') cortisone ( Cortone, Merck & Co.), dosage range from 5 mg daily to 400 mg daily;
(m' ' ) prednisone (Del tasone, Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (n' ' ) methylprednisolone (Medrol , Upjohn), dosage range from 1 mg daily to 250 mg daily, or alternate day dosing; (o'') methylprednisolone acetate (Depo-Medrol , Upjohn), intra¬ synovial, intralesional or intramuscular dosage range from 0.5 mg daily to 50 mg daily, or weekly dosage of from 20 mg to 120 mg;
(p' ' ) triamcinolone (Aristocort, Fujisawa), dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; (q' ' ) triamcinolone diacetate (Aristocort suspensions, Fujisa¬ wa) , intramuscular, intrasynovial or intralesional dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(r' ' ) betamethasone ( Celestone, Schering), dosage range from 0.2 mg daily to 12 mg daily, or alternate day dosing; (s'') betamethasone ( Celestone Sol uspan suspension, Schering), intramuscular or intralesional dosage range from 0.1 mg daily to 10 mg daily, or alternate day dosing;
(t'') dexamethasone (Decadron phosphate injection, Merck & Co.) , intramuscular, intravenous or intralesional dosage range from 0.1 mg daily to 10 mg daily;
(u'') cortisone ( Cortone suspension, Merck & Co.), intramus¬ cular dosage range from 5 mg daily to 400 mg daily; (v'') hydrocortisone (Hydrocortone phosphate injection, Merck & Co.), intramuscular, intravenous or subcutaneous dosage range from 1 mg daily to 400 mg daily;
(w' ' ) prednisolone (Hydel trasol injection, Merck & Co.), intravenous, intramuscular, intra-articular, intralesional and soft tissue dosage range from 1 mg daily to 100 mg daily; and
(x' ' ) N, N' -diphenyl-p-phenylenediamine, dosage range from 10 mg/kg daily to 250 mg/kg daily.
The following illustrate specific formulations according to the present invention.
4-guanidinocyclohexanecarboxylic acid 1 gm
W-acetylcysteine 750 mg cyproheptadine 300 mg
p-aminobenzoic acid, potassium salt 15 gm ebselen 20 gm
S-adenosylmethionine 10 gm
4- (aminoguanidino) -2-methoxybenzoic acid 5 gm deferoxamine mesylate 500 mg meclofenamic acid 5 gm
Example 22
Clinical treatment of post-event acute central nervous system trauma, including stroke and spinal cord trauma can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent compris¬ ing a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and option¬ ally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat post-event acute central nervous system trauma, including stroke and spinal cord trauma, such as, for example,
(a) heparin calcium ( Calciparine, Du Pont Multi-Source) , intravenous or subcutaneous dosage range from 5,000 units daily to 40,000 units daily;
(b) heparin sodium (Heparin Lock Flush solution, Wyeth-Ayerst Laboratories) , intravenous or subcutaneous dosage range from 5,000 units daily to 40,000 uni /tøsidaily;
(c) warfarin ( Coumadin, Du Pont) , dosage range from 1 mg daily to 15 mg daily;
(d) ticlopidine ( Ticlid, Syntex) , dosage range from 50 mg daily to 750 mg daily;
(e) aminophylline, intramuscular, intravenous, subcutaneous or oral dosage range from 5 mg/kg daily to 75 mg/kg daily;
(f) isoproterenol (Iεuprel , Sanofi Winthrop) , intravenous, intramuscular or subcutaneous dosage range from 10 μg daily to 1 mg daily;
(g) methohexital sodium, intravenous dosage range from 5 mg/kg/hr to 50/kg/hr post-trauma;
(h) tirilazad mesylate (U-74006F) , intravenous dosage range from 150 μg/kg/hr to 15 mg/kg/hr;
(i) derivative of tirilazad in which the steroid portion of the chemical structure has been replaced with the tetramethyl chroman portion of d-α tocopherol (U78517F, Upjohn) , intra¬ venous dosage range from 150 μg/kg/hr to 15 mg/kg/hr; (j) allopurinol (Zyloprim, Burroughs Wellcome) , dosage range from 50 mg daily to 800 mg daily;
(k) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily; and (1) methylprednisolone, maintenance intravenous, intramus¬ cular, subcutaneous or oral dosage range from 5 μg/kg daily to 0.1 mg/kg daily or immediate post-event treatment intravenous, intramuscular or subcutaneous dosage range from 30 mg/kg to 160 mg/kg during a 24 hour period;
( ) aspirin, dosage range from 50 mg daily to 1.3 gm daily; (n) sulfinpyrazone (Anturane, CIBA) , dosage range from 50 mg daily to 800 mg daily;
(o) dipyridamole (Perεantine, Boehringer Ingelheim) , dosage range from 25 mg daily to 400 mg daily;
(p) clofibrate (Atromid-S, Wyeth-Ayerst Laboratories) , dosage range from 100 mg daily to 2 gm daily;
(q) tissue plasminogen activator (Activase, Genentech) , in¬ travenous dosage range from 5 mg daily to 150 mg daily; (r) streptokinase (Streptase, Astra) , intravenous dosage range from 50,000 IU daily to 500,000 IU daily; and (s) iV-methyl-D-aspartate glutamate receptor antagonists ad- ministered orally, intramuscul /a0rlfy, subcutaneously or lntra- veneously such as trihexyphenidyl (Artane, Lederle), dosage range from 0.1 mg daily to 20 mg daily; ethopropazine (Paridol ) , dosage range from 10 mg daily to 400 mg daily; procyclidine (Kemadrin, Burroughs Wellcome) , dosage range from
1 mg daily to 40 mg daily; diphenhydramine (Benadryl , Parke-Davis) , dosage range from 5 mg daily to 200 mg daily; dizocilpine (Neurogard, Merck Sharp & Dohme) , dosage range from 0.1 μg/kg daily to 10 mg/kg daily; amantadine (Symmetrel , Du Pont Multi-Source Products) , dosage range from 10 mg daily to 400 mg daily; memantine, dosage range from 10 mg daily to 400 mg daily; milacemide, dosage range from 50 mg daily to 2.5 grams daily; and dextrorphan (Roche) , dosage range from 10 mg daily to 400 mg daily;
(t) low molecular weight sulphate/dermatan sulphate glyco- amino-glycan heparinoid mixtures, 6,500 Dalton mean molecular weight, intravenous, intramuscular or subcutaneous dosage range from 250 anti-factor-Xa units daily to 10,000 anti- factor-Xa units daily; and
(u) moclobemide (Aurorix, Hoffmann-La Roche) , dosage range from 50 mg daily to 600 mg daily.
The following illustrate specific formulations according to the present invention.
4-aminocyclohexanecarboxylic acid 1 gm deferoxamine mesylate 500 mgf heparin calcium 5,000 units
p-aminobenzoic acid 15 gm d-α-tocopheryl succinate 3,500 I .U. ebselen 20 gm methylprednisolone 5 mg
4-aminophenylacetic acid 5 gm ebselen //, / 10 gm moclobemide 250 mg
Example 23
Clinical treatment of post-event consequences of kidney ischemia and reperfusion can be improved by use of a composi¬ tion comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat post- event consequences of kidney ischemia and reperfusion, such as, for example,
(a) trimetazidine, dosage range from 100 μg/kg daily to 3.0 mg/kg daily;
(b) allopurinol (Zyloprim, Burroughs Wellcome) , dosage range from 50 mg daily to 800 mg daily;
(c) bucloxic acid, dosage range from 200 mg daily to 2 gm daily;
(d) indometacin, dosage range from 25 mg daily to 300 mg daily;
(e) ebselen, dosage range from 5 mg/kg daily to 1 gm/kg daily;
(f) methylprednisolone (Medrol , Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(g) methylprednisolone (Solu Medrol , Upjohn) , intramuscular or intravenous dosage range from 0.25 mg/kg daily to 3 mg/kg daily;
(h) prednisone (Del tasone, Upjohn) , dosage range from 1 mg daily to 250 mg daily, or alternate day dosing;
(i) cyclophosphamide ( Cytoxan, Bristol-Myers Oncology), dosage range from 0.1 mg/kg daily to 5 mg/kg daily;
(j) cyclophosphamide ( Cytoxan for injection, Bristol-Myers
Oncology) , intravenous, intramuscular or subcutaneous dosage range from 0.1 mg/kg daily to 5 mg/kg daily, 2 mg/kg to 5 mg/kg twice weekly or 10 mg/kg to 15 mg/kg every seven to ten days;
(k) chlorambucil (Leukeran, Burroughs Wellcome) , dosage range from 0.5 mg daily to 10 mg daily;
(1) cyclosporin A ( Sandimmune, Sandoz Pharmaceutical) , dosage range from 1 mg/kg daily to 15 mg/kg daily;
(m) azathioprine ( Imuran, Burroughs Wellcome) , dosage range from 0.1 mg/kg daily to 2.5 mg/kg daily; and (n) N, N' -diphenyl-p-phenylenediamine, dosage range from 10 mg/kg daily to 250 mg/kg daily.
The following illustrate specific formulations according to the present invention.
4-amino-2-hydroxyphenylacetic acid 1 gm nordihydroguaiaretic acid 5 gm trimetazidine 7. 5 mg
p-aminobenzoic acid 15 gm mixed tocopherols 3, 500 I.U
N, N'-diphenyl-p-phenylenediamine IE > gm
4- (aminoguanidino)phenylacetic acid 5 gm D-myo-inositol-1.2.6-trisphosphate 2C ) gm ebselen 5 gm cyclophosphamide 200 mg
Example 24
Clinical treatment of post-event consequences of reper¬ fusion subsequent to myocardial infarction can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and a medicament recognized as effective to treat post-event consequences of reperfusion subsequent to myocardial infarction, such as, for example,
(a) trimetazidine, dosage range from 100 ug/kg daily to 3.0 mg/kg daily;
(b) allopurinol ( Zyloprim, Burroughs Wellcome) , dosage range from 50 mg daily to 800 mg daily;
(c) lidocaine (Lignocainum, Polfa) , intravenous, subcutaneous or intramuscular dosage range from 0.5 mg/kg to 1 mg/kg until ectopy resolves, followed by intravenous continuous infusion at a rate of from 20 μg/kg/min to 50 ug/kg/min;
(d) procainamide ( Procan SR extended-release tablets, Parke- Davis) , dosage range from 200 mg daily to 5 gm daily;
(e) S-adrenoceptor blockers such as acebutolol (Sectral), dosage range from 20 mg daily to 1.2 gm daily; alprenolol, dosage range from 0.5 mg/kg daily to 5 mg/kg daily; atenolol ( Tenormin) , dosage range from 2.5 mg daily to 200 mg daily; betaxolol (Jerlone) , dosage range from 1 mg daily to 20 mg daily; carteolol (Car rol) , dosage range from 0.25 mg daily to 10 mg daily; esmolol (Brevibloc, Du Pont Pharmaceuticals) , intravenous dosage range from 50 μg/kg/min to 0.2 mg/kg/min; labetalol (Normodyne) , dosage range from 20 mg daily to 1.8 gm daily; metoprolol (Lopressor) , dosage range from 5 mg daily to 200 mg daily; nadolol ( Corgard) , dosage range from 4 mg daily to 240 mg daily; oxprenolol, dosage range from 0.5 mg/kg daily to 5 mg/kg daily; penbutolol (Levatol) , dosage range from 2 mg daily to 80 mg daily; pindolόl ( Visken) , dosage range from 0.5 mg daily to 60 mg daily; propranolol ( Inderal or Inderal LA) , dosage range from 4 mg daily to 320 mg daily; sotalol (Betapace, Berlex) , dosage range from 30 mg daily to
320 mg daily; and timolol (Blocadren) , dosage range from 1 mg daily to 60 mg daily;
(f) nitrates such as sodium nitroprusside, intravenous dosage range from 1 mg daily to 100 mg daily; isosorbide 5-mononitrate, dosa/ge range from 10 mg daily 100 mg daily; isosorbide dinitrate, dosage range from 2 mg daily to 240 mg daily; and sustained-release trinitroglycerin, dosage range from 1 mg daily to 540 mg daily; (g) calcium antagonists such as diltiazem ( Cardizem or Cardizem SR) , dosage range from 10 mg daily to 360 mg daily; verapamil ( Calan or Calan SR) , dosage range from 10 mg to 480 mg; nifedipine (Procardia) , dosage range from 3 mg daily to 180 mg daily; nifedipine (Procardia XL) , dosage range from 3 mg daily to 90 mg daily; nicardipine ( Cardene) , dosage range from 6 mg daily to 120 mg daily; isradipine (DynaCirc) , dosage range from 0.5 mg daily to 20 mg daily; amlodipine (Norvasc, Pfizer Labs Division) , dosage range from 0.5 mg daily to 10 mg daily; and felodipine (Plendil , Merck & Co.), dosage range from 0.5 mg daily to 20 mg daily;
(h) N, N'-dimethylthiourea, intravenous, intramuscular, sub¬ cutaneous or oral dosage range from 5 mg/kg daily to 100 mg/kg daily;
(i) W-2-mercaptopropionylglycine, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 100 mg/kg daily;
(j) deferoxamine mesylate, intravenous or subcutaneous dosage range from 1 mg/kg daily to 50 mg/kg daily;
(k) ebselen, dosage range from 5 mg/kg daily to 1 gm/kg daily;
(1) taurine, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(m) fibrinolytic substances including streptokinase, intravenous dosage range from 150,000 I.U. to 1.5 million I.U. over one hour; urokinase, intravenous dosage range from 300,000 I.U. to 3 million I.U. over one hour; /'? acylated streptokinase-plasmincomplex (anistreplase) , intra¬ venous dosage range from 3 I.U. to 30 I.U. over two minutes; and recombinant tissue plasminogen activator (alteplase, rt-PA) , intravenous dosage range from 10 mg to 100 mg over a four hour period;
(n) heparin, intravenous or subcutaneous dosage range 10,000 units/day to 25,000 units/day;
(o) aspirin, dosage range from 50 mg daily to 1.5 gm daily; (p) angiotensin converting enzyme inhibitors including captopril (Capoten) , dosage range from 2.5 mg daily to 300 mg daily; enalapril (Vasotec) , dosage range from 0.25 mg daily to 40 mg daily; fosinopril (Monopril) , dosage range from 1 mg daily to 60 mg daily; lisinopril (Zestril) , dosage range from 0.5 mg daily to 40 mg daily; ramipril (Al tace) , dosage range from 0.25 mg daily to 10 mg daily; quinapril (Accupril , Parke-Davis) , dosage range from 1 mg daily to 80 mg daily; quinapril/hydrochlorothiazide combinations (Accuretic, Parke- Davis) , dosage range from 2 mg quinapril and 1.25 mg hydro¬ chlorothiazide daily to 80 mg quinapril and 125 mg hydro¬ chlorothiazide daily; and benazepril (Lotensin, CIBA Pharmaceutical) , dosage range from 0.1 mg daily to 80 mg daily.
The following illustrate specific formulations according to the present invention.
4-amino-2-methoxyphenylacetic acid 1 gm butylated-hydroxytoluene 200 mg allopurinol 200 mg
p-aminobenzoic acid 20 gm tert-butylhydroqumone ^ 1 gm isosorbide 5-mononitrate 100 mg
4-aminophenylacetic acid 10 gm
2,6-di- ert-butyl-4- [2' -thenoyl]phenol 500 mg captopril 200 mg
Example 25
Use of agents previously recognized as having general anti-inflammatory properties and as possibly having usefulness in clinically treating chronic inflammatory diseases of vary¬ ing origin, but which at present remain under investigation can be improved by use of a composition comprising from about 1 gm to about 20 gm of at least one primary therapeutic agent comprising a primary amine benzoic acid derivative having a molecular weight of from about 100 to about 1,400 Daltons, and optionally at least one substance selected from those noted above in section (v) through section (ix) , and an agent previously recognized as having general anti-inflammatory properties and as possibly having usefulness in clinically treating chronic inflammatory diseases of varying origin, but which at present remain under investigation, such as, for example,
(a) tilomisole (WY-18,251, NSC-310,663) , dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(b) tenidap, dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(c) 1- [ (4-chlorophenyl)methyl] -2-methyl-5- (quinolinyl- ethoxy) -lH-indole-3-acetic acid, dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(d) tepoxalin, dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(e) scalaradial, dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(f) neutral macrolide of molecular formula C44 H69 N012* H20 derived from Streotomvces tsukubaensis No. 9993 (FK506) , dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(g) tirilazad mesylate (U-74006F) , intravenous dosage range from 0.15 mg/kg/hr to 15 mg/kg/hr; (h) derivative of tirilazad in which the steroid portion of the chemical structure has been replaced with the tetramethyl chroman portion of d-α tocopherol (U78517F, Upjohn) , intraven¬ ous dosage range from 150 μg/kg/hr to 15 mg/kg/hr;
(i) pentoxifylline (Hoechst-RoussellPharmaceuticals") , intra¬ venous, intramuscular or subcutaneous dosage range from 1 mg/kg daily to 100 mg/kg;
(j) indoxole, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(k) bimetopyrol, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(1) flumizole, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(m) phenidone, intravenous, intramuscular, subcutaneous or oral dosage range from 25 mg/kg daily to 1 gm/kg daily;
(n) ebselen, intravenous, intramuscular, subcutaneous or oral dosage range from 5 mg/kg daily to 500 mg/kg daily;
(o) bucolome, dosage range from 200 mg daily to 2 gm daily;
(p) sodium 2- [4- (2-oxocyclopentylmethyl)phenyl]propionate dihy-drate, dosage range from 0.1 mg/kg daily to 25 mg/kg daily;
(q) sideritoflavone, dosage range from 50 mg/kg daily to 1 gm daily;
(r) cirsiliol, dosage range from 50 mg/kg daily to 1 gm daily;
(s) hypolaetin-8-glucoside, dosage range from 50 mg/kg daily to 1 gm daily;
(t) hypolaetin, dosage range from 50 mg/kg daily to 1 gm daily;
(u) oroxindin, dosage range from 50 mg/kg daily to 1 gm daily;
(v) quercetagetin-7-glucoside, dosage range from 50 mg/kg daily to 1 gm daily;
(w) gossypin, dosage range from 50 mg/kg daily to 1 gm daily;
(x) hibifolin, dosage range from 50 mg/kg daily to 1 gm daily;
(y) gossypetin, dosage range from 50 mg/kg daily to 1 gm daily;
(z) leucocyanidol, dosage range from 50 mg/kg daily to 1 gm daily;
(a') indoprofen, dosage range from 0.5 mg/kg daily to 50 mg/kg daily;
(b' ) crude extract of Mandevilla velutina. dosage range from 50 mg/kg daily to 1 gm/kg daily;
(C ) 1- [3- (naphth-2-ylmethoxy)phenyl] -1- (thiazol-2-yl)propyl methyl ether, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(d' ) epirizole, dosage range from 5 mg/kg daily to 150 mg/kg daily;
(e') DL-2- (4-hexyloxyphenyl)glycine octyl ester, dosage range from 25 mg daily to 500 mg daily;
(f) DL-2- [4- (5.5-dimethylhexyloxy)phenyl]glycine octyl ester, dosage range from 25 mg daily to 500 mg daily; (g' ) meloxicam, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(h') kojic acid, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(i' ) 2- (2-hydroxy-4-methylphenyl)aminothiazolehydrochloride, dosage range from 0.1 mg/kg daily to 50 mg/kg daily; (j' ) 2- (p-bromophenyl) -9-dimethylaminopropyl-9H-imidazo[1,2- α] -benzimidazole, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(k' ) benoxaprofen, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(1') flunoxaprofen, dosage range from 0.1 mg/kg daily to 50 mg/kg daily;
(m' ) emorfazone, dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(n' ) misoprostol, dosage range from 10 μg/k daily to 1 mg/kg daily;
(o' ) 6-methoxy-2-naphthylacetic acid, dosage range from 1 mg/kg daily to 100 mg/kg daily;
(p' ) niflumic acid, dosage range from 250 mg daily to 5 gm daily;
(q' ) clidanac, dosage range from 0.1 mg/kg daily to 100 mg/kg daily;
(r' ) proglumetacin, dosage range from 0.5 mg/kg daily to 200 mg/kg daily; f T
(s' ) 4- (2-chlorophenyl) -2- [2- (4-isobutylphenyl)ethyl] -6,9- dimethyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3a] [1,4]diazepine
(Y-24180) , dosage range from 10 μg/kg daily to 10 mg/kg daily;
(f) paramethasone, intramuscular, intrasynovial, intra¬ lesional or oral dosage range from 1 mg daily to 200 mg daily, or alternate day dosing;
(u' ) paramethasone 21-acetate, intramuscular, intrasynovial, intralesional or oral dosage range from 1 mg daily to 200 mg daily, or alternate day dosing; and
(v' ) paramethasone disodium phosphate, intramuscular, intra¬ synovial, intralesional or oral dosage range from 1 mg daily to 200 mg daily, or alternate day dosing.
The following illustrate specific formulations according to the present invention.
4-aminophenylacetic acid, potassium salt 1 gm iV-acetylcysteine 1 gm tenidap 10 mg
4-amino-2-methoxybenzoic acid 20 gm d-α-tocopheryl succinate 3,000 I.U. neutral macrolide of molecular formula
C44 H69 N012- H20 derived from
Streptomyces tsukubaensis
No. 9993 (FK506) 3.5 g
4-aminophenylacetic acid 15 gm probucol 600 mg tilomisole 2 gm
Without further elaboration the foregoing will so fully il¬ lustrate my invention that others may, by applying current or future knowledge, adapt the same for use under various condi¬ tions of service.

Claims (59)

/'?I claim:
1. A method of treating a chronic inflammatory disease resulting from hypoxia/reperfusion site trauma; said disease or pathophysiologically related symptomology characterized in part by increased levels of lipid peroxidation and increased levels of resultant carbonyl compounds, said resultant carbon¬ yl compounds constituting a toxic group of substances which additionally contribute to the continuation of the chronic inflammatory disease or pathophysiologically related symptom¬ ology; said method comprising systemic administration of a composition comprising (1) a therapeutically effective amount of a water soluble compound having a molecular weight of from about 100 to about 1,400 Daltons of the formula
wherein Rx is -NH2; -aminoalkyl having 1-10 carbons; -NHC(=NH)NH2; - (CH2)nNHC(=NH)NH2 wherein n is 1-10; C(=NH)NH2;
- (CH2)n-CH=NC(=NH)NH2 wherein n is 1-10; -NHC(=NH)NHNH2;
- (CH2)nNHC(=NH)NHNH2 wherein n is 1-10; - (CH2)n-CH=NC(=NH)NHNH2 wherein n is 1-10; -NHNHC(=NH)NH2; - (CH2)n-NHNHC(=NH)NH2 wherein n is 1-10; and - (CH2)n-CH=N-NHC(=NH)NH2 wherein n is
1-IOJ
R2 is H; -OH; -0-CH3; -0-R' wherein R' is alkyl of 2-10 carbons; aminoalkyl wherein the alkyl group is 1-10 carbons; -S03H; -CH3; and -(CH2)nCH3 wherein n is 1-10;
R' and R" are -H, OH or CH3; and n is 0 or 1, and the pharmaceutically acceptable salts, amide and ester derivatives thereof; (2) optionally an effective amount of at least one co-agent selected from the group consisting of (a) an anti-oxidant, a free radical trapping compound, a chemical having indirect anti-oxidant properties, a vitamin, a chemical conjugating substance which facilitates kidney drug eli ina- tion, a metabolite at risk of depletion, a sulfhydryl con¬ taining chemical and a chemical which may act so as to facilitate glutathione activity and/or (b) a nonabsorbable polyamine substance, said nonabsorbable co-agent acting to covalently bind and sequester dietary carbonyl-containing products and (3) at least one medicament in an amount effective to treat said chronic inflammatory disease.
2. A method of treatment according to Claim 1 wherein the medicament recognized as effective is selected from the group consisting of a neuroactive drug; a vasoactive drug; a vas¬ cular relaxant; an immunoregulatory drug; an antibiotic; a thromboinhibitory drug; an antihistaminic drug; or a chemical selected from the group consisting of allopurinol, anthralin, 2- (p-bromophenyl) -9-dimethylamino-propyl-9H-imidazo[1,2- α]benzimidazole,4H-2-carboxamido-4-phenylthieno- [3,2-c] - [1] - benzopyran, clofibrate, codeine, Mandevilla velutina. cyste- amine, deodorized opium tincture, diphenoxylate, ephedrine and derivatives thereof, estrogen, etretinate, flumizole, gabapen- tin, ganglioside GMlf isoniazid, isotretinoin, lidocaine, linopirdine, loperamide, memantine, methoxsalen, mixed cow brain gangliosides, myelin, 4H-4-phenylthieno- [3,2-c] - [1] - benzopyran-2-carboxylic acid, procainamide, pyridoxine and pharmaceutically acceptable derivatives thereof, sulfinpyra- zone, taurine, tiapride and zileuton.
3. The method of Claim 1 wherein said chronic inflammatory disease is selected from the group consisting of: chronic gingivitis; chronic periodontitis; chronic autoimmune gastritis; ileitis; inflammatory bowel disease; interstitial cystitis; psoriasis; various forms of arthritis; tendinitis; carpel tunnel syndrome and other cumulative trauma disorders; systemic and chronic discoid lupus erythematosus; pneumoconio¬ sis; chronic obstructive pulmonary disease; inflammatory myopathies; epilepsy; inflammatory neuropathies; Alzheimer's disease; myasthenia gravis; multiple sclerosis; inflammatory site edema; and post-event hypoxia/reperfusion tissue damage subsequent to acute central nervous system trauma, stroke, kidney ischemia or myocardial infarction.
4. The method of Claim 1 wherein said therapeutically effective amount of said at least one primary agent is a dosage in the range of from 600 mg to about 20 gm per day in one or more divided doses, preferably from about 1 gm to about 20 gm per day, more preferably from about 3 gm to about 20 gm per day, and most preferably from about 6 gm to about 20 gm per day.
5. The method of Claim 1 wherein said therapeutically effec¬ tive amount of said at least one primary agent is a dosage in the range of 15 mg/kg daily to about 800 mg/kg daily, prefer¬ ably 30 mg/kg daily to about 800 mg/kg, more preferably 60 mg/kg daily to about 800mg/kg, and most preferably 120 mg/kg daily to about 800 mg/kg.
6. The method of Claim 1 wherein the composition is administered orally.
7. The method of Claim 1 wherein said therapeutically effec¬ tive amount of the at least one primary therapeutic agent is administered intravenously, intramuscularlyor subcutaneously.
8. The method of Claim 1 wherein the nonabsorbable co-agent is selected from the group consisting of: a. naturally occurring polysaccharides having S-1,2, jβ-1,3, β-1,4 and/or β-1,6 linkages containing aminosugars including the chitin class of biopolymers having the general structure of poly-S- (l->4)-iV-acetyl-D-glucosamine, and bearing at least one free primary amine group; b. deacetylated naturally occurring polysaccharides, having at least one N-acetylated residue, wherein upon chemical deacetylation thereof, said deacetylated naturally occurring polysaccharide is a high molecular weight derivative bearing primary amine groups directly linked to sugar carbons; includ¬ ing chitosan but not limited to chitosan; c. chemically aminated polysaccharides from the group con¬ sisting of: aminodeoxy polysaccharides such as 2-amino-2-deoxy- cellulose; aminoalkyl-, amino(hydroxyalkyl) -, aminoalkyl- ether-, and amino(hydroxyalkyl) -ether- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates selected from the group consisting of
H2N- (CH2)n-[carbohydrate] where n = 1-10, including alkyl isomers;
H2N-(CH2)m-CHOH-(CH2)..- [carbohydrate] , where m = 0-10 and n = 0-10;
H2N- (CH2)a-0- [carbohydrate] where n = 1-10; H2N- (CH2)m-CHOH-(CH2)a-0- [carbohydrate] where m = 0-10 and n = 0-10; aminobenzyl- derivatives of cellulose, chitin or other naturally occurring non-digestible carbohydrates selected from the group consisting of
H2N-C6H4- (CH2)n- [carbohydrate] , H2N-CH2-C6H4- (CH2)n- [carbohydrate] ,
H2N-C6H4- (CH2)a-0- [carbohydrate] where n = 0 - 10, and H2N-C6H4-(CH2)a-CHOH-(CH2)n-0- [carbohydrate] where m = 0-10 and n = 0-10, including p-, o- and m-benzene ring amino- isomers, aminomethyl- isomers and alkyl group isomers thereof; guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring non-absorbable carbo¬ hydrates selected from the group consisting of: H2N-C(=NH) - [carbohydrate] ;
H2N-C(=NH) - (CH2)n- [carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -O- (CH2)n- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H2N-C(=NH) -NH- [carbohydrate] ;
H2N-C(=NH)-NH-(CH2)a- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -NH- (CH2)n-0- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -N=CH- (CH2)n- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-N=CH-(CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-NHC(*=NH) -NH- [carbohydrate] ; H2N-NHC(=NH) -NH- (CH2)a- [carbohydrate] , where n = 1-10, in- eluding hydrocarbon hydroxylated derivatives thereof;
H2N-NHC(=NH)-NH-(CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-NHC(=NH)-N=CH-(CH2)a- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-NHC(=NH) -N=CH- (CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H2N-C(=NH) -NH-NH- [carbohydrate] ;
H2N-C(=NH) -NH-NH- (CH2)a- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-C(=NH) -NH-NH- (CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -NH-N=CH-(CH2)a- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-C(=NH) -NH-N=CH-(CH2)n-0- [carbohydrate] , where n = 1- 10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; d. primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters having one or more carbonyl trapping functional group per molecule wherein each carbonyl trapping functional group is in the ω-, ω-1 or other isomeric position within the fatty acyl chains, wherein each fatty acyl chain may have from 3 to 26 carbons, from one to five nitrogen functional groups and from one to 24 hydroxyl groups; e. synthetic polysaccharides consisting partly or entirely of aminosugars bound by 3-l,2, 0-1,3, 0-1,4 and/or 0-1,6 linkages; f. mixed polysaccharide polymeric derivatives wherin primary amine, aminoalkyl (one to ten carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, aminoguanidinyl-alkyl (one to ten carbons per alkyl group) , aminoalkylguanidinyl (one to ten carbons per alkyl group) , guanidine, aminobenzene and/or aminoalkylbenzene (one to ten carbons per alkyl group) functional groups are covalently attached to matrices such as epi-chlorohydrin copolymers of cellulose or chitin and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups; and g. non-polysaccharide polymeric derivatives wherein primary amine, aminoalkyl (one to ten carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, aminoguanidinyl-alkyl (one to ten carbons per alkyl group) , aminoalkylguanidinyl (one to ten carbons per alkyl group) , guanidine, aminobenzene and/or aminoalkylbenzene (one to ten carbons per alkyl group) functional groups are covalently attached to a synthetic non-digestible polymer selected from the group consisting of polystyrene, styrene-divinylbenzene copolymer, polyvinyl alcohol and crosslinked derivatives thereof, and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups.
9. The method of Claim 8 wherein said nonabsorbable polyamine is in a microfibrillated form or microcrystalline form having enhanced surface area, increased porosity, increased water retention capacity and enhanced chemical accessibility.
10. The method of Claim 8 wherein said therapeutically effective amount of said nonabsorbable polyamine is a dosage in the range of from 600 mg to about 20 gm per day in one or more divided doses, preferably from about 1 gm to about 20 gm per day, more preferably from about 3 gm to about 20 gm per day, and most preferably from about 6 gm to about 20 gm per day.
11. The method of Claim 8 wherein said therapeutically effec¬ tive amount of said nonabsorbable polyamine is a dosage in the range of 15 mg/kg daily to about 800 mg/kg daily, preferably 30 mg/kg daily to about 800 mg/kg, more preferably 60 mg/kg daily to about 800mg/kg, and most preferably 120 mg/kg daily to about 800 mg/kg.
12. The method of Claim 1 wherein said co-agent is selected from the group consisting of a) at least one anti-oxidant and free radical trapping compound selected from the group consisting of vitamin E derivatives such as α-tocopherol, 0-tocopherol, γ-tocopherol, δ-tocopherol, e-tocopherol, ^-tocopherol, f2-tocopherol and η-tocopherol, as well as ester derivatives thereof such as the corresponding acetate, succinate and nicotinate forms; 0- carotene; vitamin A; butylated hydroxytoluene; butylated hydroxyanisole; propyl gallate; dodecylgallate; tert- butylhydroquinone; citric acid; ubiquinols; glutathione; homocysteine; methionine; dihydrolipoic acid; W-acetyl- cysteine; prostaglandin Bx oligomers; 2-aminomethyl-4- ert- butyl-6-iodophenol; 2-aminomethyl-4-tert-butyl-6-propionyl- phenol; 2, 6-di- ert-butyl-4- [2' -thenoyl] -phenol; N, N' - diphenyl-p-phenylenediamine; ethoxyquin; probucol; ebselen; 5- [ [3 , 5-bis (1, 1-dimethylethyl) -4-hydroxyphenyl]methylene] -3- (dimethylamino) -4-thiazolidinone; 5- [ [3,5-bis (1,1-dimethyl¬ ethyl) -4-hydroxyphenyl] methylene] -3- (methyl-amino) -4- thiazolidinone; D-myoinositol-1.2.6-trisphosphate; nor- dihydroguaiaretic acid; deferoxamine; tirilazad mesylate; derivative of tirilazad in which the steroid portion of the chemical structure has been replaced with the tetramethyl chroman portion of d-α tocopherol; trimetazidine; 2- (2- hydroxy-4-methylphenyl) aminothiazole hydrochloride; and iV,iV' - dimethylthiourea, b) chemicals having indirect anti-oxidant properties selected from the group consisting of selenium and seleno- containing amino acids, c) a vitamin selected from the group consisting of vitamin A; vitamin A aldehyde, also known as retinal; vitamin A acid, also known as retinoic acid; retinyl acetate; vitamin Blf also known as thiamine; thiamine propyl disulfide; vitamin B2, also known as riboflavin; riboflavin tetrabutyrate; riboflavine 5'-phosphate ester monosodium salt; vitamin B6, also known as pyridoxine; pyridoxal; pyridoxal HCl; pyridoxal 5-phosphate; pyridoxal 5-phosphate calcium salt; pyridoxamine; pyridoxamine dihydrochloride; pyridoxamine phosphate; vitamin B12, also known as cyanocobalami ; methyl vitamin B12, also known as co-methylcobalamin; vitamin D2; vitamin D3; vitamin D4; vitamin H, also known as biotin; vitamin Kx; vitamin Kx oxide; vitamins of the K2 series; vitamin K5; vitamin K5 hydrochloride; vitamin K6; vitam?in K6 dihydrochloride; vitamin
K7; vitamin K7 hydrochloride; vitamin K-S(II); vitamin ^ ,- vitamin L2; vitamin U; methylmethioninesulfonium bromide; α- carotene; 0-carotene; γ-carotene; ω-carotene; , ψ-carotene, also known as lycopene; 7,7' , 8, 8' ,11, carotene, also known as phytofluene; vitamin Bτ, also known as carnitine; acetyl-L-carnitine; vitamin Be, also known as folic acid; folinic acid; folinic acid calcium salt pentahydrate; niacinamide; nicotinic acid; nicotinic acid sodium salt sesquihydrate; nicotinic acid monoethanolamine salt; panto¬ thenic acid; pantothenic acid sodium salt; and pantothenic acid calcium salt, d) a chemical conjugating co-agent which facilitates kidney drug elimination selected from the group consisting of glycine and derivatives thereof, e) a metabolite at risk of depletion selected from the group consisting of pantothenic acid and derivatives thereof,
f) a sulfhydryl containing substance or derivative thereof selected from the group consisting of homocysteine, acetylhomocysteine thiolactone, methionine or thioctic acid, also known as α-lipoic acid, and g) a chemical which may act so as to facilitate gluta¬ thione activity selected from the group consisting of as iV- acetylcysteine; L-2-oxothiazolidine-4-carboxylate; timonacic; cysteamine; and lipoamide derivatives including malotilate, sulfarlem and oltipraz.
13. The method of Claim 1 wherein said at least one co-agent selected from group (2) is administered intravenously, intra¬ muscularly or subcutaneously.
14. The method of Claim 1 wherein said medicament is admin¬ istered intravenously, intramuscularly or subcutaneously.
15. A method of treating a mammal suffering from a chronic inflammatory disease characterized in part by increased lipid peroxidation and increased levels of resultant carbonyl compounds; wherein said disease is selected from the group consisting of gastrointestinal tract chronic inflammatory disorders, psoriasis, arthritis, inflammatory site edema, acute central nervous system trauma, stroke and myocardial infarction; said method comprising orally and/or intravenously administering a therapeutically effective amount of a composi¬ tion of Claim 1.
16. A composition effective in treating by oral administra¬ tion a chronic inflammatory disease, the composition compris¬ ing an effective amount of at least one carbonyl trapping therapeutic agent of the formula
wherein Rx is -NH2; -aminoalkyl having 1-10 carbons; -NHC(=NH)NH2; - (CH2)nNHC(=NH)NH2 wherein n is 1-10; C(=NH)NH2;
- (CH2)„-CH=NC(=NH)NH2 wherein n is 1-10; -NHC(=NH)NHNH2;
- (CH2)nNHC(=NH)NHNH2 wherein n is 1-10; - (CH2)n-CH=NC(=NH)NHNH2 wherein n is 1-10; -NHNHC(=NH)NH2; - (CH2)n-NHNHC(=NH)NH2 wherein n is 1-10; and (CH2)n-CH=N-NHC(=NH)NH2 wherein n is 1-10;
R2 is H; -OH; - -0-CH3; -O-R' wherein R' is alkyl of 2-10 carbons; aminoalkyl wherein the alkyl group is 1-10 carbons; -S03H; -CH3;' and -(CH2)nCH3 wherein n is 1-10; R' and R" are -H,'" OH or CH3; and n is 0 or 1, and an effective amount of at least one medicament selected from the group consisting of a neuroactive drug; a vasoactive drug; a vascular relaxant; an immunoregulatory drug; an antibiotic; a throboinhibitory drug; an antihist¬ aminic drug; and a chemical selected from the group consisting of allopurinol, anthralin, 2- (p-bromophenyl) -9-dimethyl- aminopropyl-9H-imidazo[l,2-] -benzimidazole,4H-2-carboxamido- 4-phenylthieno- [3,2-c] - [1] -benzopyran, clofibrate, codeine, Mandevilla velutina, cysteamine, opium tincture, diphenoxyl¬ ate, ephedrine and derivatives thereof, estrogen, etretinate, flumizole, gabapentin, isoniazid, isotretinoin, lidocaine, linopirdine, loperamide, memantine, methoxsalen, a cow brain ganglioside, myelin, 4H-4-phenylthieno- [3,2-c] - [1] -benzopyran- 2-carboxylic acid, procainamide, pyridoxine and derivatives thereof, sulfinpyrazone, taurine, tiapride, and zileuton, wherein the carbonyl trapping therapeutic agent is present in an amount from 600 mg/day to about 20 gm/day.
17. The composition according to claim 16 wherein the neuroactive drug is a drug which affects ace ylcholine synthesis, storage or release; an acetylcholine postreceptor agonist; an acetylcholinesterase inhibitor; a cholinergic drug; an anticholinergic drug; a skeletal muscle relaxant drug; an anxiolytic drug; an antidepressant drug; a monoamine oxidase inhibitor; a vasodilator or other nootropic direct brain metabolic enhancer drug; a neurotransmission enhancer drug; an antirage drug; an anticonvulsant drug; a N-methyl-D- aspartate glutamate receptor antagonist; an antipsychotic drug; or a serotonin reuptake inhibitor.
18. The composition according to claim 16 wherein the vaso¬ active drug is an angiotensin converting enzyme inhibitor; an antihypertensive drug; an alpha adrenergic blocker; a beta adrenergic blocker or a calcium channel blocker.
19. The composition according to claim 16 wherein the vas¬ cular relaxant is an antianginal drug, a coronary vasodilator drug or a bronchodialator drug.
20. The composition according to claim 16 wherein the immuno¬ regulatory drug is a glucocorticosteroid; a nonsteroidal anti- inflammatory drug; an immunomodulator drug; an immunosuppres- sive drug; an interferon; an antimalarial drug or cortico- tropin.
21. The composition according to claim 16 wherein the anti¬ biotic drug is an aminoglycoside antibiotic drug; an ampheni- col antibiotic drug; an ansamycin antibiotic drug; a 0-lactam antibiotic drug; a lincosamide antibiotic drug; a macrolide antibiotic drug; a polypeptide antibiotic drug; a tetracycline antibiotic drug; a 0-lactamase inhibitor; an antiseptic; a surfactant; or a chemical selected from the group consisting of D-cycloserine, mupirocin, tuberin and imipenem in combina¬ tion with cilastatin sodium.
22. The composition according to claim 16 wherein the throm- boinhibitory drug is an anticoagulant drug, an antithrombotic drug or a thrombolytic drug.
23. The composition of claim 16 additionally comprising an effective amount of at least one carbonyl trapping co-agent selected from the group consisting of a nonabsorbable primary amine polymer having at least one free primary amine group, an anti-oxidant, selenium and seleno-containing amino acids, a vitamin, a substance which facilitates glutathione biological activity, glycine and derivatives thereof which facilitate kidney drug elimination, a metabolite at risk of depletion, a sulfhydryl containing agent and derivatives thereof, and a free radical trapping substance.
24. The composition of Claim 16 together with a pharmaceu¬ tically acceptable carrier.
25. The composition of Claim 23 together with a pharmaceu¬ tically acceptable carrier.
26. A composition according to Claim 24 wherein the pharma¬ ceutically acceptable carrier is an aqueous solution or suspension for injection, a comestible product for oral use, or a combination thereof.
27. A composition according to Claim 25 wherein the pharma¬ ceutically acceptable carrier is an aqueous solution or suspension for injection, a comestible product for oral use, or a combination thereof.
28. A composition according to Claim 26 wherein the commest- ible product for oral use is a tablet for oral use, a sustained-release tablet or a foodstuff.
29. A composition according to Claim 27 wherein the commest- ible product for oral use is a tablet for oral use, a sustained-release tablet or a foodstuff.
30. The composition of Claim 16 for treating chronic gingivi¬ tis and/or chronic periodonditis wherein the medicament is selected from the group consisting of: a tetracycline; a surfactant; ebselen; a nonsteroidal anti-inflammatory drug; a glucocorticoid substance; a penicillin; a penicillin in combination with clavulanate potassium; a macrolide antibiotic substance; a cephalosporin; and a chemical selected from the group consisting of metronidazole, chlorhexidine, D-cyclo- serine, imipenem and imipenem optionally in combination with cilastatin sodium.
31. The composition of Claim 16 for treating chronic auto¬ immune gastritis wherein the medicament is selected from the group consisting of: sodium guaiazulene-3-sulfonate and ebselen.
32. The composition of Claim 16 for treating ileitis, includ¬ ing Crohn's disease wherein the medicament is selected from the group consisting of: sulfasalazine; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; methylprednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; hydrocortisone, as well as pharmaceutically acceptable ester and salt deriva¬ tives thereof; metronidazole; ebselen; sustained-release formulations of 5-aminosalicylic acid; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceutically acceptable ester derivatives thereof; triamcinolone, as well as pharmaceutically acceptable ester and ether derivatives thereof; betamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; diphenoxylate; diphenoxylate in combination with atropine sulfate; deodorized opium tincture; codeine; azathioprine; 6-mercaptopurine; cyclosporins A through I; and methotrexate.
33. The composition of Claim 16 for treating inflammatory bowel disease, including ulcerative colitis wherein the medicament is selected from the group consisting of: sulfa¬ salazine; 5-amino-salicylic acid; 7- [3- (4-acetyl-3-methoxy-2- propylphenoxy)propoxy] -3,4-dihydro-8-propyl-2H-l-benzopyran-2- carboxylic acid; glutathione; zileuton; olsalazine; disodium azodisalicylate; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; eicosapentaen¬ oic acid; salicylazosulfapyridine; sustained-release formula¬ tions of 5-aminosalicylic acid; diazo sulfanilamide ethylene polymer of 5-aminosalicylic acid; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceutically acceptable ester derivatives thereof; methylprednisolone, as well as /3/ pharmaceutically acceptable ester and salt derivatives thereof; triamcinolone, as well as pharmaceutically acceptable ester and ether derivatives thereof; betamethasone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; azathioprine; 6-mercaptopurine; diphenoxylate; deodorized opium tincture; codeine; loperamide; corticotropin; cyclo- sporins A through I; scopolamine; trihexyphenidyl; benztropine mesylate; procyclidine; biperiden; biperiden lactate; etho- propazine; propantheline bromide; and oxybutynin chloride.
34. The composition of Claim 16 for treating interstitial cystitis wherein the medicament is selected from the group consisting of: propantheline bromide; oxybutynin chloride; benztropine mesylate; trihexyphenidyl; procyclidine; biperiden; ethopropazine; scopolamine; benztropine mesylate; and biperiden lactate.
35. The composition of Claim 16 for treating psoriasis wherein the medicament is selected from the group consisting of: 7- [3- (4-acetyl-3-methoxy-2-propylphenoxy)propoxy] -3,4- dihydro-8-propyl-2H-l-benzopyran-2-carboxylic acid; eicosa¬ pentaenoic acid; dexamethasone, as well as pharmaceutically accerptable ester and salt derivatives thereof; methotrexate; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisolone, as well as pharma¬ ceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceu¬ tically acceptable ester derivatives thereof; methylpred¬ nisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; triamcinolone, as well as pharmaceu¬ tically acceptable ester and ether derivatives thereof; beta¬ methasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; alclometasone 17,21-dipropionate; fluticasone propionate; mometasone 17- (2-furoate) ; clobetasol propionate; coal tar topical compositions; methoxsalen; etretinate; isotretinoin; anthralin; cyclosporins A through I; vitamin D3, topically applied; and salicylic acid.
36. The composition of claim 16 for treating rheumatoid arthritis wherein the medicament is selected from the group consisting of: meclofenamic acid; mefenamie acid; flufenamic acid; amfenac; ethyl 2-amino-3-benzoylphenylacetate; diclo- fenac; etodolac; metiazinic acid; indomethacin; fenclozic acid; isofezolac; sulindac; tolmetin; glucametacin; cinmeta- cin; fenclofenac; fenbufen; butibufen; ketorolac tromethamine; tinoridine; fenoprofen; flurbiprofen; ibuprofen; ketoprofen; naproxen; bucloxic acid; the (S) (+) enantiomer of carprofen; phenylbutazone; oxyphenbutazone; feprazone; diflunisal; imidazole salicylate; sulfasalazine; benorylate; piroxicam; isoxicam; auranofin; aurothioglucose; gold sodium thiomalate; hydroxychloroquine; chloroquine; methotrexate; D-penicilla¬ mine; cyclophosphamide; prednisone, as well as pharmaceu¬ tically acceptable ester derivatives thereof; dexamethasone, as well as pharmaceutically acceptable ester and salt deriva¬ tives thereof; methylprednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; (10-methoxy-4H- benzo[4,5]cyclo-hepta- [1,2-b] -thiophene-4-yliden)aceticacid; cyclosporins A through I; neutral macrolide of molecular formula C44H69N012-H20 derived from Streptomyces tsukubaensis No. 9993; rapamycin; azathioprine; nabumetone; eicosapentaenoic acid; aloxiprin; azapropazone; fenopron; amiprilose; chlor¬ ambucil; aceclofenac; apocynin; capsaicin; 6- (2,4-difluoro- phenoxy) -5-methyl-sulfonylamino-1-indanone; dapsone; solubilized chicken type II collagen; 15-deoxyspergualin; diacetyl-splenopentin; diaveridine; ditazol; droxicam; (Z)-3- [4- (acetyloxy) -5-ethyl-3-methoxy-l-naphthalenyl] -2-methyl-2- propenoic acid; ebselen; l-p-chloro-benzyl-2-dimethyl-amino- methylcyclohexen-1,2; etoclofene; felbinac; fenclorac; fenclozic acid; fendosal; isoxepac; leflunomide; lobenzarit; lonazolac-Ca; 5- [ [3,5-bis(1,1-dimethylethyl) -4-hydroxy- phenyl]methylene] -3- (dimethylamino) -4-thiazolidinone; 5- [[3,5- bis(1,1-dimethylethyl) -4-hydroxyphenyl]methylene] -3- (methyl¬ amino) -4-thiazolidinone; bumadizon-calcium; azapropazone; D- myoinositol-1.2.6-trisphosphate; ibufenac; nimesulide; oxamethacin; oxaprozin; suxibuzone; pirprofen; proquazone; triamcinolone acetonide; suprofen; tenoxicam; tiaprofenic acid; tolfenamic acid; difenpyramide; isofezolac; tiopronin; 5-thiopyridoxine; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisolone, as well as pharmaceutically acceptable ester and salt deriva- /37 tives thereof; cortisone, as well as pharmaceutically accept¬ able ester and salt derivatives thereof; triamcinolone, as well as pharmaceutically acceptable ester and ether deriva¬ tives thereof; betamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; aspirin; calcium acetylsalicylate; choline salicylate; choline magnesium trisalicylate; magnesium salicylate; salsalate; N, N'-diphenyl-p-phenylenediamine; tenidap; 1-isobutyl- 3,4- diphenylpyrazole-5-acetic acid and carprofen.
37. The composition of Claim 16 for treating anklosing spondylitis wherein the medicament is selected from the group consisting of: isoxicam; ketoprofen; diclofenac; fenclofenac; phenylbutazone; prenazone; nabumetone; indomethacin; sulindac; carprofen; dexamethasone, as well as pharmaceutically accept¬ able ester and salt derivatives thereof; proquazone; ibupro- fen; tenoxicam; piroxicam; tiaprofenic acid; tolfenamic acid; pirprofen; hydrocortisone, as well as pharmaceutically accept¬ able ester and salt derivatives thereof; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceutically acceptable ester derivatives thereof; methyl¬ prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; triamcinolone, as well as pharmaceu¬ tically acceptable ester and ether derivatives thereof; beta¬ methasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; aspirin; calcium acetylsalicylate; choline salicylate; choline magnesium trisalicylate; magnesium salicylate; salsalate; imidazole 2-hydroxybenzoate; difluni¬ sal; sulfasalazine; benorylate; naproxen; and oxyphenbutazone.
38. The composition of claim 16 for treating osteoarthritis wherein the medicament selected from the group consisting of prednisone, as well as pharmaceutically acceptable ester derivatives thereof; nabumetone; ketoprofen; phenylbutazone; the (S) (+) enantiomer of carprofen; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; diclofenac; diflunisal; diphenpyramide; fenbufen; oxy¬ phenbutazone; indomethacin; glucametacin; isoxicam; lonazolac- Ca; S-adenosylmethionine; bumadizon-calcium; diacetylrhein; proquazone; naproxen; nimesulide; oxamethacin; pirprofen; prenazone; sulindac; suprofen; tenoxicam; tiaprofenic acid; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisolone, as well as phar¬ maceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; methylprednisolone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; triamcinolone, as well as pharmaceutically acceptable ester and ether derivatives thereof; betamethasone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; aspirin; calcium acetylsalicylate; choline salicylate; choline magnesium trisalicylate; magnesium salicylate; salsalate; and etodolac.
39. The composition of claim 16 for treating tendinitis or tenosynovitis wherein the medicament is selected from the group consisting of: the (S) (+) enantiomer of carprofen; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; diclofenac; fenbufen; nimesulide; oxamethacin; pirprofen; proquazone; sulindac; tenoxicam; tiaprofenic acid; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharma¬ ceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceutically acceptable ester derivatives thereof; methylprednisolone, as well as pharmaceu¬ tically acceptable ester and salt derivatives thereof; triam¬ cinolone, as well as pharmaceutically acceptable ester and ether derivatives thereof; betamethasone, as well as pharma¬ ceutically acceptable ester and salt derivatives thereof; indomethacin; aspirin; pyridoxine; pyridoxal; pyridoxal 5- phosphate; and pyridoxamine.
40. The composition of Claim 16 for treating carpel tunnel syndrome and other cumulative trauma disorders wherein the medicament is selected from the group consisting of: diclo¬ fenac; dexamethasone acetate; methylprednisolone acetate; hydrocortisone acetate; pyridoxine; pyridoxal; pyridoxal 5- phosphate; and pyridoxamine.
41. The composition of Claim 16 for treating chronic discoid or systemic lupus erythematosus wherein the medicament is selected from the group consisting of: hydroxychloroquine; quinacrine; chloroquine; amodiaquine; triquine composition; 15-deoxyspergualin; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; leflunomide; cyclosporins A through I; methylprednisolone, as well as phar¬ maceutically acceptable ester and salt derivatives thereof; eicosapentaenoic acid; hydrocortisone, as well as pharmaceu¬ tically acceptable ester and salt derivatives thereof; pred¬ nisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceu¬ tically acceptable ester and salt derivatives thereof; pred¬ nisone, as well as pharmaceutically acceptable ester deriva¬ tives thereof; triamcinolone, as well as pharmaceutically acceptable ester and ether derivatives thereof; triamcinolone acetonide; fluocinolone acetonide; fluocinonide; flurand- renolide; betamethasone valerate; betamethasone 17,21- dipropionate; aspirin; azathioprine; and cyclophosphamide.
42. The composition of Claim 16 for treating pneumoconiosis due to inhalation of asbestos particles, inhalation of stone dust or quartz or inhalation of other causitive agents such as graphite, coal dust, particles produced by metal grinding, talc or corn dust wherein the medicament is selected from the group consisting of: D-penicillamine; 4H-4-phenylthieno- [3,2- c] - [1] -benzopyran-2-carboxylic acid; 4H-2-carboxamido-4- phenylthieno- [3,2-c] - [1] -benzopyran; JV-acetylcysteine; dexa¬ methasone; indomethacin; prednisolone, as well as pharmaceu¬ tically acceptable ester and salt derivatives thereof; hydro¬ cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; flurbiprofen; and S-carboxy- methylcysteine.
43. The composition of Claim 16 for treating chronic obstruc¬ tive pulmonary disease wherein the medicament is selected from the group consisting of: D-penicillamine; 4H-4-phenylthieno-
[3,2-c] [1] -benzopyran-2-carboxylic acid; 4H-2-carboxamido-4- phenylthieno- [3,2-c] [1]benzopyran; iV-acetylcysteine; dexa¬ methasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; indomethacin; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; hydrocortisone, as well as pharmaceutically accept¬ able ester and salt derivatives thereof; flurbiprofen; S- carboxy-methylcysteine; prednisone; andmethylprednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof.
44. The composition of Claim 16 for treating inflammatory myopathies wherein the medicament is selected from the group consisting of: prednisone; methotrexate; cyclophosphamide; chlorambucil; azathioprine; and diazepam.
45. The composition of Claim 16 for treating inflammatory neuropathies wherein the medicament is selected from the group consisting of: cortisone, as well as pharmaceutically accept¬ able ester and salt derivatives thereof; prednisone, as well as pharmaceutically acceptable ester derivatives thereof; methylprednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; triamcinolone, as well as pharmaceutically acceptable ester and ether derivatives there¬ of; betamethasone, as well as pharmaceutically acceptable ester and salt derivatives thereof; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; and ebselen.
46. The composition of Claim 16 for treating epilepsy wherein the medicament is selected from the group consisting of: dizocilpine; phenytoin; phenytoin-polyvinylpyrrolidone coprecipitate; phenytion in combination with phenobarbital; phenobarbital; primidone; carbamazepine; ethosuximide; clonazepam; valproic acid; divalproex sodium; acetazolamide; acetazolamide sodium; prednisone; corticotropin; diazepam; lorazepam; felbamate; zonisamide; gabapentin; lamotrigine; and vigabatrin.
47. The composition of Claim 16 for treating Alzheimer's disease wherein the medicament is selected from the group consisting of: vasodilator or other nootropic direct brain metabolic enhancer co-agents including idebenone, propento- phylline, pentoxifylline, citicoline, ebiratide, exifone, flunarizine, nimodipine, nicergoline, razobazam, rolipram, sabeluzole, phosphatidylserine, vinpocetine, ergoloid mesylates, bromvincamine, cyclandelate, isoxsuprene, naf- ronyl, papaverine, suloctidil, vinburnine, vincamine, vindeburnol, naloxone, ethyl 5-isopropyloxy-4-methyl-0- carboline-3 -carboxylate , N' -methyl-0-carboline-3-carboxamide, methyl 6,7-dimethoxy-4-ethyl-0-carboline-3-carboxylate, ethyl 5-methoxy-4-ethyl-0-carboline-3-carboxylate, ifenprodil, piracetam, aniracetam, pyroglutamic acid, tenilsetam, pramiracetam, oxiracetam, rolziracetam, etiracetam and dupracetam; neurotransmission enhancer co-agents including amantadine, calcium hopantenate, lisuride, and indeloxazine; ifenprodil; tiapride; psychotherapeutic co-agents including haloperidol, bromperidol, thioridazine, thiothixene, fluphen- azine, perphenazine optionally with amitriptyline, and molindone; acetylcholinesterase inhibitors including physostigmine optionally with phosphatidylcholine, heptyl¬ physostigmme, tacrine optionally with phosphatidylcholine, (*/.) -9-amino-l,2,3,4-tetrahydroacridin-1-ol optionally with phosphatidylcholine, metrifonate, velnacrine, methanesulfonyl fluoride, phenylmethylsulfonyl fluoride, huperzine A, huper¬ zine B, edrophonium, miotine and galanthamine; calcium channel blocker co-agents including diltiazem, verapamil, nifedipine, nicardipine, isradipine, amlodipine and felodipine; biogenic amines and co-agents related thereto including clonidine, guanfacine, alaproclate, fipexide, zimeldine and citalopram; antirage co-agents including propranolol, carbamazepine and fluoxetine; benzodiazepine tranquilizers including diazepam, prazepam, chlordiazepoxide optionally with clidinium or amitriptyline or esterified estrogen, oxazepam and clorazepate dipotassium; angiotensin converting enzyme inhibitors includ¬ ing captopril optionally with hydrochlorothiazide, enalapril optionally with hydrochlorothiazide, enalaprilat, fosinopril, lisinopril, ramipril, epicaptopril, alacepril, quinapril, perindopril, delapril, cilazapril, pivalopril, rentiapril, zofenopril and zofenoprilat; co-agents which may enhance acetylcholine synthesis, storage or release including phos¬ phatidylcholine, 4-aminopyridine, 3,4-diaminopyridine, choline, vesamicol, tetra-phenylurea, nicotinamide, secoverine and bifemelane,* acetylcholine postsynaptic receptor agonists including arecoline, oxotremorine, bethanechol, ethyl nipecotate and levacecarnine; ganglioside GM^- mixed cow brain gangliosides; specific monoamine oxidase-A inhibitors includ¬ ing moclobemide; N-methyl-D-aspartate glutamate receptor antagonists including milacemide, trihexyphenidyl, etho- propazine, procyclidine, diphenhydramine, dizocilpine, amantadine and memantine; nonsteroidal anti-inflammatory co- agents including naproxen, flurbiprofen, aspirin, mesalamine, phenylbutazone, sulindac, oxaprozin, D-penicillamine, salsalate, diflunisal, piroxicam, indomethacin, etodolac, meclofenamate, ibuprofen, fenoprofen, ketoprofen, mefenamie acid, nabumetone, auranofin, tolmetin, ketorolac tromethamine, diclofenac and deferoxamine; (-)deprenyl; thiamine; thiamine disulfide 0,O-diisobutyrate; anfacine; antioxidant co-agents which may be used in combination including ascorbic acid, α- tocopherol, N-acetylcysteine, 0-carotene, D-penicillamine, cysteamine, ebselen and deferoxamine; specific monoamine oxidase-B inhibitors including lazabemide; linopirdine; D- cycloserine; serotonergic receptor antagonists including ketanserin and mianserin; and estrogen.
48. The composition of Claim 16 for treating myasthenia gravis wherein the medicament is selected from the group consisting of: prednisone; azathioprine; pyridostigmine; neostigmine; atropine; propantheline; and ephedrine and derivatives thereof.
49. The composition of Claim 16 for treating multiple sclerosis wherein the medicament is selected from the group consisting of: 15-deoxyspergualin; leflunomide; methyl¬ prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceu¬ tically acceptable ester derivatives thereof; dexamethasone; corticotropin; cyclosporins A through I; amantadine; diazepam; clonazepam; baclofen; carbamazepine; phenytoin; isoniazid; primidone; propranolol; amitriptyline; oxybutynin chloride; propantheline bromide; imipramine; carbachol; bethanechol chloride; phenoxybenza ine; tizanidine; chlorpromazine; diacetylrhein; alfa-2a interferon; alf a-2b interferon; alfa-N3 interferon; beta interferon; gamma-lb interferon; copolymer-1; 4-aminopyridine; 3,4-diaminopy /riI'dfme; cyclophosphamide; pred¬ nisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; triamcinolone, as well as pharmaceu¬ tically acceptable ester and ether derivatives thereof; azathioprine; and bovine myelin.
50. The composition of Claim 16 for treating inflammatory site edema wherein the medicament is selected from the group consisting of: cyproheptadine; clemastine; setastine; indo¬ methacin; piroxicam; phenylbutazone; dexamethasone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; phenidone; nordihydroguaiaretic acid; ketoconazole; supro¬ fen; ketoprofen; indoprofen; sudoxicam; naproxen; meclofenamic acid; ibuprofen; diclofenac; fenoprofen; hydroxychloroquine; 2, 6-diamino-.W-{ [1- (1-oxotridecyl) -2-piperidinyl]methyl}- hexanamide; bucloxic acid; butibufen; carprofen; the (S) (+) enantiomer of carprofen; 6- (2,4-difluorophenoxy) -5-methyl- sulfonylamino-1-indanone; loxoprofen; diaveridine; ditazol; droxicam; (Z) -3- [4- (acetyloxy) -5-ethyl-3-methoxy-l-naph- thalenyl] -2-methyl-2-propenoic acid; ebselen; 1-p-chloro- benzyl-2-dimethyl-aminomethylcyclohexen-l,2; etoclofene flufenamic acid; benzydamine; mefenamie acid; fenbufen felbinac; fenclorac; fenclozic acid; fendosal; isoxepac imidazole salicylate; isoxicam; tolmetin; leflunomide isofezolac; l-isobutyl-3,4-diphenylpyrazole-5-acetic acid; S- adenosylmethionine; D-myoinositol-1.2.6-trisphosphate; diacetylrhein; cinmetacin; tinoridine; nimesulide; prenazone; naphthypramide; proquazone; ketorolac; hydrocortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisolone, as well as pharmaceutically acceptable ester and salt derivatives thereof; cortisone, as well as pharmaceutically acceptable ester and salt derivatives thereof; prednisone, as well as pharmaceutically acceptable ester derivatives thereof; methylprednisolone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; triamcinolone, as well as pharmaceutically acceptable ester and ether derivatives thereof; betamethasone, as well as pharmaceutically acceptable ester and salt derivatives there¬ of; and jV,iV' -diphenyl-p-phenylenediamine.
51. The composition of Claim 16 for treating post-event acute central nervous system trauma, ncluding stroke and spinal cord trauma wherein the medicament is selected from the group consisting of: heparin calcium; heparin sodium; warfarin; ticlopidine; aminophylline; isoproterenol; methohexital sodium; tirilazad mesylate; derivative of tirilazad' in which the steroid portion of the chemical structure has been re¬ placed with the tetramethyl chroman portion of d-α tocopherol; allopurinol; ebselen; methylprednisolone; aspirin; sulfin- pyrazone; dipyridamole; clofibrate; tissue plasminogen activator; streptokinase; trihexyphenidyl; ethopropazine; procyclidine; diphenhydramine; dizocilpine; amantadine; memantine; milacemide; dextrorphan; moclobemide; and low molecular weight sulphate/dermatan sulphate glycoaminoglycan heparinoid mixtures.
52. The composition of Claim 16 for treating post-event consequences of kidney ischemia and reperfusion wherein the medicament is selected from the group consisting of: trimetazidine; allopurinol; bucloxic acid; indometacin; ebselen; methylprednisolone; prednisone; cyclophosphamide; chlorambucil; cyclosporins A through I; azathioprine; and iV,iV'-diphenyl-p-phenylenediamine.
53. The composition of Claim 16 for treating myocardial infarction wherein the medicament is selected from the group consisting of: trimetazidine; allopurinol; lidocaine; pro- cainamide; acebutolol; alprenolol; atenolol; betaxolol carteolol; esmolol; labetalol; metoprolol; nadolol oxprenolol; penbutolol; pindolol; propranolol; sotalol timolol; sustained-release trinitroglycerin; sodium nitro- prusside; isosorbide 5-mononitrate; isosorbide dinitrate; diltiazem; verapamil; nifedipine; nicardipine; isradipine; amlodipine; felodipine; iV, N'-dimethylthiourea; iV-2- mercaptopropionylglycine; deferoxamine; ebselen; taurine; streptokinase; urokinase; acylated streptokinase-plasmin complex; recombinant tissue plasminogen activator; heparin,* aspirin; captopril; enalapril; fosinopril; lisinopril; ramipril; quinapril; quinapril/hydrochlorothiazide combina¬ tions; benazepril; and clofibrate.
54. The composition of Claim 16 for treating an inflammatory disease comprising the method of Claim 1 and additionally administering a medicament p -rr /eefvv/iioously recognized as having general anti-inflammatory properties and, preferably, as having usefulness in clinically treating chronic inflammatory diseases of varying origin, said previously recognized agent wherein the medicament is selected from the group consisting of: tilomisole; tenidap; 1- [ (4-chlorophenyl)methyl] -2-methyl- 5- (quinolinylmethoxy) -lH-indole-3-acetic acid; tepoxalin; scalaradial; neutral macrolide of molecular formula C44H69N012* H20 derived from Streptomyces tsukubaensis No. 9993; tirilazad mesylate; derivative of tirilazad in which the steroid portion of the chemical structure has been replaced with the tetra¬ methyl chroman portion of d-α tocopherol; pentoxifylline; indoxole; bimetopyrol; flumizole; phenidone; -V,iV'-diphenyl-p- phenylenediamine; ebselen; bucolome; sodium 2- [4- (2-oxocyclo- pentylmethyl)phenyl]propionate dihydrate; sideritoflavone; cirsiliol; hypolaetin-8-glucoside; hypolaetin; oroxindin; quercetagetin-7-glucoside; gossypin; hibifolin; gossypetin; leucocyanidol; indoprofen; crude extract of Mandevilla velutina; 1- [3- (naphth-2-ylmethoxy)phenyl] -1- (thiazol-2- yDpropyl methyl ether; epirizole; DL-2- (4-hexyloxyphenyl) - glycine octyl ester; DL-2- [4- (5.5-dimethyl-hexyloxy)phenyl] - glycine octyl ester; meloxica ; kojic acid; 2- (2-hydroxy-4- methylphenyl)aminothiazole hydrochloride; 2- (p-bromo-phenyl) - 9-dimethylaminopropyl-9H-imidazo[1,2-α]benzimidazole;benoxa- profen; flunoxaprofen; emorfazone; misoprostol; 6-methoxy-2- naphthylacetic acid; niflumic acid; clidanac; perisoxal; proglumetacin; 4- (2-chlorophenyl) -2- [2- (4-isobutylphenyl) - ethyl] -6, 9-dimethyl-6H-thieno [3,2-f] [l,2,4]triazolo- [4,3a] [1,4]diazepine; paramethasone; paramethasone21-acetate; and paramethasone disodium phosphate.
55. The composition of claim 23 wherein the nonabsorbable primary amine polymer having at least one free primary amine group is selected from the group consisting of a. naturally occurring polysaccharides having 0-1,2, 0-1,3, 0-1,4 and/or 0-1,6 linkages containing aminosugars including the chitin class of biopolymers having the general structure of poly-0- (l->4)-N-acetyl-D-glucosamine, and bearing at least one free primary amine group; b. deacetylated naturally occurring polysaccharides, having at least one iV-acetylated residue, wherein upon chemical deacetylation thereof, said deacetylated naturally occurring polysaccharide is a high molecular weight derivative bearing primary amine groups directly linked to sugar carbons; includ¬ ing chitosan but not limited to chitosan; c. chemically aminated polysaccharides from the group con¬ sisting of: aminodeoxy polysaccharides such as 2-amino-2-deoxy- cellulose; aminoalkyl-, amino(hydroxyalkyl) -, aminoalkyl- ether-, and amino(hydroxyalkyl) -ether- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates selected from the group consisting of
H-.N- (CH2)n- [carbohydrate] where n = 1-10, including alkyl isomers;
H2N- (CH2)a-CHOH- (CH2)a- [carbohydrate] , where m = 0-10 and n = 0-10;
H2N- (CH2)a-0- [carbohydrate] where n = 1-10; H2N- (CH2)m-CHOH-(CH2)n-0- [carbohydrate] where = 0-10 and n = 0-10; aminobenzyl- derivatives of cellulose, chitin or other naturally occurring non-digestible carbohydrates selected from the group consisting of
H2N-C6H4- (CH2)a- [carbohydrate] , H2N-CH2-C6H4- (CH2)n- [carbohydrate] ,
H2N-CβH4- (CH2)a-0- [carbohydrate] where n = 0 - 10, and H2N-C6H4- (CH2)_.-CHOH- (CH2)a-0- [carbohydrate] where m = 0-10 and n = 0-10, including p-, o- and m-benzene ring amino- isomers, aminomethyl- isomers and alkyl group isomers thereof; guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring non-absorbable carbo¬ hydrates selected from the group consisting of: H2N-C(=NH) - [carbohydrate] ;
H2N-C(=NH) - (CH2)a- [carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-0- (CH2)a- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H2N-C(=NH) -NH- [carbohydrate] ;
H2N-C(=NH)-NH- (CH2)a- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -NH- (CH2)a-0- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -N=CH- (CH2)a- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-C(=NH) -N=CH-(CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-NHC(*=NH) -NH- [carbohydrate] ;
H2N-NHC(=NH) -NH- (CH2)a- [carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof;
H2N-NHC(=NH)-NH-(CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-NHC(=NH)-N=CH-(CH2)a- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-NHC(=NH) -N=CH- (CH-,)-,-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H2N-C(=NH) -NH-NH- [carbohydrate] ;
H2N-C(=NH) -NH-NH- (CH2)a- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-C(=NH) -NH-NH- (CH2)a-0- [carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof;
H2N-C(=NH)-NH-N=CH- (CH2)a- [carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated deriva¬ tives thereof;
H2N-C(=NH)-NH-N=CH-(CH2)a-0- [carbohydrate] , where n = 1- 10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; d. primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters having one or more carbonyl trapping functional group per molecule wherein each carbonyl trapping functional group is in the ω-, ω-1 or other isomeric position within the fatty acyl chains, wherein each fatty acyl chain may have from 3 to 26 carbons, from one to five nitrogen functional groups and from one to 24 hydroxyl groups; e. synthetic polysaccharides consisting partly or entirely of aminosugars bound by 0-1,2, 0-1,3, 0-1,4 and/or 0-1,6 linkages; f. mixedpolysaccharide polymeric derivatives wherinprimary amine, aminoalkyl (one to ten carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, aminoguanidinyl-alkyl (one to ten carbons per alkyl group) , aminoalkylguanidinyl (one to ten carbons per alkyl group) , guanidine, aminobenzene and/or aminoalkylbenzene (one to ten carbons per alkyl group) functional groups are covalently attached to matrices such as epi-chlorohydrin copolymers of cellulose or chitin and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups; and g. non-polysaccharide polymeric derivatives wherein primary amine, aminoalkyl (one to ten carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, aminoguanidinyl-alkyl (one to ten carbons per alkyl group) , aminoalkylguanidinyl (one to ten carbons per alkyl group) , guanidine, aminobenzene and/or aminoalkylbenzene (one to ten carbons per alkyl group) functional groups are covalently attached to a synthetic non-digestible polymer selected from the group consisting of polystyrene, styrene-divinylbenzene copolymer, polyvinyl alcohol and crosslinked derivatives thereof, and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups.
56. A composition of Claim 16 additionally containing an effective amount of an anti-oxidant.
57. A composition of Claim 36 additionally containing an effective amount of an anti-oxidant.
58. A composition of Claim 38 additionally containing an effective amount of an anti-oxidant.
59. A composition of Claim 39 additionally containing an effective amount of an anti-oxidant.
)
AU26378/95A 1994-05-11 1995-05-11 Compositions for treatment of chronic inflammatory diseases Ceased AU698881B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24160394A 1994-05-11 1994-05-11
US08/241603 1994-05-11
PCT/US1995/006044 WO1995031194A1 (en) 1994-05-11 1995-05-11 Compositions for treatment of chronic inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2637895A true AU2637895A (en) 1995-12-05
AU698881B2 AU698881B2 (en) 1998-11-12

Family

ID=22911379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26378/95A Ceased AU698881B2 (en) 1994-05-11 1995-05-11 Compositions for treatment of chronic inflammatory diseases

Country Status (4)

Country Link
EP (1) EP0759750A4 (en)
AU (1) AU698881B2 (en)
CA (1) CA2190107A1 (en)
WO (1) WO1995031194A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
CA2495537C (en) * 2000-08-29 2010-03-30 Nobex Corporation Immunoregulatory compounds and derivatives and methods of treating diseases therewith
WO2003095421A1 (en) * 2002-05-09 2003-11-20 Mimotopes Pty Ltd Amino acid analogues
GB0218590D0 (en) * 2002-08-09 2002-09-18 Pfizer Ltd Therapeutic use of aryl amino acid derivatives
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
IL157397A (en) * 2003-08-14 2013-03-24 Dpharm Ltd Compounds, pharmaceutical compositions comprising same and uses thereof for the preparation of a medicament for the treatment of epilepsy
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty Compositions and methods of treatment for inflammatory diseases
PT1737469T (en) * 2004-03-23 2018-10-19 Biocon Ltd Methods and compositions employing 4-aminophenylacetic acid compounds
DE102005001113A1 (en) * 2005-01-08 2006-07-20 Regeneratio Pharma Gmbh Use of metal complexes of tetrapyrrole heterocycles for the treatment of inflammatory stomach / intestinal diseases
ITRM20050390A1 (en) * 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
US8614236B2 (en) 2006-12-12 2013-12-24 University Of Washington Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
DK2365802T3 (en) 2008-11-11 2017-11-13 Univ Texas RAPAMYCINE MICROCAPLES AND USE FOR CANCER TREATMENT
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
PT2396081T (en) 2009-02-16 2017-07-11 Nogra Pharma Ltd Alkylamido compounds and uses thereof
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
MX2014012652A (en) 2012-04-18 2014-11-25 Nogra Pharma Ltd Methods of treating lactose intolerance.
DK2968281T3 (en) 2013-03-13 2020-11-02 Univ Texas MTOR INHIBITORS FOR PREVENTING THE GROWTH OF THE INTESTINAL POLYPH
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes
CA3049125C (en) * 2017-01-18 2021-11-16 Tairx, Inc. Compositions for use in treating inflammatory bowel diseases and intestinal colitis
US20200000756A1 (en) * 2017-01-24 2020-01-02 Gt Biopharma, Inc. Neostigmine combination and compositions
RU2711624C2 (en) * 2017-06-30 2020-01-17 Общество с ограниченной ответственностью "ФБК" Combined agent based on nsiad, muscle relaxant and vitamin
WO2019023175A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. Pharmaceutical compositions and methods utilizing neostigmine and a nk-1 antagonist for treating myasthenia gravis
CA3128302A1 (en) 2019-02-08 2020-08-13 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
WO2024090329A1 (en) * 2022-10-24 2024-05-02 国立大学法人東北大学 Composition for ameliorating inflammation associated with chronic hypoxia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117910A (en) * 1961-11-15 1964-01-14 Osterweil Jacob Medicinal compositions
FR6409M (en) * 1966-12-07 1968-10-28
US3956504A (en) * 1972-06-02 1976-05-11 Philip Nicholas Sawyer Method of preventing thromboses
US4272512A (en) * 1980-01-31 1981-06-09 Colgate-Palmolive Company Antigingivitis composition
JPS58194814A (en) * 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd Drug having immunoregulating activity
DE3800968A1 (en) * 1988-01-15 1989-07-27 Asche Karl W Substance in powder form as pharmaceutical
JP2974146B2 (en) * 1989-01-28 1999-11-08 三省製薬株式会社 Topical melanin production inhibitor
US4959205A (en) * 1989-03-23 1990-09-25 Collagen Corporation Composition and method for treatment of dermal inflammation
EP0604641B1 (en) * 1992-06-30 2002-03-20 SHAPIRO, Howard, K. Use of a combination containing an amine or amine-related derivative of benzoic acid and an amino-polysaccharide in the manufacture of a medicament for the treatment of inflammatory diseases

Also Published As

Publication number Publication date
EP0759750A4 (en) 1998-05-27
EP0759750A1 (en) 1997-03-05
AU698881B2 (en) 1998-11-12
WO1995031194A1 (en) 1995-11-23
CA2190107A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
AU698881B2 (en) Compositions for treatment of chronic inflammatory diseases
US8178516B2 (en) Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) Compositions and method for treatment of chronic inflammatory diseases
US6746678B1 (en) Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
CA2392879C (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US20200297625A1 (en) Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
US6562865B1 (en) Composition comprising a tramadol material and an anticonvulsant drug
JPH08512055A (en) Pharmaceutical composition and its use for the treatment of neurological disorders and psychosis-related conditions
CA2695504C (en) Compositions and methods for treatment and prevention of osteoarthritis
US4609647A (en) Cytidyl diphosphocholine-drug composition and process
US6872751B2 (en) Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
US20140194428A1 (en) Combination treatments for bipolar disorders
AU2015202432B2 (en) Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
Krishna et al. Drug Review
US20150306043A1 (en) Combination treatments for bipolar disorders
WO2014052849A1 (en) Combination treatments for bipolar disorders
EP2900225A1 (en) Combination treatments for bipolar disorders
ZA200203690B (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders.